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Abstract	  
Neutrophils are the major cellular constituent of blood leukocytes and play 
a central role in the inflammatory response, expressing an array of 
destructive molecules and antimicrobial processes that characterise the 
cells as front-line defenders of the innate immune system, thus neutrophils 
are crucial to host defence. It is now appreciated that neutrophils produce 
and respond to a variety of inflammatory signals and are able to regulate 
both the innate and adaptive immune response. The molecular changes 
that underlie this regulation are poorly defined, yet represent an attractive 
area of research to fully elucidate the role and regulatory capacity of 
neutrophils within the immune response. RNA-Seq provides an accurate 
and robust mechanism for global characterisation of cellular transcripts. 
 
Neutrophils were isolated from healthy donors and incubated with or 
without inflammatory cytokines for 1 h. RNA was extracted and analysed by 
RNA-Seq using the SOLiD or Illumina platforms. Raw data was quantified 
using a number of software packages which formed a bioinformatic 
pipeline for data analysis which was developed during the course of the 
research. Results were validated by a selection of traditional laboratory 
functional assays.  
 
Priming of neutrophils by GM-CSF and TNFα was found to induce 
differential gene expression and activation of transcription factors, which 
led to differential regulation of apoptotic pathways. Stimulation of 
neutrophils with inflammatory cytokines/chemokines (IL-1β, IL-8, G-CSF, 
IFNγ) resulted in expression of discrete gene sets and differential activation 
of signalling pathways. Stimulation of neutrophils with IL-6 did not induce 
any significant expression of genes but result in activation of STAT 
signalling. Comparison of gene expression of neutrophils isolated by 
density gradient and magnetic bead preparation revealed significant 
differences in gene expression and function, in part attributable to levels of 
contamination associated with each isolation method. Bead isolation was 
found to enrich a more heterogeneous neutrophil population including a 
subpopulation of neutrophils expressing transcripts previously associated 
with low density granulocytes. 
 
Thus, RNA-Seq and bioinformatic analysis has provided a full 
characterisation of neutrophil gene expression under inflammatory 
conditions and identified several new areas of research that could lead to 
targeted drug design for the treatment of inflammatory disease. 
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INDEL Insertions and/or  deletions 
INS Insulin 
IPA Ingenuity pathway analysis 
ISRE Interferon-stimulated response elements 
ITGAL Integrin, alpha L 
ITGAM Integrin, alpha M 
ITGB7 Integrin, beta 7 
ITK IL2-inducible T-cell kinase 
JAK Janus kinase 
JNK C-Jun N-terminal kinase 
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JSLE   Juvenile systemic lupus erythematosus 
JUN   Jun proto-oncogene 
kDa   kilo Dalton 
LCN2   Lipocalin 2 
LDGs   Low-density granulocytes 
LEF1   Lymphoid enhancer-binding factor 
LPS   Lipopolysaccharide 
LTF   Lactotransferrin 
MAC-1   Macrophage-1 antigen 
MAPK   Mitogen-activated protein kinase 
MDS   Multi-dimensional scaling 
MeV   Multiple experiment viewer 
MCL-1   Myeloid cell leukaemia 
MCL -1L  Mcl-1 long-form 
MCL -1S  Mcl-1 short-form 
MCL -1ES  Mcl-1 extra-short-form 
MMP8   Matrix metalloproteinase 8 
MMP9   Matrix metalloproteinase 9 
MPO   Myeloperoxidase 
mRNA   Messenger ribonucleic acid 
miR   micro-RNA 
NADPH Nicotinamide Adenine Dinucleotide Phosphate  
NAMPT  Nicotinamide Phosphoribosyltransferase 
ncRNA   non-coding RNA 
NDG   Normal density granulocytes 
NGAL   Neutrophil gelatinase-associated lipocalin 
NGFR   Nerve growth factor receptor 
NGS   Next generation sequencing 
NETs   Neutrophil extracellular traps 
NF-κβ   Nuclear factor kappa beta 
NK-cells  Natural killer cells 
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PAF   Platelet activating factor 
PAMP   Pathogen-associated molecular pattern 
PBMC   Peripheral blood mononucleated cell 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
pDC   plasmacytoid dendritic cell 
PEST   Proline-glutamic acid-serine-threonine 
PFA   Paraformaldehyde 
PI   Propridium iodide 
piRNA   piwi-interacting RNA 
PMA   Phorbol 12-myristate 13-acetate 
PRR   Pattern recognition receptor 
PRSS33  Protease, serine, 33 
PSGL-1  P-selectin glycoprotein ligand-1 
PU.1 Spleen Focus Forming Virus Proviral Integration 
Oncogene 
PVDF Polyvinylidene fluoride 
qPCR quantitative polymerase chain reaction 
rRNA Ribosomal ribonucleic acid 
RA Rheumatoid arthritis 
RAM Random access memory 
RAMP Resolution associated molecular pattern 
RIN RNA intergrity number  
RNA Ribonucleic acid 
RNASE2 Ribonuclease 2 
RNASE3 Ribonuclease 3 
RNA-Seq Ribonucleic acid sequencing  
RPKM Reads per kilobase per million 
S1PR1 Sphingosine-1-phosphate receptor 1 
SAM Sequence alignment map 
SD Standard deviation 
21	  
	  
SDF-1 Stromal derived factor -1 
SDS Sodium dodecyl sulphate 
SEM Standard error of mean 
SIGLEC8 Sialic acid binding Ig-like lectin 8 
SLE Systemic lupus erythematosus 
SMPD3 Sphingomyelin Phosphodiesterase 3  
SNP Single nucleotide polymorphism 
snRNA Small nuclear RNA 
snoRNA Small nucleolar RNA 
SOCS3 Suppressor of cytokine signalling-3 
STAT Signal transducer and activator of transcription 
TB Terabyte  
TBC1D4 TBC1 domain family, member 4 
TCR T-cell receptor 
TEMED Tetramethylethylenediamine 
TGF  Tumor growth factor-beta 
THBS1 Thrombospondin 1 
Th-cells T-helper cells 
TLR Toll-like receptor 
TMEM170B Transmembrane protein 170B 
TNF-α Tumour necrosis factor-alpha 
TRAIL TNF-related apoptosis-inducing ligand 
TRAT1 T-cell receptor associated transmembrane adaptor 1 
tRNA transfer ribonucleic acid 
TSS Transcriptional start site 
TYK2 Tyrosine kinase 2 
UV Ultra violet 
VCF Variant calling file 
ZMW   Zero mode waveguide 
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Table	  Ab.1	  Bioinformatic	  file	  formats	  and	  file	  extension	  abbreviations	  
 
File	  format	   File	  
extension	  
Summary	  Sam	  file	   .SAM	   Sequence	  Alignment	  Map	  –	  output	  format	  from	  high-­‐throughput	  mappers	  such	  as	  Bowtie,	  Tophat,	  or	  BWA	  	  Bam	  file	   .BAM	   Binary	  format	  of	  a	  SAM	  file	  –	  smaller	  file	  size	  and	  can	  be	  processed	  faster	  than	  an	  equivalent	  SAM	  file.	  General	  feature	  format	  /	  General	  transfer	  format	   .GFF/.GTF	   Reference	  file	  listing	  various	  sequence	  features	  and	  attributes	  such	  as	  gene	  boundaries	  and	  coding	  frame	  FASTA	   .FASTA	   Text	  based	  file	  for	  nucleotide	  sequence	  data	  Colorspace	  Fasta	   .CSFASTA	   Similar	  to	  FASTA	  but	  nucleotide	  format	  is	  encoded	  in	  colorspace	  Fasta	  Quality	  file	  	   .QUAL	   List	  of	  quality	  values	  for	  nucleotide	  sequence	  to	  accompany	  a	  FASTA	  format	  file	  Fastq	   .FASTQ	   FASTA	  format	  file	  where	  nucleotide	  sequence	  and	  quality	  value	  are	  encoded	  into	  a	  single	  ASCII	  character	  to	  decrease	  digital	  footprint	  Variant	  calling	  file	   .VCF	   Text	  file	  containing	  data	  on	  individual	  genomic	  positions,	  used	  primarily	  to	  list	  SNPs	  and	  indels	  Binary	  variant	  calling	  file	   .BCF	   Binary	  format	  of	  a	  .vcf	  used	  for	  faster	  processing	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Chapter	  1:	  Introduction	  	  
1.1 Project Overview 
Neutrophilic polymorphonuclear leukocytes (neutrophils) were first 
described by Paul Ehrlich in the late nineteenth century using cell-staining 
techniques to investigate the subpopulations of white blood cells 1. Ehrlich 
discovered three sub-types of cells each featuring polymorphous nuclei 
that could be distinguished from each other by their individual staining 
properties. Whilst eosinophils and basophils were named due to their 
cytoplasm staining positively with eosin and basic dyes respectively, the 
third subtype exhibited a tendency to retain neutral dyes and was so 
termed the neutrophil 2.  
Neutrophils are the most abundant leukocyte found in circulating blood, 
accounting for 40-60% of the total white blood cell population 3. They form 
the major cellular constituent of the innate immune system and are 
indispensable for defence against invading bacterial and fungal pathogens 
due to their ability to phagocytose cells and micro-organisms, release lytic 
enzymes from internal granules, and produce reactive oxygen metabolites 
with antimicrobial potential 4,5. Their highly-conserved mechanisms of anti-
microbial activity, coupled with a characteristic short life span, have 
historically defined the neutrophil as a one dimensional effector cell with 
little capacity to influence the more complex, adaptive arm of the immune 
system, predominantly regulated by T-cells and B-cells.  
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However, in recent years, this view of neutrophils has been profoundly 
altered. Neutrophils are now known to produce and release numerous 
cytokines, chemokines and angiogenic/fibrogenic factors 6. They have also 
been shown, following cytokine stimulation, to express MHC Class II 
molecules and present antigen-to and activate T-cells 7. 
The perceived role of neutrophils in inflammatory disease has also been 
altered in recent years. Neutrophil dysregulation has been associated with 
the pathogenesis of a variety of chronic inflammatory diseases such as 
rheumatoid arthritis (RA) 8, juvenile (and adult) systemic lupus 
erythematosus (SLE) 9, chronic obstructive pulmonary disease (COPD) 10, 
asthma 11 and alcoholic hepatitis 12. This current view of neutrophils places 
them central to the immune system with a significant capacity to regulate, 
influence and affect both the innate and adaptive response in health and 
disease. Despite a greater appreciation for neutrophil involvement in the 
immune response, relatively little work has focused on the underlying 
mechanisms of neutrophil activation and regulation in the context of 
inflammation, instead focusing more on the traditionally associated 
mechanisms of functions such as chemotaxis, phagocytosis and apoptosis.  
Quantifying the transcriptional output of a cell has often been used by 
researchers to unpick the mechanisms by which a cell behaves under 
normal conditions, or adapts and responds to a changing environment or 
signal. The sensitivity of quantification of transcriptomes has grown 
exponentially over the past 2 decades, firstly with the development of 
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array-based technologies and real-time quantification by polymerase chain 
reaction (PCR).  Subsequently, the successful development of micro-array 
technology provided the first means to quantify the entire population of 
transcripts within a cell or tissue population. However, the greatest 
technological advancement has come in the area of massively high-
throughput sequencing (HTS). Today, whole genome/exome/transcriptome 
sequencing can now be performed over the course of a few days/weeks 
within a research lab for a few thousand pounds. This represents a minute 
fraction of the cost and time expended on the first large scale genome 
project,  the Human Genome Project, which over the course of its 13 years 
was estimated to have cost over $3 billion 13. 
This thesis aims to define a set of modern tools and bioinformatic software 
packages that can consistently, accurately and robustly quantify the gene 
expression profile of neutrophils using RNA-Seq. This pipeline will then be 
utilised to investigate the changes in gene expression following stimulation 
of neutrophils with inflammatory cytokines. Finally, the differences in two 
commonly used neutrophil isolation methods and the influence of inherent 
cellular contamination will be analysed, including their effect on neutrophil 
function and gene expression of both in vitro stimulated and unstimulated 
neutrophils. 
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1.2 Neutrophils 
Examples of cells with phagocytic abilities are found in organisms as 
distantly related as the slime mould Dictyostelium discoideum  14 and the 
African clawed frog Xenopus laevis 15. Indeed, such is the level of 
evolutionary conservation between species, that both zebrafish and rodents 
are often used as model organisms for in vivo studies of neutrophil function 
despite their neutrophils comprising a much lower proportion of the 
leukocyte population (15-20%) than in higher mammals 2. In humans, 
neutrophils comprise up to 60% of all leukocytes and are produced at a 
rate of 5 x 1010 – 30 x 1010 cells /day  16. The vast majority are retained in the 
bone marrow, and only a small fraction is released into the circulating 
peripheral blood, such that the concentration of neutrophils in blood is 
approximately 3-5 x 106/mL. 
1.2.1 Neutrophil production and maturation 
Granulocyte-colony stimulating factor (G-CSF) is essential for regulating the 
production and release of neutrophils from the bone marrow, whilst the 
chemokine receptors 4 (CXCR4) and 2 (CXCR2) are central to regulating 
neutrophil retention and release from the bone marrow, respectively. 
CXCR4 acts with its ligand, stromal derived factor -1 (SDF-1), which is 
produced by bone marrow stromal cells, to retain neutrophils in the bone 
marrow. Conversely, growth regulated protein (Gro)α and Groβ released by 
stromal cells acts through CXCR2 to increase neutrophil release 17.  
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Levels of SDF-1 are tightly regulated by G-CSF, which in turn is regulated 
by levels of Interleukin (IL)-17A produced by neutrophil-regulatory T-Cells. 
IL-17A release is dependent on levels of IL-23 released by tissue 
macrophages and dendritic cells. Uptake of apoptotic neutrophils by 
macrophages and dendritic cells results in a decrease in IL-23 levels. Thus, 
a reciprocal negative feedback loop exists such that as levels of neutrophils 
in tissue increases, levels of G-CSF decrease, ultimately leading to a 
decrease in neutrophil release from the bone marrow 18 (Fig 1.1-inset). 
Neutrophil maturation is largely dependent on the transcription factors 
CCAAT/Enhancer binding protein alpha – zeta (C/EBPα-ζ) and PU.1. 
Terminal differentiation into either a monocyte or a granulocyte lineage is 
ultimately decided by the balance of expression between these two 
transcription factors 19.  
1.2.2 Neutrophil granules 
Neutrophil granules and granule proteins are produced sequentially during 
neutrophil maturation. Granule proteins serve mainly as antimicrobial 
proteins aiding pathogen killing during phagocytosis. Granules have 
historically been classified into 3 types based on their protein content: 
azurophilic (primary) granules, which contain myeloperoxidase (MPO); 
specific (secondary) granules, which contain lactoferrin; and gelatinase 
(tertiary) granules, which contain matrix metalloproteinase 9 (MMP9). 
However, more recently, neutrophil granules have been further classified 
into several sub-types. For example, azurophilic granules can be 
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differentiated into defensinhi and defensinlow 20, whilst specific granules can 
be sub-divided into at least 4 sub-types; lactoferrinhi, cysteine-rich secretory 
protein 3 (CRISP3)hi, gelatinasehi and ficolin-1hi 18,21–23. The mechanism 
underlying the existence of separate granules has been termed “targeting 
by timing of biosynthesis”24 whereby proteins expressed at similar stages of 
maturation are localised to similar granule subtypes. This allows for 
differences in the mobilization of proteases, with the granules formed last 
during maturation being most likely to be released first. It is also important 
that some of these granule proteins are localised to different 
compartments as they can antagonise the activities of each other: for 
example neutrophil elastase (found in azurophil granules) can digest 
neutrophil gelatinase-associated lipocalin (NGAL) (found in specific 
granules) 18,23. Neutrophils also contain secretory vesicles that contain 
proteins and receptors associated with neutrophil adhesion and migration. 
Upon neutrophil activation, vesicles containing adhesion molecules such as 
β2integrins are incorporated into the neutrophil surface membrane where 
they facilitate neutrophil migration into tissues. 
1.2.3 Activation, rol l ing, adhesion and extravasiation 
Neutrophil migration from peripheral blood is mediated by interactions 
with vascular endothelium, predominantly at postcapillary venules 18. 
Neutrophils move to the site of inflammation along a chemotactic gradient. 
Expression of L-selectin on neutrophils and both E-selectin and P-selectin 
on endothelial cells mediate tethering and lumal rolling of neutrophils by 
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binding of P-selectin glycoprotein ligand-1 (PSGL-1) and other glycosylated 
ligands 25. Neutrophils are further activated by chemokines and 
proinflammatory agents presented on the surface of endothelial cells, such 
as CXCL8 (IL-8) and CXCL2 (MIP-2). This in turn, activates integrins such as 
β2 integrin (CD18) leading to high-affinity binding with integrin ligands 
expressed on the surface of endothelial cells, such as intracellular adhesion 
molecules 1 and 2 (ICAM-1 and ICAM-2). The interaction of integrin alpha L 
(ITGAL) and integrin alpha M (ITGAM) with ICAM1 is important for 
neutrophil adhesion and intraluminal crawling, allowing neutrophils to 
move to endothelial borders in preparation for extravasation 26. Following 
firm adhesion to the endothelial layer, neutrophil movement into tissues 
can occur in one of two ways; paracellular migration, where neutrophils 
squeeze between endothelial cells, or less-commonly, transcellular 
migration, where neutrophils pass through an individual endothelial cell. 
Neutrophil transmigration is facilitated by several neutrophil surface 
molecules, including CD54 (ICAM-1) 27, CD31 (platelet/endothelial cell 
adhesion molecule 1 – PECAM-1) 28, CD44 29, and CD47 (integrin 
associated protein – IAP) 30. Once in the tissue, neutrophils continue to 
move along a chemotactic gradient towards the source of inflammation 
where they can carry out other immune processes, such as cytokine release, 
phagocytosis and NETosis (Fig 1.1). 
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Fig	   1.1	  Overview	  of	  neutrophil	  production	  and	   function.	  Peripheral	  blood	  neutrophils	  
migrate	  to	  site	  of	  inflammation	  via	  chemotactic	  signalling	  and	  transmigrate	  into	  tissue	  
following	   a	   number	   of	   sequential	   processes	   (rolling,	   adhesion	   and	   transmigration)	  
where	  they	  can	  carry	  out	  their	  key	  functions,	  such	  as	  cytokine	  release,	  phagocytosis	  or	  
NETosis.	  Neutrophils	  subsequently	  become	  apoptotic	  during	  inflammation	  resolution.	  
(Inset)	   Neutrophil	   release	   from	   the	   bone	   marrow	   is	   regulated	   by	   levels	   of	   G-­‐CSF	  
expressed	  by	  stromal	  cells.	  As	  levels	  of	  apoptotic	  neutrophils	  increase	  in	  tissue,	  G-­‐CSF	  
levels	   are	   decreased	   through	   the	   down-­‐regulation	   of	   IL-­‐23	   and	   IL-­‐17	   release	   by	  
macrophages	  and	  Th17	  cells,	  respectively.	  	  
	  
	  
1.3 Neutrophil function 
1.3.1 Priming  
Neutrophils exist in one of three activation states; quiescent (also known as 
unprimed), primed or activated  31. Under normal conditions, neutrophils 
patrol the vascular system in large numbers in a dormant (or unprimed) 
state. In the absence of any stimulating factors, peripheral blood 
neutrophils rapidly undergo constitutive apoptosis resulting in a short 
lifespan, typically less than 24 h 32.  
Apoptotic neutrophil 
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Stromal cell 
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 IL-23 
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Cytokine release 
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Upon exposure to a variety of inflammatory stimuli (such as chemokines, 
cytokines, bacterial peptides or by adhesion), neutrophils become primed. 
Priming involves several rapid molecular changes; intracellular granules 
containing pre-formed receptors are mobilised to the plasma membrane, 
receptor affinity is altered, and components of the Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) oxidase complex are assembled at the 
plasma membrane  33. Additionally, priming involves other, less rapid 
molecular changes, for example, increased gene expression resulting in the 
production of cytokines or chemokines, and stabilisation of proteins 
involved in apoptosis, ultimately extending the life of a primed neutrophil  
3. The overall consequence of priming is a neutrophil which is capable of a 
rapid and increased response to subsequent activation signals. A major 
advantage of priming is as a regulatory step to ensure peripheral blood 
neutrophils are not inappropriately or non-specifically activated, leading to 
unregulated release of the neutrophils toxic armoury and unnecessary 
localised tissue damage. Interestingly, studies using platelet activating 
factor (PAF) have revealed that neutrophil priming can be reversed  34, 
suggesting that in the absence of an activation stimulus a mechanism exists 
to allow neutrophils to be returned to a quiescent state for subsequent 
recycling at the inflammatory site 34. 
1.3.2 Pattern recognition receptors (PRR) 
The primary role of neutrophils is to identify and destroy pathogenic 
organisms from the body. In order to achieve this, neutrophils must first be 
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able to differentiate between foreign antigens (for example bacterial 
peptides), host antigens (for example immunoglobulins and complement 
factors) and host (self) proteins before initiating an appropriate immune 
response. Consequently, neutrophils express a variety of pattern 
recognition receptors (PRR) such as Toll-like receptors (TLRs), Nod-like 
receptors (NLRs) and C-type lectin receptors 5,35. PRRs can be activated by 
microbial structures, more commonly-known as pathogen associated 
molecular patterns (PAMPs) or endogenous signals produced by host cells 
in response to trauma, ischemia or tissue damage, more commonly known 
as damage-associated molecular (DAMPs) 35. More recently, a new class of 
pattern molecules has been proposed. Due to their anti-inflammatory 
actions, members of the heat shock protein (HSP) family (among others) 
have been termed resolution associated molecular patterns (RAMPs) 36. This 
highlights the importance of pattern recognition receptors in both the 
activation and resolution of neutrophil function. 
 
1.3.3 Phagocytosis 
Following neutrophil priming and chemotaxis towards a source of 
pathogenic insult, clearance of foreign microbes is achieved by 
phagocytosis. Phagocytosis is triggered by the interactions of opsonised 
particles with specific receptors on the surface of neutrophils. For example, 
complement receptors (CR) such as CR1 and CR3 bind to particles 
opsonised with complement, whereas particles opsonised with γ-
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immunoglobulin (IgG) are phagocytosed via interaction with Fcγ receptors 
(FcγR) (which bind the Fc portion of immunoglobulins). Ultimately, 
microorganisms are internalised by the neutrophil into a membrane-bound 
vacuole, known as a phagosome. 
Neutrophils express 3 classes of FcγR. The low-affinity binding receptors 
FcγRIIA (CD32) and FcγRIIIB (CD16) are both expressed on unprimed 
neutrophils. On the other hand, expression of the high-affinity receptor 
FcγRI (CD64), although present in synovial neutrophils from rheumatoid 
arthritis (RA) patients 37 is only expressed on healthy neutrophils following 
activation by IFNγ 38.  
The mechanism of pathogen internalisation is dependent on the specific 
interactions between the neutrophil and the microorganism, for example 
interactions may be direct through activation of PRR by PAMPs, or may be 
mediated by opsonins 2. Phagocytosis of opsonised particles is largely 
mediated by either the FcγRs or complement receptors (CR). Engulfment is 
initiated by the localised clustering of phagocytic receptors (for example 
FcγRs) following ligation with their cognate ligand. Subsequently, extended 
membrane structures, or pseudopodia, engulf the particle forming an 
intracellular phagosome. It can take less than 20 s to internalise a 
microorganism. Interestingly, CR-mediated phagocytosis does not result in 
the formation of pseudopodia, but instead, the opsonised particle appears 
to sink into the neutrophil 39. 
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Microbial killing within the phagosome is achieved via a two step process; 
firstly, internal granules fuse with the phagosome membrane, releasing 
their content into the phagosomal lumen. Simultaneously, reactive oxygen 
species (ROS) are produced via assembly of the NADPH oxidase complex 
on the phagosomal membrane 2. These processes produce a hostile intra-
phagosomal environment that leads to the destruction of the engulfed 
microorganism. 
In addition to an effective mechanism of pathogen clearance – since 
neutrophils can express MHCII molecules 40 -  phagocytosis also serves to 
provide antigens to the adaptive immune system. This highlights the 
important role that neutrophils play as both an innate effector, but also an 
immune-regulator of both the innate and adaptive immune system. 
1.3.4 NETosis 
In the last decade, evidence has emerged that neutrophils are capable of a 
specialised form of programmed cell death, mechanistically distinct from 
either necrosis or apoptosis. Under conditions of increased stimulation or 
overwhelming numbers of bacteria, neutrophils are able to extrude 
neutrophil extracellular traps (NETs) which act as an additional antimicrobial 
mechanism in the neutrophil armoury. NETosis is characterised by NADPH-
oxidase-dependent dissolution of the nucleus and intracellular membranes, 
followed by the rupture of the plasma membrane and expulsion of 
decondensed chromatin 41 (Fig 1.2). NETs are decorated with a variety of 
cellular proteins, such as granule proteins (which form the greatest 
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proportion of NET-associated proteins), nuclear proteins (such as histones) 
and cytoplasmic proteins (such as calcium-binding proteins).  The 
advantages of NET formation in host defence are numerous. Firstly, NETs 
provide a physical barrier, preventing microbial spread. Secondly, the 
concentration of anti-microbial proteins that decorate NETs increases their 
efficiency and promotes synergistic actions of proteases. Thirdly, the 
restricted dispersion of proteases limits the amount of localised tissue 
damage induced by localised NETosis 42.  
  
 
Fig	   1.2	   Neutrophil	   NETs.	   Neutrophils	   stimulated	   with	   PMA	   for	   2h	   to	   induce	   NET	  
formation.	   Cells	   stained	   for	   DNA	   using	   DAPI.	   Viewed	   under	   fluorescent	   microscope	  
(x40	  magnification)	  	  
 
Following the formation of NETs, it is generally assumed that the 
neutrophil will die, as this is considered a specialised form of cell death. 
However, evidence suggests that, under certain conditions, NETs can be 
formed from mitochondrial DNA alone, without decreasing the potential 
life-span of the neutrophils 43. 
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Importantly, NETs are also known to have a role in signalling, by activation 
of plasmacytoid dendritic cells (pDC) via their Toll-like receptor 9 (TLR9) 44, 
which is triggered by DNA. NETs have also been implicated in CD4+-cell 
priming via a TLR9 independent mechanism 42. Further evidence to support 
the notion that NETs are an evolutionary-conserved process is the 
discovery of several bacterial strategies for evading NETs, for example, 
Streptococcus pneumonia is capable of altering its capsule charge, thereby 
decreasing its binding-affinity to NETs 45. Bacteria are also capable of 
expressing nucleases on their surface 46 or releasing endonucleases 47 which 
can degrade NETs. 
Despite a clear host advantage for NETosis formation, numerous  studies 
have implicated NETs in the pathogenesis of several diseases 48, cystic 
fibrosis 49, periodontitis 50, preeclampsia 51 and autoimmune conditions 
such as systemic lupus erythematosus (SLE) 9,44,52–54 and rheumatoid arthritis 
55. The formation of NETs in autoimmune conditions can lead to the release 
of nuclear and protein neo-antigens as a potential mechanism for auto-
antibody production. 
 
1.3.5 Apoptosis 
In order to balance the high rate of neutrophil production and release into 
peripheral blood, neutrophils must also regulate the rate at which they 
undergo apoptosis and are removed from circulation. Apoptosis is an 
evolutionary-conserved mechanism of cell death that is tightly-regulated 
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and ensures that the destructive proteases and lytic enzymes contained in 
neutrophil granules are not released into the surrounding environment, 
thereby minimising their potential for localised tissue damage 56. In the 
absence of any stimulating factors, neutrophils can undergo constitutive 
apoptosis within 8 h 57. Apoptosis leads to several morphological changes 
that are characteristically distinct from changes that occur during necrosis. 
These include: condensation of nuclear chromatin; nuclear fragmentation, 
leading to the loss of the characteristic neutrophil multi-lobed nucleus; 
DNA and protein degradation; retention of organelles and plasma 
membrane disruption and blebbing 56,58,59. Apoptotic neutrophils also 
exhibit molecular alterations on their cell surface, either by down-regulation 
of cell-surface receptors such as FcγRs (CD16 and CD32), complement 
receptors  (CD35 and CD88), or TNF receptor (CD120b) 60  or by the 
exposure of new cell surface molecules such as phosphatidylserine (PS). 
Under normal conditions, PS is held on the inner leaflet of the plasma 
membrane by the actions of the enzyme flippase 61. However, during the 
early stages of apoptosis, PS translocates to the outer surface of the plasma 
membrane where it facilitates the recognition of apoptotic neutrophils by 
macrophages 62. This molecular switch is the basis of an apoptosis assay 
whereby fluorescently-labelled annexin V binds to exposed PS on the 
surface of apoptotic neutrophils and can be quantified by flow cytometry. 
Neutrophil apoptosis can be activated via two pathways, dependent on 
whether the activating signal originates internally or externally to the cell.  
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1.3.5.1 The intrinsic apoptosis pathway 
The intrinsic apoptosis pathway is regulated by members of the B-cell 
leukaemia-2 (Bcl-2) family of proteins, and in neutrophils is activated by an 
absence of anti-apoptotic factors, for example during constitutive 
apoptosis or in response to stress signals originating from within the cell, 
such as DNA damage. Interactions of the Bcl-2 family members (of which 
there are both pro- and anti-apoptotic members) ultimately leads to the 
de-polarisation and permeabilization of the mitochondrial membrane and 
the release of cytochrome-c into the cytosol 63. 
1.3.5.2 The extrinsic apoptosis pathway 
Exposure of neutrophils to pro-apoptotic signals results in apoptosis via the 
receptor-mediated extrinsic pathway. Molecules, including tumour necrosis 
factor-alpha (TNFα) Fas-ligand (FASLG) and TNF-related apoptosis-
inducing ligand (TRAIL) bind to one of several “death receptors” expressed 
on the surface of neutrophils. These include FAS-receptor (FASR), TNF-
receptor super-family member 10 (TNFRSF10) and nerve growth factor 
receptor (NGFR).  These receptors are members of the larger TNF receptor 
super-family and are characterised by a cytoplasmic region of 
approximately 80 amino acids, known as a “death domain” 64. Following 
activation of receptors via attachment with corresponding ligand, several 
cytoplasmic proteins are recruited to the death domain forming a death-
inducing signalling complex (DISC).  These proteins include Fas-associated 
via death domain (FADD), and pro- cysteine-aspartic proteases-8 (pro-
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caspase-8). Formation of the DISC initiates a signalling cascade leading to 
activation of caspase 8 and other downstream caspases 65,66.  
 
Fig	   1.3	   Schematic	   summary	   of	   the	   extrinsic	   apoptosis	   pathway	   in	   neutrophils.	  
Activation	  of	  death	  receptors	  for	  example	  Fas-­‐receptor	  (FasR)	  by	  its	  ligand	  Fas-­‐ligand	  
(FasL)	   induces	  formation	  of	  the	  death	   inducing	  signalling	  complex	  (DISC)	  comprising	  
of	  the	  receptor	  death	  domain	  (DD),	  Fas-­‐associated	  via	  death	  domain	  (FADD)	  and	  pro-­‐
caspase-­‐8.	   Activation	   of	   caspase	   8	   leads	   to	   the	   initiation	   of	   a	   caspase	   cascade	  
ultimately	  leading	  to	  apoptosis.	  Adapted	  from	  64,67.	  
 
 
 Ultimately, activation of either apoptosis pathway leads to the activation of 
initiator caspases, which sequentially cleave their inactive pro-caspase 
targets into shorter, active forms during a caspase cascade. The action of 
the caspase cascade results in the cleavage and degradation of a number 
of target cellular proteins which culminates in the disassembly of the cell 
and the exposure of “eat me” signals (such as PS) on the neutrophil surface 
leading to their clearance by phagocytic cells, such as macrophages or 
activated neutrophils 68.  
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1.3.6 Inflammation resolution 
Appropriate activation of neutrophil apoptosis is crucial to limit any 
collateral damage by neutrophil granule proteins. Apoptotic neutrophils 
can also regulate the immune response, for example, by the secretion of 
annexin-1. The rapid release of annexin-1 from tertiary granules can induce 
increased uptake by macrophages 69. Furthermore, uptake of apoptotic 
neutrophils results in the release of several anti-inflammatory mediators 
from phagocytic cells, such as IL-10, tumour growth factor-β (TGF-β) and 
prostaglandin-E2 (PGE2) which are crucial for the resolution of inflammation  
70,71. 
 
1.4 Neutrophils and disease 
1.4.1 Neutrophil impairment 
Given the indispensable role of neutrophils in host defence, it is 
unsurprising that disorders relating to impaired neutrophil function share a 
common phenotype of increased incidence of infection and overall 
immune deficiency in the patient 72. For example, impairment of neutrophil 
adhesion and extravasation due to defective integrin or selectin expression 
is characteristic of leukocyte adhesion disorder (LAD) 73 , while an estimated 
1 in 200,000 people suffer from chronic granulomatous disease (CGD), a 
group of inherited diseases caused by a defect in any of 4 subunits of the 
phagocyte NADPH oxidase complex 75.  
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Neutrophil myeloperoxidase (MPO) deficiency, is a disorder affecting 
approximately 1 in 4000 individuals 76. Deficiency is often due to point 
mutations in the MPO gene, resulting in defective post-translational 
processing of the MPO precursor protein. Deficiency of MPO prevents the 
formation of hypochlorous acid (HOCl) from chloride and hydrogen 
peroxide (H2O2) 72. Interestingly, despite the fact that neutrophils may be 
deficient of MPO, they do not have impaired bacterial killing ability in vitro, 
patients are usually asymptomatic unless presenting with other clinical 
disorders such as diabetes, whereby patients exhibit increased fungal 
infections 72. This observation suggests a level of redundancy in neutrophil 
bacterial killing mechanisms. 
 
1.4.2 Neutrophils and inflammatory disease 
In contrast to diseases where neutrophil function is impaired, inappropriate 
or over-activation of neutrophils is associated with a number of 
inflammatory diseases. For example, neutrophils have been implicated in 
the pathogenesis of systemic lupus erythematosus (SLE) 77, Behçet’s 
Disease 78, COPD 10 and RA 3. Inappropriate release of neutrophil proteases 
and other anti-microbial proteins can lead to localised tissue damage, 
which characterises the pathology of each of the above diseases. 
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1.4.3 Low density granulocytes 
Heterogeneity in granulocyte density has been known for almost two 
decades. In 1986, Hacbarth and Kajdacsy-Balla first described a sub-set of 
granulocytes that they termed “low buoyant density granulocytes” in the 
peripheral blood of patients with systemic lupus erythromatosis (SLE), 
rheumatoid arthritis (RA) and acute rheumatic fever, which correlated with 
disease activity 79. More recently, low density granulocytes (LDGs) have 
been additionally associated with disease activity in a number of conditions 
such as HIV-1 80 and SLE 81,  whilst their function and phenotype have been 
further characterised. 
 
LDGs are a sub-population of granulocytes which, due to their lower 
density, sediment in the PBMC fraction following density-gradient 
centrifugation of whole blood. They have been shown to have increased 
capacity for type I interferon (IFN) production, increased secretion of pro-
inflammatory cytokines  81, decreased ability to phagocytose bacteria, but 
an increased tendency to form NETs compared to mature neutrophils 52. 
LDGs are CD15high and CD14low (compared to monocytes which are CD15low 
and CD14high), whilst also expressing the mature granulocyte markers 
CD10 and CD16 32. Conversely, the transcriptional profile of LDGs (in 
addition to their low density properties) suggests they are a sub-population 
of immature granulocytes 52. The precise function of LDGs remains unclear 
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but understanding their function and precise role in inflammatory 
conditions is currently of great interest and importance. 
 
1.4.4 Treatment of inf lammatory disease 
A hallmark of inflammatory disease is elevated cytokine levels at sites of 
inflammations. This is best demonstrated by the efficacy of anti-cytokine (or 
anti-cytokine receptor) therapies in treating a wide range of inflammatory 
diseases. Whilst multiple cytokines are elevated in these diseases, often, 
specific cytokine-blockade is highly successful at alleviating symptoms and 
decreasing disease activity. Indeed, therapies of this nature represent the 
front-line treatment for several debilitating inflammatory diseases 82. 
However, responses of patients to specific therapies are often 
heterogeneous, and will often need to switch therapies before disease 
activity is controlled. This suggests that inflammatory diseases have 
heterogeneous pathology and different cytokines are responsible for 
driving the inflammatory response in different patients. Table 1.1 lists 
several examples of cytokines (or their cognate receptors) targeted by anti-
inflammatory disease therapies, and the diseases they are administered for.  
Despite having a central role in several inflammatory diseases, direct 
targeting of neutrophils is unfeasible as a form of therapy due to the 
resulting neutropenia and increased risk of developing infections. However, 
modifying specific neutrophil functions by directly (or indirectly) targeting 
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cytokine signalling may lead to much more efficient regulation of 
neutrophils in inflammatory disease without compromising host-defence. 
 
Table	  1.1	  Current	  (or	  clinical	  trial	  phase)	  cytokine-­‐targeting-­‐therapies	  for	  inflammatory	  
diseases:	  Vasculitis	  (V);	   Inflammatory	  bowel	  disease	  (IBD);	  Rheumatoid	  arthritis	  (RA);	  
Cancer	   (C);	   Multiple	   sclerosis	   (MS);	   Acute	   gout	   (AG);	   Still’s	   disease	   (SD);	   juvenile	  
idiopathic	  arthritis	  (JIA);	  ulcerative	  colitis	  (UC);	  Crohn’s	  disease	  (CD);	  Psoriatic	  arthritis	  
(PA);	  psoriasis	  (P);	  Ankylosing	  spondylitis	  (AS);	  Behçet’s	  disease	  (BD).	  
 
Drug	  name	   Target	  cytokine	  (or	  cytokine	  receptor)	   Disease	   Refs	  
Tocilizumab	   IL-­‐6	  receptor	   V/IBD/RA/C	   83	  
MOR103	  (phase	  II)	  
Mavrilimumab	  
GM-­‐CSF	  GM-­‐CSF	  receptor	   MS/RA	   	  84,85	  
Anakinra	   IL-­‐1	  receptor	   AG/SD/JIA/RA	   3,86–88	  
Infliximab	  
(Remicade®)	  
Golimumab	  
Adalimumab	  
(Humira®)	  
Etanercept	  (Enbrel®)	  
Certolizumab-­‐pegol	  
(Cimzia®)	  
TNFα	   RA/UC/CD/IBD/PA/P/AS/BD	   89–94	  
	  Fontolizumab	   IFNγ	   CD	   95	  
Secukinumab	   IL-­‐17A	   RA/P	   96	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1.5 Systems biology 
1.5.1 Implementation 
Systems biology is a relatively recent area of biological research. The 
development of high powered computing and analytical approaches which 
generate large amounts of data (such as proteomics, genomics and 
metabolomics) have necessitated a new approach to scientific research. 
The fundamental goal of systems biology is to integrate comprehensive 
biological data sets from diverse systems in an attempt to understand 
complex interactions at the molecular level, thus providing a mechanism of 
predicting phenotype changes in a biological system following a defined 
stimulus 97.  
This approach has been applied to several areas of biology, such as 
analysing the entire kinase population (also known as the kinome) of 
Drosophila melanogaster during cell-cycle 98 or temporal analysis of gene-
promoter activity of amino-acid biosynthesis genes in Escherichia coli 99. 
In addition to individual systems based projects studying specific cells or 
pathways, broader, multi-institutional research consortiums are attempting 
to integrate data from multiple bioinformatic projects in an attempt to 
tackle wider conceptual problems such as inflammatory disease or patient 
drug-response. For example, a recently funded consortium led by the 
Queen Mary hospital, London – in collaboration with the charity Arthritis 
Research UK – will attempt to apply a stratified approach to understanding 
patient heterogeneity and drug response in rheumatoid arthritis (RA) 100. 
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This example of a multi-faceted research approach highlights how systems 
biology (or more specifically bioinformatic data) can successfully be up-
scaled to undertake much broader scientific questions 101. 
   
1.5.1 Transcriptomics 
Genomic studies attempt to quantify the entire genome of an organism. 
This information is encoded by a cell’s DNA and is virtually identical in all 
somatic cells of an organism, for example the information encoding the 
insulin gene (INS) is present in cells as disparate as pancreatic beta-cells 
and dendritic cells. Whilst, there may be variations in the copy number or 
epigenetic features, the hard-coded DNA sequence will be identical in 
both cell types, yet only in pancreatic beta-cells will the information be 
translated to produce the insulin protein. 
In contrast, transcriptomics focuses solely on the information contained 
with the RNA population. The population of RNA transcripts is both cell 
specific and dynamically regulated and can be thought of as the functional 
intent of a cell. Furthermore, since an estimated 92-94% of eukaryotic 
genes are subject to alternative splicing 102 an RNA population may not 
only be different between two different populations of cells but also 
between similar cells stimulated differently. 
In simplistic terms, transcriptomics attempts to define a level of gene 
expression at a specific time or under specific conditions by quantifying the 
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abundance of mRNA transcripts pertaining to each gene in an organism’s 
genome 97.  
1.5.1.1 Sanger sequencing 
The first successful method of sequencing DNA fragments was developed 
in 1977 by Fred Sanger and colleagues using chain-terminating inhibitors 
103. Nucleotide-specific sequence fragments were created using terminating 
dideoxynucleotides for each of the 4 bases. Populations relating to each 
base-type were then placed in separate lanes of a gel and subject to 
electrophoresis. Since fragments were fluorescently labelled, and the 
terminating base-type was known, fragments could then be “read” by 
virtue of their migration distance through the gel 104. This method of 
sequencing became the gold-standard in genetic research for over 25 
years, until several technological advancements were made during the 
undertaking of the human genome project between 1990-2003 105. This 
technique is still employed for targeted-sequencing, but for larger projects 
and genome/transcriptome wide analysis it has been superseded by more 
high-throughput approaches 101. 
1.5.1.2 SAGE 
Early attempts to define an entire transcriptome utilised serial analysis of 
gene expression (SAGE) technology to sequence small unique fragments 
(15-20 bp) of cDNA transcripts (reverse transcribed from the RNA 
population) relating to each gene 106. SAGE uses traditional Sanger 
technology to sequence short sequence tags which can be uniquely 
48	  
	  
associated with the original mRNA fragment to which it relates. The 
abundance of tags relating to each gene can then be used to get a 
quantification of gene expression. However, this technology is relatively 
expensive and often the short fragments cannot be uniquely associated to 
a specific gene. In addition, since only a small fragment of the parent 
mRNA is analysed, any isoforms of the same gene are often 
indistinguishable from each other and cannot be quantified 107. 
Consequently, this technology is now more often used as a way of 
sequencing smaller, specific areas of a genome or transcriptome rather 
than a wider, global approach to gene expression. 
1.5.1.3 Microarrays 
Although initially developed as far back as the early 1980’s to screen a 
small subset of genes in tumour cells 108, microarray technology has been 
consistently developed and improved, such that it became the first 
technology to be thought of as a truly high-throughput transcriptomic 
technology. Until recently, microarrays were the most established and 
popular method for studying nucleotide sequences on a massive scale. 
Microarrays contain thousands of single-stranded sequences of DNA (or 
RNA), known as probes, which are attached to specific location of a glass- 
or polymer-slide. Typically the RNA (or DNA) sample being measured is 
converted into a population of complementary fragments (cRNA/cDNA) 
and is labelled with a fluorescent dye. The sample is subsequently washed 
over the microarray, enabling labelled sequences with high complementary 
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sequence-similarity to bind to the microarray probes. Relative abundance 
of sequences can then be estimated by optical fluorescent measurement of 
each specific probe location on the microarray 109.  
The hybridisation of labelled sequences to well characterised probes is a 
fundamental aspect of all microarray experiments. However, several 
different technological and conceptual variations of microarray technology 
exist providing huge versatility in the analysis of nucleotide sequences. For 
example, high-density oligonucleotide microarrays employ a dual probe 
system whereby one probe is designed to include a single “mismatched” 
nucleotide at the centre of the probe in comparison to the “perfect match” 
paired-probe. This serves as an internal control for hybridisation estimation 
and improves the accuracy of the system 110. Elsewhere, microarray 
technology has been adapted to investigate protein-binding DNA-
sequences by chromatin immunoprecipitation (ChIP) (a process more 
commonly known as ChIP-chip) 111, epigenetic studies 112, and 
quantification of non-coding RNA such as microRNA 113.  
Although microarrays are a well-established and relatively inexpensive 
technology, they do present several limitations. For example, a priori 
knowledge of probe sequences is required to quantify expression levels of 
known gene transcripts, such that quantification of novel transcripts is not 
possible. Additionally, non-specific hybridisation of sequences to partially 
complementary probes increases the inherent background noise of a 
microarray experiment affecting the quantification accuracy 114. 
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Furthermore since hybridisation efficiencies can differ between probes, 
comparison of hybridisation results of different probes within a single 
experiment may not be as accurate as comparison of results for a single 
probe across multiple experiments 115. Importantly, since quantification of 
probe hybridisation relies on an analogue measurement of fluorescence, 
the dynamic range of quantification is often limited to a few orders of 
magnitude, meaning that sequences present in low abundance are poorly 
defined whilst measurements of sequences with extremely high abundance 
can often become saturated 107. 
 
1.5.2 RNA-Seq 
Sequencing of RNA molecules using modern, so called “next generation” 
sequencing technology platforms (RNA-Seq) has, in recent years grown in 
popularity. Upwards of millions of fragments of DNA or RNA are 
sequenced in parallel using precise sequencing chemistry. Following 
sequencing, the use of powerful bioinformatic techniques enables the 
researcher to determine where each of the millions of reads originated 
from within the genome. This in turn builds up a density profile of mapped 
reads which, when cross-referenced with known gene locations can give a 
digital representation of the transcript abundance in the original sample for 
each gene.  The rapid increase in speed and capacity, coupled with a 
dramatic decrease in cost has led to RNA-Seq superseding microarrays as 
the principal technology in transcriptomics. RNA-Seq offers several 
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advantages over microarray technology. Firstly, unlike microarray-based 
technologies, RNA-Seq is not limited to detecting transcripts that 
correspond to previously known sequences, making it suitable for studies 
involving non-model organisms 107. Secondly, RNA-Seq has a much higher 
dynamic range of detection than microarrays, (shown to be approximately 5 
orders of magnitude) 116- meaning that low and highly expressed transcripts 
are equally well detected.  
However, the greatest advantage of RNA-Seq technology over microarrays 
is the variety of data available from a single experiment. For example, 
quantification of gene expression of both coding 117 and non-coding RNA 
populations 118, splice-variant usage 119, single nucleotide polymorphism 
(SNP) discovery and allele specific expression 120 can all be extracted from 
the raw data of a single RNA-Seq experiment. Conversely, to gather such 
information using microarrays would require multiple bespoke arrays 
independently analysed, resulting in much higher costs and the 
introduction of unwanted technical variance. 
 
1.5.3 Next generation sequencing 
Inasmuch as Sanger sequencing is regarded as the first generation of 
sequencing technology, the 3 sequencing platforms provided by Roche 
(454 sequencing), Applied Biosystems’ Sequencing by Oligonucleotide 
Ligation and Detection (SOLiD) and Illumina (Genome analyser I/II and 
HiSeq) represent the first iteration of the 2nd generation sequencers (also 
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known as next generation sequencing – NGS). Each were developed and 
released to market within months of each other but crucially, differed in 
their underlying mechanisms and sequencing chemistry. However, in the 
most simplistic terms, each of the technologies rely on the addition of 
deoxynucleotides (dNTPs) to a template DNA strand complementary to the 
DNA sequence fragment being sequenced, the platforms differ in their 
method of measurement and quantification of this addition. A short 
summary of the 3 platforms is detailed below. 
1.5.3.1 Library preparation 
Prior to sequencing by any of the sequencing platforms, sample DNA/RNA 
is subject to several preparation steps eventually producing a library of 
read fragments. Although, the specifics of each step are subtly different 
dependent on the eventual sequencing platform – for example read 
lengths differ greatly between sequencing platforms – the processes are 
largely similar.  
1.5.3.2 RNA enrichment 
The first step in processing an RNA sample is to enrich the population of 
RNA to be sequenced from a sample of total RNA, for example the mRNA 
transcripts or the microRNA population. This improves signal strength and 
avoids unnecessary sequencing of unwanted transcript populations. For 
standard RNA-Seq experiments enrichment can be achieved in a number of 
ways: 
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a) Terminator exonuclease treatment 
Treatment of total RNA with a terminator exonuclease results in the 
removal of sequences without a 5’-cap, a physical feature of mRNA 
transcripts but not non-coding RNA (ncRNA). Thus ribosomal RNA (rRNA), 
tRNA and microRNA populations are depleted. 
b) Ribosomal RNA depletion 
Ribosomal RNA accounts for approximately 80% of a total RNA sample 121, 
hence strategies to deplete ribosomal RNA can efficiently enrich the 
remaining populations. This method is particular popular in studies that 
wish to quantify the microRNA populations – such as piwi-interacting RNA 
(piRNA) or small nucleolar RNA (snoRNA) – in addition to mRNA transcripts. 
c) Duplex-specific-nuclease (DSN) 
Enrichment and normalisation of low abundant transcripts within a 
population can be achieved by DSN treatment. DSN is a nuclease originally 
found in the Kamchatka crab Paralithodes camtschaticus 122. The nuclease 
digests double-stranded DNA (dsDNA) with high specificity. During library 
preparation, following conversion of RNA to dsDNA (see later section for 
more details of library preparation) the sample is briefly denatured and 
then incompletely re-natured and DSN digested. Sequences which are 
highly abundant anneal more rapidly than less abundant sequences, thus 
digestion with DSN enriches low abundant transcripts and removes the 
most  highly abundant population such as rRNA and transferRNA (tRNA) 122. 
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d) Poly-adenylated (Poly-A) tail selection. 
In addition to a 5’-cap, mature mRNA transcripts feature a poly-A tail. This 
feature can be exploited by magnetic bead selection to positively select 
the mRNA population from a total-RNA sample. This method provides the 
most effective way of enriching mRNA transcripts and is the most widely 
used technique for sample enrichment. However, final yield of mRNA can 
be affected by this enrichment method, in particular if the RNA sample is 
degraded since Poly-A tail integrity is most likely to be affected during 
RNA degradation 123 
 
If the sample purity is of great importance and enough total RNA is 
available a combination of the above treatments can be carried out to 
increase purity – albeit at the cost of a lower yield of enriched sample 117. 
The effect of these different treatments on the eventual sensitivity of the 
sequencing experiment is non-trivial and in addition to affecting which 
transcripts are detected in a sample, can also influence the amount of reads 
that ultimately map to intronic regions of the genome, since the population 
of immature mRNA (which still contain intron sequences) can be more- or 
less-enriched by the above treatments 124. 
1.5.3.3 Fragmentation and cDNA conversion 
Enriched RNA is subsequently converted into complementary DNA (cDNA) 
by reverse transcriptase and fragmented, typically by DNAse I treatment or 
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sonication 107. Fragment lengths are dependent on the sequencing 
platform being used but can vary between 35 and 700 nucleotides long. 
1.5.3.4 Adapter ligation and amplification 
Single strands of cDNA are synthesised into double stranded cDNA, 
treated to generate blunt ends of sequences, and adapter sequences are 
ligated to both ends to aid in downstream sequencing protocols. Similar to 
read lengths, the size and sequence of the adapter sequences are both 
platform-specific. Finally sequences are amplified by PCR and fragments 
are size-selected by gel extraction. 
 
1.5.4 Roche 454 sequencing 
The 454 sequencing platform employs a “sequencing by synthesis” 
approach, quantifying the incorporation of dNTPs to a DNA template by 
the indirect measurement of pyrophosphate (PPi) release (Fig 1.3). Sample 
DNA is amplified, fragmented and hybridised with a sequencing primer in a 
reaction volume. Subsequently, each of the 4 dNTPs (adenine, guanine, 
cytosine or thymine) are added sequentially to the reaction mix. DNA 
polymerase catalyses the addition of a complementary dNTP to the 
template strand resulting in the release of PPi (which is proportional to the 
amount of nucleotide incorporation). The presence of ATP sulfurylase and 
adenosine 5´ phosphosulfate (APS) in the reaction volume results in the 
conversion of PPi to ATP. The ATP can then drive a luciferase-mediated 
conversion of luciferin to oxyluciferin, a reaction that generates visible light 
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proportionally to the amount of ATP generated – which can be measured in 
real-time. Finally the addition of a nucleotide-degrading enzyme - apyrase, 
removes any unincorporated dNTPs in preparation for a subsequent cycle 
of dNTP addition. Progressive iterations of nucleotide incorporation allows 
single-nucleotide resolution sequencing of reads by measurement of the 
signal peaks produced during addition 125.  
The 454 platform produces the largest sequence reads of any of the 3 
platforms discussed (200-700 nucleotides long). This is of great importance 
for downstream quantification of sequence reads, either when mapping 
reads to a reference genome or using reads for de novo assembly of a 
genome where a reference sequence is not available, for example in non-
model organisms. The larger reads make the assembly process much less 
computationally demanding and require much less sequencing depth than 
would be necessary with much shorter reads 126. However, since dNTPs are 
added sequentially, sequences with areas of successive nucleotides 
(homopolymers) are poorly quantified and subject to sequencing errors 125. 
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Fig	   1.3	  A	  schematic	   representation	  of	  Roche’s	  454	  sequencing	   technology.	  dNTPs	  are	  
sequentially	   added	   to	   a	   reaction	   volume	   containing	   millions	   of	   copies	   of	   target	  
sequence	   with	   annealed	   sequencing	   primer.	   (i)	   DNA	   polymerase	   catalyses	   the	  
elongation	  of	   the	  sequencing	  primer.	   (ii)	   incorporation	  of	  a	  nucleotide	   results	   in	   the	  
release	  of	  pyrophosphate	  (PPi).	  (iii)	  PPi	  and	  APS	  are	  converted	  to	  ATP	  by	  the	  actions	  
of	   Sulfurylase.	   (iv)	   Luciferase	   and	   ATP	   catalyse	   the	   conversion	   of	   luciferin	   to	  
oxyluciferin	   which	   produces	   light	   in	   the	   visible	   range.	   Detection	   of	   light	   produced	  
allows	  quantification	  of	  nucleotide	  addition.	  Adapted	  from	  127,128.	  
	  
 
1.5.5 I l lumina sequencing (Genome analyser I/ I I  and HiSeq)  
Illumina sequencing technology makes use of reversible dye terminators to 
sequentially measure each nucleotide position by measurement of 
fluorescent emission (Fig 1.4). As with pyrosequencing, sample RNA is 
enriched, fragmented and adapter sequences ligated. However, sequences 
are attached  to a glass slide by their adapter sequences and amplified in 
situ in a process called bridge amplification 129, this increases the platforms 
throughput capacity over other platforms 130. A primer sequence is 
annealed to fragment reads and sequencing proceeds in a single base 
P 
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synthesis fashion. Unlike pyrosequencing, all four dNTP types are added 
together during sequencing cycles to ensure competitive binding of 
nucleotides –  this increases sequencing accuracy of homopolymers . Each 
of the 4 dNTPs are modified to include a terminating group which inhibits 
sequence extension and are labelled with a different dye for identification. 
During each cycle, (due to the terminating group) a single nucleotide is 
incorporated to the primer sequence. Following the incorporation of a 
dNTP the remaining unincorporated nucleotides are washed away and the 
newly incorporated nucleotide identity is determined by laser excitation of 
the dye. Both the terminating group and labelled dye are cleaved from 
incorporated nucleotide and the cycle is repeated for the addition of the 
next nucleotide. Extension of template sequence continues for the entire 
length of sequence read.  
The entire process is carried out on an 8-lane flow cell, which enables 
massively-parallel sequencing of millions of reads 131. 
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Fig	   1.4	   Schematic	   representation	   of	   Illumina	   sequencing	   technology.	   (A)	   Target	  
sequence	   is	   attached	   to	   flow-­‐cell	   and	   sequencing	   primer	   is	   annealed.	   (B)	   DNA	  
polymerase	   catalyses	   the	   addition	   of	   1	   of	   4	   possible	   dNTPs.	   Incorporated	   dNTP	   is	  
identified	  by	  laser	  excitation.	  (C)	  Terminating	  group	  and	  dye	  portion	  is	  removed	  from	  
incorporated	  dNTP	  and	  the	  process	  is	  repeated	  for	  full	  length	  of	  target	  sequence.	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1.5.6 SOLiD™ sequencing by Applied Biosciences 
Similarly to the Illumina platform, the SOLiD™ sequencing platform 
sequences millions of fragmented reads in parallel on a flow cell following a 
standard set of read library preparation steps (enrichment, fragmentation, 
conversion to cDNA, adapter ligation and size selection). However, the 
SOLiD™ platform has several features which distinguish it from both the 
Illumina and 454 platforms. Firstly, unique read fragments are attached to a 
micro-bead (approximately 1 µm in diameter) and amplified by PCR (in a 
process known as emulsion-PCR) to produce a monoclonal bead with 
thousands of identical reads attached to it, this amplifies the signal when 
detecting nucleotide additions during sequencing. The beads are 
subsequently attached to the flow cell for sequencing 129. Secondly, rather 
than employing a polymerase for template extension, the SOLiD™ 
platform relies upon ligation of labelled probes for strand extension 132. 
Thirdly, raw sequencing data is encoded using a “colorspace” encoding 
system which increases accuracy of base calling by deciphering between 
sequencing errors and legitimate SNP events in the read fragments 133,134. 
 
1.5.6.1 Di-base probes 
Rather than the sequential addition of single dNTPs by a polymerase as 
seen in the 454 and Illumina platforms, the SOLiD™ platform uses a 
“sequencing by ligation” approach whereby fluorescently labelled di-base 
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probes are ligated to the primer strand by the enzyme ligase 131. Probes are 
8 nucleotides long and are labelled with one of 4 fluorescent dyes. The 
sequences of the probes differ in the first two bases of the 3’ end, thus 
each possible combination of two bases is represented by 16 different 
probes (4 probes of each colour). The remaining portion of the probe is 
made up of random hexamers. For each di-base, the reverse sequence (for 
example CA and AC), the complementary sequence (for example CA and 
GT) and the reverse complementary sequence (for example CA and TG) are 
always represented by the same colour (Fig 1.5).  
 
 
Fig	   1.5	   Representation	   of	   the	   2	   base	   colorspace	   encoding	   system	   employed	   by	   the	  
SOLiD™	  sequencing	  platform	  di-­‐base	  probes.	  Each	  of	  the	  16	  different	  combinations	  of	  
2	   bases	   are	   represented	   by	   one	   of	   4	   colours.	   Pairs	   of	   the	   same	   colour	   are	   either	  
reversed,	  complementary	  or	  reversed-­‐complementary	  of	  each	  other.	  Adapted	  from	  135.	  
 
1.5.6.2 SOLiD™ sequencing steps  
Sequencing begins with the ligation of di-base probes to the primer 
sequence under competitive conditions (all 16 possible probes are present) 
(Fig 1.6A). Following ligation, sequences are imaged and the fluorophore 
portion of probe is removed such that a 5 nucleotide portion is 
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incorporated into primer sequence. The process is repeated for the entire 
length of the sequence fragment (Fig 1.6B) (for example a 35 nucleotide 
sequence fragment requires 7 ligation cycles). Since only information on 2 
nucleotides of each probe is available, only 2 in every 5 nucleotides in a 
sequence-fragment are interrogated per ligation cycle (Fig 1.7). 
Furthermore, since each colour probe relates to one of 4 possible 
nucleotide pairings, it is not possible to determine the base sequence from 
a single interrogation. Thus, following ligation cycles, the newly extended 
primer sequence (and primer) are removed and a new primer sequence is 
added which is offset by 1 nucleototide (n-1) (Fig 1.6C). Ligation cycles are 
repeated for new primer round and a further 3 primer rounds (n-2,n-3 and 
n-4) (Fig 1.6D). Following a total of 5 primer rounds, each nucleotide will 
have been interrogated twice on two separate primer rounds (Fig 1.7), 
providing sufficient information to decode the sequencing information from 
colorspace into basespace (raw nucleotide information).  
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Fig	  1.6	  SOLiD	  sequencing	  methods.	  A)	  Read	  library-­‐fragments	  are	  attached	  to	  a	  micro-­‐
bead	   and	   annealed	  with	   a	   primer	   sequence	   in	   preparation	   for	   sequencing.	   B)	   16	   Di-­‐
base	   probes	   labelled	   with	   one	   of	   4	   coloured	   dyes	   competitively	   bind	   to	   primer	  
sequence	   extending	   template	   strand,	   ligation	   catalysed	   by	   ligase	   enzyme.	   Di-­‐base	  
probe	   incorporation	   is	   imaged	   by	   laser	   excitation.	   Fluorophore	   portion	   of	   probe	   is	  
removed	  and	  process	  of	  probe	  ligation	  is	  repeated	  for	  entire	  length	  of	  read-­‐fragment.	  
C)	  Newly	  formed	  extended	  sequence	  is	  removed	  and	  primer	  sequence	  is	  reset	  using	  a	  1	  
nucleotide	   shorter	   primer	   (n-­‐1).	   D)	   Probe	   incorporation	   steps	   are	   repeated	   for	   4	  
additional	  primer	  rounds.	  Adapted	  from	  135.	  
 
 
 
Fig	  1.7	  Representation	  of	  the	  dual	  interrogation	  of	  read	  positions	  by	  multiple	  ligation	  
cycles	  and	  primer	  rounds	   in	  SOLiD	  sequencing	  platform.	  Di-­‐base	  probe	   incorporation	  
during	   SOLiD	   sequencing	   extends	   a	   primer	   sequence	   by	   5	   bases	   at	   a	   time,	  
interrogating	   the	   first	   two	  bases	  on	   each	   cycle.	  Multiple	   ligation	   and	  primer	   rounds	  
result	   in	   each	   read	   position	   being	   measured	   twice	   on	   separate	   primer	   rounds.	  
Colorspace	   encoded	   information	   can	   them	   be	   used	   to	   accurately	   determine	   the	  
original	  nucleotide	  sequence.	  	  	  Adapted	  from	  135.	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1.5.6.3 Colorspace 
The bioinformatic advantage of the colorspace encoding system is two-
fold. Firstly, having each read position interrogated twice improves the 
accuracy of base calling. Secondly, since each read position is represented 
by two colours, if an appropriate reference sequence is available, 
colorspace encoding system provides a means to distinguish between 
sequencing errors and true single nucleotide polymorphisms (SNPs) that 
may exist between the reference sequence and the sample sequence. For 
example, due to the structure of the encoding system, SNPs are identified 
by both colours of a particular read position differing from the reference 
sequence, whereas a sequencing error would result in a single change in 
colour to the reference (Fig 1.8) 136. 
 
Fig	   1.8	   Example	   of	   colorspace	   encoding	   in	   the	   SOLiD™	   platform.	   Encoding	   enables	  
downstream	   identification	   of	   valid	   single	   nucleotide	   polymorphisms	   (SNP)	   or	  
sequencing	  errors.	  There	  are	  3	  possible	  single	  nucleotide	  polymorphism	  of	  the	  central	  
nucleotide	   in	   a	   3	   nucleotide	   codon,	   each	   change	   results	   in	   a	   two	   colour	   change	   in	  
colorspace.	  Conversely,	  an	  error	  in	  sequencing	  would	  cause	  a	  single	  change	  in	  colour	  
and	   consequently	   a	   change	   in	   2	   nucleotides	   when	   converted	   back	   to	   basespace.	  
Adapted	  from	  135.	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1.5.7 Indexing/barcoding 
An added benefit of all of the above technologies is the ability to “index” 
read fragments (also known as barcoding). Since the adapter sequences 
can be modified to include an additional bespoke sequence (usually 6-10 
nucleotides long), read fragments from a common RNA sample can be 
indexed. This means that up to 96 RNA samples from separate 
experiments, time points or even organisms can be run in parallel on the 
same flow chip without losing information on which sample the reads 
originated from, the raw sequencing data is re-grouped into sample data 
sets following sequencing129,137. 
 
1.5.8 Paired-end sequencing  
An alternative approach to sequencing a read library which is available on 
each of the discussed platforms is paired-end sequencing. Rather than 
sequencing a read in a single direction as per single-end sequencing. 
Paired-end sequencing incorporates an additional sequencing step 
initiated at the opposite end of the read, thus two portions of the same 
fragment are sequenced in opposite directions. The benefit of this 
approach is not only the additional information that can be collected from 
a single sequencing run but that since both portions of sequencing data 
are known to originate from the same read fragment this information can 
be used to more accurately map both reads to the reference genome in 
the bioinformatic mapping stage. For example a short read containing an 
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area of nucleotide repetition may map to multiple areas of the genome 
due to its low sequence complexity. However, paired reads originating 
from the same area of the genome which are separated by an estimated 
distance are much less likely to map to multiple genome locations and are 
therefore much easier to assign a mapping location. Variations of paired 
end sequencing include mate-pair sequencing where two portions of a 
single read are sequenced in the same direction and the resulting distance 
between mate-pairs is much larger (2k-5k nucleotides) 104. 
 
1.5.9 Future generation sequencing 
The fundamental mechanics of each of the 3 platforms described above 
have not been altered in almost a decade. Constant development of the 
technology has meant that successive iterations of the hardware and 
software in each platform have seen improvements in sequencing speed, 
capacity and accuracy and a reduction in costs of both the sequencing 
machinery and biological reagents. However, future generations of 
sequencing technology are emerging and could provide a significant 
increase in speed and usability such that whole genome sequencers could 
become more commonplace in the laboratory or clinical environment. For 
example nanopore-technology is a method of sequencing a strand of DNA 
or RNA by passing it through a nanopore where an electrical current exists 
across the pore. As individual bases pass through the pore they can be 
identified by the amount to which they disrupt the current across the pore 
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101,138. Alternatively, Pacific Biosciences technology employs nucleotides 
which are fluorescently labelled on their phosphate group. Using nano-
visualisation chambers known as zero mode waveguides (ZMWs) which 
have a volume of 20 zeptolitres (10-21 litre), the incorporation of nucleotides 
can be detected against the high background signal of surrounding 
unincorporated nucleotides 128. The advantage of both these systems is 
that nucleotide incorporation or movement across a nano-pore can be 
measured without the need for interruption, thus sequencing can be 
measured in real time with the only limiting factor being the rate at which a 
DNA/RNA polymerase can operate 139. The successful development of a 3rd 
generation of sequencers will decrease the amount of time taken to 
sequence a human genome to a matter of minutes rather than days 140. 
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1.6 Bioinformatic software 
The primary function of any high-throughput sequencing technology is to 
turn a biological sample of DNA or RNA into digital data. A single 
sequencing run can produce upwards of 60GB of raw data 141 which, when 
typed equates to approximately 22x106 sheets of A4 paper (size 12 font, 
single line spacing). In addition to being computationally demanding due 
to its size, data from a next generation sequencing platform is also 
produced in a raw format. Following a sequencing run, data is filtered to 
remove incomplete reads and adapter sequences. Indexed data can be 
separated into sample-associated sets, finally, the raw data is then collated 
into a single file (or pair of files dependent on sequencing platform) 
containing only the read data and an accompanying quality value for each 
read position. Thus, a raw data file from a single sample in an RNA-Seq 
experiment may simply contain > 40x106 lines of data each 50 characters 
long (for a 50bp single-end experiment).  
For RNA-Seq data, several computational processes are required to extract 
meaningful data from the raw dataset produced by a next generation 
sequencer. These include: assembly of transcriptome, read mapping to 
reference sequence and expression quantification. Each process requires a 
specific set of software which often allows running parameters to be 
manually altered to improve performance depending on the type of input 
data provided and/or output data required.  
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1.6.1 Transcriptome assembly 
If an adequate reference sequence is not available (for example in 
transcriptome studies using non-model organisms), quantification of gene 
expression can be achieved by de novo assembly of a transcriptome using 
sequenced reads. Successful assembly relies on sufficient depth of 
coverage from sequence reads and is aided by larger read lengths such as 
those produced by the 454 platform. Software programs such as Trinity 142, 
Trans-ABySS 143 and Rnnotator 144 are able to de novo assemble 
transcriptomes using RNA-Seq data, whilst software such as Cufflinks 145, 
Scripture 146 and ERANGE 116  are able to use a reference sequence to  
build upon in a process known as ab initio assembly 147. The use of either 
de novo or ab initio assembled transcriptomes provides a way of 
identifying and quantifying novel transcripts that may be present in a cell 
specific manner. 
 
1.6.2 Read mapping 
Quantification of raw sequence data begins with the process of mapping 
reads back to a reference sequence (also known as read alignment). 
Mapping involves the determination of genomic origin for each read within 
a dataset 148. Reads can be mapped to a reference genome or 
transcriptome sequence. Mapping to a genome sequence provides a more 
comprehensive quantification of reads since reads which map (either 
partially or entirely) to non-coding areas (for example intronic regions) are 
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also quantified. Ideally, mapping of reads would result in the assignment of 
each raw read to a single location within the reference sequence producing 
a mapping profile which can be transformed into an expression profile for 
each location (based on the number of reads which are assigned to that 
location). However, in reality, several factors impact the level of mapping 
achievable. Firstly, the reference sequence is often not a perfect 
representation of the biological source of RNA that was sequenced. For 
example, sample (or cell-specific) SNPs and insertion-deletion events 
(indels) represent areas of variation between samples which cannot be 
represented by a ubiquitous reference sequence. De novo assembly of a 
reference sequence using raw reads can limit this level of inherent variation 
but often requires a much greater read-depth coverage, ultimately 
increasing the overall cost of a sequencing experiment for very little added 
accuracy 149. Secondly, the use of sequencing platforms which produce 
relatively short reads (35-50bp) such as SOLiD™ or Illumina increases the 
chances of reads mapping to multiple locations, in particular for areas of 
high repetition 107. Thirdly, high levels of sequencing errors (as might be 
expected from low integrity RNA samples) can heavily impact the mapping 
rates 150. Thus, the percentage of reads mapped during the mapping 
process can inform on both the success of the sequencing experiment and 
original quality of the RNA sample.  
Mapping software programs take a raw sequencing file (such as a .fastq or 
a .csfasta for colorspace reads) as input, and where necessary an 
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accompanying quality file (.qual). Often the reference sequence to be used 
for mapping against will be heavily indexed by the mapping software prior 
to a mapping run such that the large volume of data included in a 
reference genome (or transcriptome) can be computationally managed, 
ultimately this makes the mapping process much quicker and decreases the 
amount of random access memory (RAM) required by the software. Reads 
are aligned to the reference sequence based on their entire sequence but 
often, to increase mapping speed, a small portion of the read (known as 
the seed) is used to initially map the read to a number of locations, once 
the seed sequence is aligned, the remaining portion of the read is aligned 
and the number of possible mapping locations decreased. Mapping builds 
up a profile of alignments against the reference sequence that can 
subsequently be quantified by downstream software (Fig 1.9A-B). When 
mapping to a reference genome reads that align entirely within transcribed 
portions of the genome (that is, exons) will be mapped easily by any 
mapping software. However, reads that originate from transcripts that were 
subject to splicing events are much harder to align to a reference genome. 
Indeed, for several mapping programs – such as Bowtie 151, Burrows-
Wheeler alignment tool (BWA) 152 and short oligonucleotide alignment 
program (SOAP) 153 – reads  relating to spliced transcripts will fail to map to 
a reference genome, thereby reducing the overall percentage of reads 
mapped (Fig 1.9C). To avoid this, several mappers have been designed to 
be able to handle reads that span splice junctions (Fig 1.9D), these 
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programs include Blat 154, Tophat 155, GSNAP 156, SpliceMap 157 and 
MapSplice 147,158. 
 
 
	  
	  
Fig	  1.9.	  Schematic	  representation	  of	  read	  mapping	  of	  NGS	  data.	  A)	  Read	  fragments	  and	  
reference	   sequence	   are	   provided	   to	   mapping	   software.	   B)	   Reads	   are	   aligned	   to	  
reference	  sequence	  to	  produce	  a	  virtual	  alignment	  profile.	  C)	  Within	  a	  read	  library,	  a	  
proportion	   of	   the	   reads	   will	   originate	   from	   spliced	   transcripts,	   standard	   mapping	  
software	   will	   fail	   to	   align	   reads	   that	   span	   splice	   junctions.	   D)	   Specialized	   mapping	  
software	   such	   as	   Tophat	   155	   can	   align	   read	   portions	   independently	   thus	   allowing	  
mapping	  of	  reads	  that	  span	  splice	  junctions. 
 
 
Of the multiple different mapping software packages available, many 
employ different mathematical algorithms when aligning reads. This 
variation in software is highlighted by the vast difference in speed and 
accuracy achievable by each of the mappers. For example, a comparison in 
2011 of the most commonly used mappers available revealed that the 
percentage reads mapped ranged from 17.7% - 88.7% and time taken 
varied between 1.5 h – 145 h amongst 8 different mappers – despite each 
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software being provided with identical raw data 148.   A common feature of 
most mapping software is the ability to manually alter the mapping 
parameters and levels of confidence in aligning reads. For example, the 
number of allowed mismatched bases between reads and reference in a 
valid alignment or the number of multiple mapping locations permissible 
before excluding a read from alignment can both be altered to increase the 
number of reads mapped – often at the cost of accuracy 155. 
 
1.6.3 Expression quantif ication 
Following mapping, reads must be annotated and assigned to a 
biologically meaningful unit for example, exons, transcripts or genes. Since 
mapping of reads produces a set of genomic (or transcriptomic) 
coordinates for each read, annotation is reliant on a suitable set of 
reference coordinates relating to the genomic feature to which the reads 
are to be quantified. For example, the simplest approach is to quantify the 
number of reads that align to known genes within the genome, thereby 
arriving at an expression value for each gene. However, this approach 
makes no allowances for genes that overlap and also eliminates the 
possibility of quantifying novel transcripts. Alternatively, each exon can be 
quantified independently, allowing for quantification of: whole genes (by 
aggregation of exon expressions); exons, or individual splice variants of a 
specific gene. The choice of software for quantification and annotation is 
therefore crucial to the type of quantification required. 
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1.6.3.1 Sequence alignment map (SAM file) 
The output file produced from the previously described 
mapping/alignment software is predominantly a sequence alignment map 
(.sam file) or an equivalent binary version (.bam). Both of these file types 
are compatible with most annotation/quantification software. Sam/bam 
files contain information on: sequenced reads, including quality values for 
each base position; alignment information, such as the number of locations 
a read aligned to in the reference sequence; and number of mismatches 
and/or indels within read sequence (compared to reference sequence 
provided during mapping stage). 
1.6.3.2 Count-based quantification 
Broadly, there are two popular approaches to quantifying RNA-Seq data, 
the first of these is count based quantification. Software programs such as 
edgeR 159, DESeq 160 and DEGSeq 161 quantify the number of reads which 
align to any portion of a genes within a reference sequence (including 
intronic and untranslated regions). This number is then normalised to the 
size of the entire read library for that sample, such that values for a single 
gene can be compared between separate samples. This method of 
quantification is often used for broad analysis of differential expression of 
genes since no calculations of individual exons are made 162. However, 
since reads are only normalised to their library size, no allowance is made 
for the size of each gene. For example, given two hypothetical genes 
(Gene A and Gene B), assuming Gene B was twice as long as Gene A, and 
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both genes had equal expression within a sample, Gene B would have 
twice as many reads mapping to it due to its size alone. Consequently, 
count based quantification would incorrectly identify Gene B as having 
double the expression value of Gene A. Thus, direct comparison of 
expression values for two genes within the same sample set is not 
achievable using the count based approach.  
1.6.3.3 Fragment-based quantification  
Alternatively, the software program Cufflinks 145 is able to quantify 
expression values for individual exons of a transcripts, based on a set of 
splice locations provided to the software or by de novo discovery of 
alternative spice junctions during mapping stage. Consequently, due to 
individual quantification each exon of a gene, in addition to gene 
expression analysis, Cufflinks can be used to quantify expression of 
alternative isoforms of genes and novel transcripts. However, since 
alternative isoforms of a gene often share large portions of common 
sequence, quantification is achieved using a high degree of statistical 
assumption and modelling of the variation within a single transcript 149. 
1.6.3.4 Reads per kilobase of exon model per million mapped reads 
(RPKM) 
Importantly, Cufflinks employs an additional normalisation step and 
produces the expression metric, reads per kilobase of exon model per 
million mapped reads (RPKM) 116, which is defined as: 
 
76	  
	  
 
RPKM	  	  =	  	  	  	  	  	  	  	  	   	  	  No.	  of	  mapped	  reads	  x	  1	  kilobase	  x	  1	  million	  mapped	  reads	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Length	  of	  transcript	  x	  No.	  of	  total	  reads	  	  
	  
 
Therefore, in addition to normalising to the total number of reads in each 
sample, RPKM is also normalised to the size of the transcript. This means 
that expression values for two genes within the same sample can be 
compared. Equally, expression of a single gene in multiple separate 
experiments can be compared. 
1.6.4 Differential expression testing 
Following quantification of gene expression by either count-based or 
RPKM-based techniques, a variety of statistical tests can be performed 
between multiple data sets to determine if genes are differentially 
expressed (DE) between samples. Each of the software programs available 
for annotation and quantification of gene expressions provide a method of 
determining DE genes, but vary in the way the data is modelled. Cufflinks 
used a negative binomial distribution to model the data for differential 
analysis whereas several of the count based software programs use a 
Poisson distribution (for example edgeR, DEGSeq and DESeq). Whilst the 
distribution of read fragments across a genome in distinct locations (genes) 
can be thought of as a Poisson distribution a negative binomial modelling 
is considered more appropriate when modelling variation that arises from 
multiple biological replicates since Poisson-based analyses are prone to 
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high levels of false positives due to an underestimation of the biological 
variance 149,163. 
1.6.4.1 False discovery rate 
The traditional threshold for significance in a biological experiment is p< 
0.05 – that is, there is less than a 5% chance of the observed quanta 
occurring by chance alone. When dealing with a large number of variable 
such as during a global gene expression analysis, this threshold no longer 
provides a satisfactory measure of significance. For example, if comparing 
the expression values for every gene in the human genome (approximately 
23,000 genes) for genes that are DE between two samples, using a p< 0.05 
would result in > 1000 genes being false positives. Hence, it is more 
appropriate with transcriptome and genomic studies to use a transformed 
p-value (known as a q-value) which applies a false discovery rate (FDR) of 
5% to the data. Therefore, q< 0.05 implies that there is less than 5% 
chance the gene(s) in question are differentially expressed by chance alone 
allowing for a 5% false discovery rate. FDR is controlled by Benjamini-
Hochberg correction 164. 
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1.7 Summary 
Neutrophils play a key role in host defence via a number of evolutionarily 
conserved anti-microbial mechanisms2,23,165. Rather than acting merely as a 
front-line defensive cell, neutrophils are now recognised as central to the 
inflammatory response through the production of several inflammatory 
mediators regulating both the innate and adaptive immune systems 5. The 
global molecular changes that underlie neutrophil priming and immune 
regulation are poorly defined, yet represent an attractive area of research 
to fully elucidate the role and regulatory capacity of neutrophils during the 
immune response. The speed, accuracy, and robust nature of RNA-Seq as a 
quantification platform, and the ability to extract data relating to multiple 
genetic features from a single sequencing experiment have all contributed 
to RNA-Seq superseding micro-array analysis as the gold-standard method 
of transcriptome analysis. However, a global approach to analyse 
neutrophil gene expression using RNA-Seq has yet to be undertaken. A 
greater understanding of the molecular properties of both quiescent and 
primed neutrophils will not only expand our knowledge of neutrophil 
biology but will inform on how neutrophils contribute to many inflammatory 
diseases, ultimately providing new areas of research into neutrophil 
regulation in health and disease. 
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1.8 Hypothesis and aims 
The hypothesis that this project sought to test was:  
 
Different cytokines lead to changes in neutrophil phenotype, but do so via 
different signalling pathways that lead to the switching on or off of different 
sets of genes. 
 
The aims of this project were to: 
 
1. Develop and define a robust pipeline of bioinformatic software 
programs and protocols to accurately quantify and analyse the 
neutrophil transcriptome under conditions of simulated 
inflammation by in vitro stimulation. 
 
2. Quantify the changes in gene expression in neutrophils following 
priming with inflammatory cytokines. 
 
3. Identify changes in gene expression profiles between neutrophils 
stimulated with different inflammatory mediators. 
 
4 .  Analyse the effects of neutrophil isolation methods and neutrophil 
purity on gene expression and function. 	  
80	  
	  
Chapter	   2:	   Materials	   and	  
Methods	  
2.1 Materials 
	  
Table	  2.1	  Cell	  isolation	  and	  culture 
Cell	  isolation	  and	  culture	  
Materials	   Supplier	  
Lithium	  heparin	  vacuette	  	   Greiner	   Bio-­‐one,	   Thermo	   Fisher	  
Scientific	  (Gloucestershire,	  UK)	  Safety	  butterfly	  needles	  
RPMI	  1640	  (+	  25mM	  HEPES	  with	  L-­‐
glutamine)	   Gibco,	   Life	   technologies	   (Paisley,	  
UK)	  Dulbecco’s	   phosphate	   buffered	  
saline	  
Polymorphprep	  ™	   Axis-­‐shield	  (Cambridge,	  UK)	  
Isoton	  diluent	   Beckman	  Coulter	  Inc.	  
Ammonium	  Chloride	  lysis	  buffer	  
- Ammonium	  Chloride	  (NH4Cl)	  
- Potassium	  hydrogen	  carbonate	  
(KHCO3)	  
- Ethylenediaminetraacetic	  acid	  
(EDTA)	  
Sigma	  (Poole,	  UK)	  
Foetal	  bovine	  serum	   Invitrogen,	   Life	   technologies	  (Paisley,	  UK)	  
Lymphoprep	  ™	  
Stemcell	   technologies	   (Grenoble,	  
France)	  
EasySep®	   Human	   Neutrophil	  
enrichment	  kit	  
HetaSep®	  
Rapid	  Romanowsky	  stain	   HD	  Supplies	  (Aylesbury,	  UK)	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Human	  AB	  serum	  
Sigma	  (Poole,	  UK)	  Paraformaldehyde	  (PFA)	  
Dimethyl	  sulphoxide	  (DMSO)	  
	  
	  
Table	  2.2	  Cytokines/chemokines/stimulants/inhibitors	  	  
Cytokines/Chemokines/Stimulants/Inhibitors	  
Materials	   Supplier	  
Recombinant	  human	  G-­‐CSF	  
Sigma	  (Poole,	  UK)	  Recombinant	  human	  IL-­‐6	  
Recombinant	  human	  IL-­‐1β	  
Recombinant	  human	  IL-­‐8	   Invitrogen,	   Life	   technologies	  (Paisley,	  UK)	  
Recombinant	  human	  IL-­‐10	   	  
Recombinant	  human	  IFN-­‐α	  	   	  
Recombinant	  human	  IFN-­‐β	  	   	  
Recombinant	  human	  GM-­‐CSF	   Roche	   diagnostics	   (East	   Sussex,	  
UK)	  Recombinant	  human	  IFN-­‐γ	  
Recombinant	  human	  TNF-­‐α	   Calbiochem	  (Nottingham,	  UK)	  
fMLP	  
Sigma	  (Poole,	  UK)	  
PMA	  
LPS	   Source	   BioScience	   (Nottingham,	  UK)	  
MALP	   Enzo	  Life	  Sciences	  (Exeter,	  UK)	  
JAK-­‐1	  inhibitor	  
Calbiochem	  (Nottingham,	  UK)	  
Wedelolactone	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Table	  2.3	  Primary	  and	  secondary	  antibodies	  
Primary	  and	  Secondary	  antibodies	  
Materials	   Supplier	  
anti-­‐human	  STAT1	  	  (#9175)	  
Cell	  Signalling	  (Massachusetts,	  
USA)	  
anti-­‐human-­‐phosphorylated	  STAT1	  
(#9177)	  
anti-­‐human	  STAT3	  (#9138S)	  
anti-­‐human-­‐phosphorylated	  STAT3	  
(4904P)	  
anti-­‐human	  ERK	  (#9102)	  
anti-­‐human-­‐phosphorylated	  ERK	  
(#9106S)	  
anti-­‐human	  p38	  (#9212)	  
anti-­‐human-­‐phosphorylated	  p38	  
(#9216S)	  
anti-­‐human-­‐AKT	  (#9272)	  
anti-­‐phosphorylated-­‐AKT	  (#4060S)	  
anti-­‐human-­‐IKβα	  (#9242)	  
anti-­‐human-­‐phosphorylated	  NFκβ	  
(#3033S)	  
Rabbit-­‐anti-­‐IL-­‐1β	  (#12703)	  
Mouse	  anti-­‐human	  β-­‐actin	  (#8226)	   Abcam	  (Cambridge,	  UK)	  
Mouse	  anti-­‐human	  GAPDH	  (G8795)	  
Sigma	  (Poole,	  UK)	  HRP-­‐conjugated-­‐sheep	  anti-­‐mouse	  
(A5906)	  
HRP-­‐conjugated	  donkey-­‐anti-­‐rabbit	  
(25005179)	  
GE	  healthcare	  Life	  Sciences	  
(Buckinghamshire,	  UK)	  
FITC-­‐conjugated	  mouse	  anti-­‐human	  
CD11b	  (FAB16991P)	  
R&D	  Biosystems	  (Oxfordshire,	  
UK)	  FITC-­‐conjugated	  mouse	  anti-­‐human	  
CD4	  (FAB3791F)	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FITC-­‐conjugated	  mouse	  anti-­‐human	  
CD15	  (F0830)	  
Dako	  UK	  (Cambridgeshire,	  UK)	  
FITC-­‐conjugated	  mouse	  anti-­‐human	  
CD64	  (FAB12571F)	  
R&D	  Biosystems	  (Oxfordshire,	  
UK)	  
FITC-­‐conjugated	  mouse	  anti-­‐human	  
CD16	  (555406)	  
BD	  Biosiences	  (Oxfordshire,	  UK)	  
FITC-­‐conjugated	  mouse	  anti-­‐human	  
L-­‐Selectin	  (BBA33)	  
R&D	  Biosystems	  (Oxfordshire,	  
UK)	  
FITC-­‐conjugated	  mouse	  anti-­‐human	  
IgGI	  isotype	  (SC-­‐2855)	  
Santa	  cruz	  biotechnology	  
(Heidleberg,	  Germany)	  
	  
	  
Table	  2.4	  Samples	  preparation	  and	  western	  blot 
Sample	  preparation	  and	  western	  blot	  
Materials	   Supplier	  Laemmli	  buffer	  	   -­‐Glycerol	  	   -­‐Sodium	  dodecyl	  sulphate	  (SDS)	  -­‐Tris	  
Thermo	   Fisher	   Scientific	  (Gloucestershire,	  UK)	  
	   -­‐	  Dithiothreitol	  (DTT)	  -­‐Bromophenol	  blue	   Sigma	  (Poole,	  UK)	  Hydrochloric	  acid	  (HCl)	   VWR	   International	  (Leicestershire,	  UK)	  Glycine	  
Sigma	  (Poole,	  UK)	  
Sodium	  Chloride	  Ammonium	  persulphate	  (APS)	  Isopropanol	  Methanol	  Tween-­‐20	  Tetramethylethylenediamine	  (TEMED)	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Sodium	  azide	  Hydrogen	  peroxide	  (H202)	  Whatman	  filter	  paper	  Polyacrylamide	   Geneflow	   (Staffordshire,	  UK)	  (Kiddeminster,	  UK)	  Biotinylated	   protein	   ladder	   detection	  pack	   Cell	   signalling	  (Massachusetts,	  USA)	  BLUeye	  prestained	  protein	  ladder	  	   Geneflow	   (Staffordshire,	  UK)	  Phosphatase	  inhibitor	  cocktail	  II	   Calbiochem	   (Nottingham,	  UK)	  Marvel	   non-­‐fat	   (<	   1%)	   dried	   milk	  powder	   Home	   Bargains	   (Liverpool,	  UK)	  Ponceau	  S	   	  Millipore	   (Hertfordshire,	  UK)	  
Bovine	  serum	  albumin	  Kodak®	   photographic	   Fixer	   and	  Developer	  Immobilon	   Western	  Chemiluminescent	  HRP	  Substrate	  Polyvinylidene	   fluoride	   (PVDF)	  membrane	   	  GE	  Healthcare	  Life	  Sciences	  (Buckinghamshire,	  UK)	  Enhanced	   chemiluminescence	  hyperfilm	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Table	  2.5	  Neutrophil	  chemiluminescence	  and	  apoptosisaa 
Neutrophil	  chemiluminescence	  and	  apoptosis	  	  
Materials	   Supplier	  Hank’s	   balanced	   salt	   solution	  (HBSS)	   Gibco,	   Life	   technologies	  (Paisley,	  UK)	  Luminol	   Sigma	  (Poole,	  UK)	  Propidium	  iodide	  Alexa	   Fluor	   488-­‐conjugated	  Annexin-­‐V	  (#A13201)	   Life	  technologies	  (Paisley,	  UK)	  
	  
	  
Table	  2.6	  RNA	  isolation	  cDNA	  synthesis	  and	  qPCR	  	  
RNA	  isolation,	  cDNA	  synthesis	  and	  qPCR	  materials	  
Materials	   Supplier	  Trizol®	  	   Gibco,	   Life	   technologies	  (Paisley,	  UK)	  Chloroform	   Sigma	  (Poole,	  UK)	  2-­‐Propanol	  (molecular	  grade)	  Ethanol	  (molecular	  grade)	  RNase-­‐free	  DNase	  set	   Qiagen	  (Crawley,	  UK)	  RNeasy	  mini	  kit	  Quantitech	  SYBR	  green	  PCR	  kit	  Superscript	   III	   first	   strand	   cDNA	  synthesis	  kit	   Invitrogen,	   Life	   technologies	  (Paisley,	  UK)	  RNase	  OUT	  Random	  primers	   Promega	  (Southampton,	  UK)	  Specific	  primers	   Eurofins	  (UK)	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2.2 Methods 
2.2.1 Ethical approval 
Ethical approval for the study of neutrophils from adult healthy controls was 
granted by the University of Liverpool Committee for Research Ethics 
(CORE). All participants gave written, informed consent. 
 
2.2.2 Leukocyte isolation 
Blood was collected from healthy volunteers by venupuncture into lithium 
heparin-coated vacuettes and processed immediately. Blood taken for 
RNA-Seq processing was taken from volunteers at a similar and consistent 
time of the day (9 am - 11 am) to mitigate variation from the innate 
immunity circadian rhythm as recently described 166.  
2.2.2.1 Magnetic bead isolation of neutrophils by negative selection 
The EasySep® Human Neutrophil enrichment kit was used, following the 
manufacturer’s instructions. Whole blood was gently mixed with HetaSep 
solution at a ratio of 1:5 (1 part HetaSep to 5 parts Blood) and incubated at 
37 °C for 20-30 min until plasma/erythrocyte interphase was at 
approximately 60% of the total volume. The leukocyte-rich plasma layer 
was carefully removed and washed in a 4-fold volume of recommended 
media (Mg2+ and Ca2+ -free PBS, + 2% FBS and 1 mM EDTA). Cells were 
centrifuged at 500 g for 5 min and resuspended in a 4-fold volume of 
recommended media. Cells were centrifuged at 120 g for 10 min to 
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remove platelet contamination and resuspended at 5 x 107 nucleated cells 
per mL. 
A volume of between 0.5 and 2 mL of nucleated cells at 5 x 107/mL was 
used in each neutrophil bead purification process, dependent on the 
number of purified cells required. 50 µL of EasySep® neutrophil enrichment 
cocktail, containing a mix of tetrameric antibody complexes produced from  
monoclonal antibodies directed against the cell surface antigens CD2, 
CD3, CD9, CD19, CD36, CD56 and glycophorin A – whilst being bi-specific 
for dextran – was added per 1 mL of nucleated cells and incubated for 10 
min at room temperature. 100 µL of EasySep® dextran-coated nanoparticle 
beads were added per 1 mL of nucleated cells and incubated for a further 
10 min at room temperature. The cell/antibody/bead solution was adjusted 
to a total volume of 2.5 mL with recommended media and placed into an 
EasySep® magnet for 5 min at room temperature. Unbound neutrophils 
were poured off and placed into EasySep® magnet for a further 5 min. 
Highly-pure, unbound neutrophils were briefly centrifuged and 
resuspended in RPMI 1640 media plus 25 mM HEPES to a concentration of 
5 x 106/mL. Following the erythrocyte sedimentation step, the neutrophil 
isolation procedure from whole blood was performed at room temperature 
and would typically take less than 100 min to complete. 
2.2.2.2 Polymorphprep™ isolation of neutrophils 
Neutrophils were isolated by single-step centrifugation of whole blood 
onto Polymorphprep™ density gradient as per the manufacturer’s 
88	  
	  
recommendation. Briefly whole blood was layered onto Polymorphprep™ 
at a ratio of 1:1 and centrifuged at 500 g for 35 min. Granulocytes were 
carefully removed and resuspended in RPMI 1640 media plus 25 mM 
HEPES and centrifuged at 500 g for 5 min to remove any remaining 
Polymorphprep™. Cells were resuspended in media and contaminating 
erythrocytes were removed by hypotonic lysis by the addition of 
ammonium chloride (13.4 mM KHCO3, 155 mM NH4Cl and 96.7 mM EDTA 
in 500 mL distilled water) at a ratio of 1:9 media:lysis buffer for 3 min. 
Platelet contamination was removed by further centrifugation of the cells at 
150 g for 3 min. Neutrophils were counted using a Beckman Coulter 
Multisizer 3 and the suspension volume adjusted to give a final 
concentration of 5 x 106/mL. Cells were incubated with gentle agitation at 
37 °C and supplemented with 10% (v/v) human AB serum for incubations 
>4 h. The entire neutrophil isolation procedure from whole blood was 
performed at room temperature and would typically take less than 90 min 
to complete. 
2.2.2.3 Lymphocyte isolation 
Lymphocytes were isolated by carefully removing the upper PBMC band 
following whole blood centrifugation over Polymorphprep™ (as described 
in previous section). Cells were layered onto Lymphoprep™ density 
gradient, centrifuged for 20 min at 600 g and resuspended in RPMI (+ 
HEPES) media at 1x106 /mL. 
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2.2.3 Cytospins  
Purity of neutrophil isolations was determined by cytospin and visual 
identification of stained cells. 20 µL of cells at 5 x 106 cells/mL was added 
to 180 µL of PBS plus 10 mM EDTA. The suspension was placed into a 
single cytology funnel (VWR) and centrifuged onto a glass slide (VWR) at 30 
g for 5 min using a Shannon 3 cytospin and immediately stained with Rapid 
Rowmanowsky stain. Neutrophil purity was typically >96% and >98% 
following Polymorphprep™ or magnetic bead isolation, respectively. 
 
2.2.4 Flow cytometric analysis of neutrophil cell  surface markers 
For the measurement of cell surface markers by flow cytometry, 20 µL of 
neutrophils at 5 x 106 cells/mL (equating to 1 x 105 neutrophils) were 
washed in 100 µL PBS plus 0.1% (w/v) BSA, centrifuged at 1000 g for 3 min, 
resuspended in 10 µL PBS plus 0.1% (w/v) BSA and incubated at 4 °C in the 
dark with 2-5 µL of fluorescently-conjugated antibody (as indicated in the 
text). Following 30 min incubation cells were fixed in 2% paraformaldyhyde 
(PFA) for no more than 15 min at room temperature in the dark. Cells were 
centrifuged at 1000 g for 3 min and resuspended in 200 µL of PBS plus 
0.1% (w/v) BSA and stored at 4 °C prior to analysis. A minimum of 5000 
gated events were analysed using a Guava Easycyte flow cytometer 
(Millipore). Where applicable a suitable isotype control was used to control 
against non-specific staining.  
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2.2.5 Flow cytometry measurement of neutrophil apoptosis 
For measurement of neutrophil apoptosis/necrosis by flow cytometry, 105 
cells were incubated in 100 µL HBSS with 10 µg/mL of FITC-conjugated 
annexin V in the dark, following 15 min, 1 µg/mL propidium iodide (PI) was 
added and samples were measured immediately on a Guava Easycyte flow 
cytometer. A minimum of 5000 gated events were collected per sample.  
 
2.2.6 Preparation of protein lysates 
Neutrophils were centrifuged at 1000 g for 3 min following culture under 
appropriate conditions (as indicated in the text), the supernatant carefully 
aspirated, and the pellet immediately lysed in boiling Laemmli buffer 
containing 10% (v/v) glycerol, 100mM DTT, 3% (w/v) SDS, 1 M Tris-HCL (pH 
6.8) and 0.001% (w/v) bromophenol blue to a final concentration of 5 x 104 
cells/µL. For incubations >4 h neutrophils were additionally washed with 
PBS to remove supplemented human AB serum prior to lysis. For 
measurement of protein phosphorylation, Laemmli buffer was additionally 
supplemented with phosphatase inhibitors (phosphatase inhibitor cocktail 
II, Calbiochem, Nottingham, UK). Samples were boiled for 5 min with 
occasional vortexing and stored at -20 °C. 
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2.2.7 Western blotting 
Whole cell extracts were briefly boiled and centrifuged. 10-25 µL of protein 
lysate (equivalent to 5-15 x 104 cells) was loaded per well of an 8-15% 
polyacrylamide gel (dependent on size of protein under investigation) using 
a 4.5% stacking gel. 10µL of biotinylated and/or pre-stained molecular 
weight ladders were also loaded to allow for molecular weight 
determinations. Samples were electrophoresed at a constant 180-200V for 
approximately 60 min using a BioRad Mini Protean III electrophoresis kit 
until proteins were suitably resolved. Proteins were transferred to a PVDF 
membrane by electrophoresis in a BioRad mini Protean III transfer kit at a 
constant 100V for 60-90 min, depending on thickness of gel. Successful 
transfer of proteins was confirmed by briefly staining the membrane in 
Ponceau S (0.01% (w/v) in 5% (v/v) acetic acid) stain.  
To decrease non-specific binding of antibodies, membranes were 
incubated at room temperature for at least 1h in blocking buffer. 
Membranes were subsequently incubated overnight with primary antibody 
in wash buffer containing either 5% (w/v) non-fat dried milk or 5% (w/v) 
bovine serum albumin (BSA) at 4 °C with gentle agitation. Following 
washing of membranes for 3 x 5 min in washing buffer, membranes were 
incubated at room temperature for at least 1h with an appropriate 
horseradish-peroxidase (HRP)-conjugated secondary antibody in wash 
buffer containing 5% (w/v) non-fat dried milk (for specific concentrations 
see Table 2.7). Following further washing of the membrane in wash buffer 
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(3 x 5 min), the bound antibodies were detected using enhanced 
chemiluminescence (ECL) reagents and careful exposure of the membrane 
to hyper-film in a dark-room. Quantification of western blots by 
densitometry was carried out using the AQM Advanced 6 Imaging 
Software (Windows) and a digital film scanner. 
 
2.2.8 Measurement of neutrophil respiratory burst 
Neutrophil respiratory burst was measured by luminol-enhanced 
chemiluminescence. Luminol is a membrane permeable molecule and is 
therefore suitable for quantification of both intra and extracellular reactive 
oxygen species (ROS). Luminol is oxidised by the enzymatic products of 
myeloperoxidase and NADPH oxidase during the respiratory burst, 
resulting in a release of energy in the form of light which can be quantified 
using a plate reader. 
Cells at 5 x 106/mL were incubated in RPMI 1640 media with (or without) a 
priming cytokine for 30 min at 37 °C with gentle agitation. 2 x 105 cells (40 
µL) were added to an opaque 96-well microtitre plate and volume adjusted 
to 100 µL with media. 100 µL of HBSS containing 100 µM luminol, and 
either 1 µM fMLP or 0.2 mg/mL PMA were added to cells and immediately 
measured on a FLUOstar Omega plate reader at 37 °C plus 5% CO2.  
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Table	  2.7	  Western	  blot	  antibody	  concentrations	  
Western	  blot	  antibody	  concentrations	  
Primary	  antibody	   Secondary	  antibody	  
STAT	  1	  	   Rabbit	  (1:20,000)	  
Phosphorylated	  STAT1	   Rabbit	  (1:20,000)	  
STAT	  3	   Rabbit	  (1:20,000)	  
Phosphorylated-­‐STAT	  
3	   Rabbit	  (1:20,000)	  
ERK	   Rabbit	  (1:20,000)	  
Phospho-­‐ERK	   Rabbit	  (1:20,000)	  
p38	   Mouse	  (1:10,000)	  
phosphophorylated-­‐
p38	   Mouse	  (1:10,000)	  
AKT	   Rabbit	  (1:20,000)	  
Phosphorylated-­‐AKT	   Rabbit	  (1:20,000)	  
IκBα	   Rabbit	  (1:20,000)	  
Phosphorylated-­‐NFκB	   Rabbit	  (1:20,000)	  
Beta	  actin	   Mouse	  (1:10,000)	  
IL-­‐1B	   Rabbit	  (1:20,000)	  
GAPDH	   Mouse	  (1:10,000)	  
 
2.2.9 Extraction and isolation of neutrophil RNA 
 Neutrophils at 5 x 106/mL were centrifuged at 1000 g for 3 min, the 
supernatant aspirated and the pellet lysed in 1mL of TRIzol® per 5x106 cells. 
Cells were further lysed by pipetting the solution several times through a 
20 gauge needle and syringe, to obtain a homogenized solution, which 
was incubated at room temperature for 5 min. 200 µl of chloroform was 
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added per 1mL of Trizol® and the solution was vigorously mixed for 15 
seconds, incubated at room temperature for 2-3 min, before being 
centrifuged at 10,000 g for 15 min at 4 °C. The upper aqueous layer, 
containing RNA, was carefully removed and added to an equal volume of 
molecular grade isopropanol.  This was stored for at least 24h at -20 °C to 
ensure complete precipitation of the RNA. Samples were then centrifuged 
at 10,000 g for 30 min at 4 °C, washed in 70% (v/v) ethanol, pelleted and 
re-suspended in 100 µL of RNase-free water. The RNA was further purified 
using a Qiagen RNeasy kit according to the manufacturers protocol, which 
included a 15 min DNase digestion step to eliminate any contaminating 
genomic DNA. RNA-Seq samples were prepared into a final elution of 30 µl 
of RNase-free water and stored at -150 °C.  All RNA samples were 
transported by courier on dry ice to either the Centre for Genomic 
Research (University of Liverpool) or BGI International, Hong Kong. In each 
case, transportation took less than 60 h and samples were quality-checked 
both after arrival, and following library construction. 
 
2.2.10 cDNA synthesis for PCR 
cDNA was synthesized from total RNA using the Superscript III First Strand 
cDNA synthesis kit (Qiagen), as per the manufacturers protocols. The total 
amount of RNA per sample within each experiment was adjusted to an 
equal amount prior to cDNA synthesis. RNA from each sample was added 
to 1 µL of random primers (250 ng), 1 μL dNTPs and the reaction volume 
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was adjusted to 13 µL by adding RNase-free water. Samples were heated 
to 65°C for 5 min in a heat-block and rapidly cooled on ice for at least 1 
min to allow primer annealing. A master-mix of 4 µL first-strand buffer, 1 µL 
RNaseOUT (RNase inhibitor), 1 µL (0.1M) DTT and 1 µL (200 units/µL) 
Superscript III reverse transcriptase, were added to each sample before 
incubation in a Thermo PX2 thermal cycler. cDNA synthesis was initiated at 
25 °C for 5 min, completed at 50 °C for 60 min and the reaction was 
terminated by a final 15 min at 70 °C. Samples were cooled to 4 °C before 
being stored at -20 °C until further use. 
 
2.2.11 Quantitative (real-t ime) PCR 
Transcript levels were quantified using the Quantitect SYBR Green qPCR 
detection kit (Qiagen), following the manufacturer’s protocol. Briefly, 1 µL 
of cDNA was added to 0.8 µL of each forward and reverse primer (10 pM) 
and 10 µL of QuantiTect, in a total reaction volume of 20 µL. Each sample 
was prepared in duplicate or triplicate and run on a Roche LightCycler 480 
qPCR machine in an opaque 96-well microtitre plate using the cycling 
protocol shown in (Table 2.8). Relative amounts of target transcripts were 
quantified by normalising their Ct values against those of a suitable 
housekeeping gene (as indicated in the text) using the Pfaffl method 167. 
Primer sequences shown in Table 2.9. 
 
 
96	  
	  
Table	  2.8	  qPCR	  cycling	  parameter Cycling	  stage	   Step	   Temperature	  (°C)	   Time	  (min)	   No.	   of	  cycles	  1	   Taq	  Activation	   95	   15	   1	  
2	   Denaturation	   95	   1	   45	  Primer	  Annealing	   55	   0.5	  Elongation	   72	   0.5	  3	   Melt	   Curve	  Analysis	   60	   0.5	   1	  
	  
	  
Table	  2.9	  Primer	  sequences	  and	  PCR	  product	  size 
PCR	  primers	  
Gene	  of	  
Interest	  
Primer	  Sequence	  (5’	  to	  3’)	   Product	  
size	  (bp)	  
FADD-­‐f	   CACAGACCACCTGCTTCTGA	   176	  
FADD-­‐r	   CTGGACACGGTTCCAACTTT	   	  
FOS-­‐f	   CTCCGGTGGTCACCTGTACT	   137	  
FOS-­‐r	   GTCAGAGGAAGGCTCATTGC	   	  
ICAM1-­‐f	   AGCTTCGTGTCCTGTATGGCCC	   128	  
ICAM1-­‐r	   ACACTTGAGCTCGGGCAATGGG	   	  
IL1B-­‐f	   CACTACAGCAAGGGCTTCAGGC	   98	  
IL1B-­‐r	   TTCTCCTGGAAGGTCTGTGGGC	   	  
IL8-­‐f	   AAAAGCCACCGGAGCACTCCAT	   143	  
IL8-­‐r	   AGAGCCACGGCCAGCTTGGA	   	  
JUN-­‐f	   TGGCAGAGTCCCGGAGCGAA	   121	  
JUN-­‐r	   CGAAGCTGAGCGCACGTCCT	   	  
NAMPT-­‐f	   GCCAGCAGGGAATTTTGTTA	   100	  
NAMPT-­‐r	   TGTCACCTTGCCATTCTTGA	   	  
SOCS3-­‐f	   CTGGTCCCCTCCCGGTTGGT	   112	  
SOCS3-­‐r	   TGTTGGCGGCCGTGAAGTCC	   	  
97	  
	  
TNF-­‐f	   CAGAGGGCCTGTACCTCATC	   219	  
TNF-­‐r	   GGAAGACCCCTCCCAGATAG	   	  
ACTB-­‐f	   CATCGAGCACGGCATCGTCA	   211	  
ACTB-­‐r	   TAGCACAGCCTGGACAGCAAC	   	  
B2M-­‐f	   ACTGAATTCACCCCCACTGA	   114	  
B2M-­‐r	   CCTCCATGATGCTGCTTACA	   	  
GAPDH-­‐f	   CTCAACGACCACTTTGTCAAGCTCA	   106	  
GAPDH-­‐r	   GGTCTTACTCCTTGGAGGCCATGTG	   	  
PPIA-­‐f	   GCTTTGGGTCCAGGAATGG	   60	  
PPIA-­‐r	   GTTGTCCACAGTCAGCCATGGT	   	  
	  
	  
2.2.12 Statist ics 
Statistical analysis of RNA-Seq data was performed by Cufflinks 
bioinformatic software 145, incorporating a false discovery rate (FDR) of 5% 
using Benjamini-Hochberg correction for multiple testing 164,168. Unless 
otherwise stated, all other data was judged for significance using the 
Student’s t-test for either paired or independent samples, as necessary. 
Significance was calculated using GraphPad/Prism version 6.0. (GraphPad 
software, San Diego, CA. USA). Error bars represent SEM unless otherwise 
stated and differences were considered significant if p < 0.05.  
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2.2.13 Bioinformatic software 
Several bioinformatic software programs were used to analyse both raw 
and annotated RNA-Seq data, (Table 2.10) provides details on the release 
versions used for analysis of data presented. Further details of individual 
bioinformatic software used can be found in Chapter 3. 
 
Table	  2.10	  Release	  versions	  of	  bioinformatic	  software	   
Bioinformatic	  software	  versions	  
Bioinformatic	  
software	   Version	  
Bowtie	   2.0.07	  
Tophat	   1.4.1-­‐2.0.4	  
Cufflinks	   2.02	  
Samtools	   0.1.18	  
IPA	   n/a	  
IGV	   2.2.7	  
Microsoft	  
Office	   2011	  edition	  
R	   2.15.2	  
EdgeR	   3.0.8	  
DESeq	   1.10.1	  
cummeRbund	   2.6.2	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Chapter	   3:	   Defining	   a	  
bioinformatic	   pipeline	   for	  
analysis	   of	   neutrophil	   gene	  
expression	  
Results presented within this chapter were included in a publication in 
which I was co-lead author: 
 
Wright	  HL†,	  Thomas	  HB†,	  Moots	  RJ,	  Edwards	  SW	  (2013)	  RNA-­‐Seq	  Reveals	  
Activation	  of	  Both	  Common	  and	  Cytokine-­‐Specific	  Pathways	  following	  
Neutrophil	  Priming.	  PLoS	  ONE	  8(3):	  e58598.	  doi:10.1371/journal.pone.0058598	  
3.1 Introduction 
Neutrophils are the most abundant white blood cell in the circulation, 
representing between 40-60% of the leukocyte population. On average, up 
to 1010 neutrophils are released from the bone marrow per day 169. These 
terminally-differentiated cells patrol the vascular system in search of 
inflammatory signals arising from pathological insult or localised cellular 
injury. Armed with a variety of anti-microbial enzymes and the ability to 
rapidly release reactive oxygen metabolites, neutrophils are the major 
cellular component of the innate immune system.  
Historically, neutrophils were regarded as one-dimensional innate cells, 
with little influence on surrounding immune cells owing to an incapacity for 
de novo gene expression and a short half-life of between 6-8 h. It is now 
well established that neutrophils play a central role in initiating and 
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propagating both the innate and adaptive immune responses by the 
production and release of numerous cytokines and chemokines 5.  
Despite the increased appreciation of neutrophil gene expression, few 
studies have focused on how neutrophil gene expression profiles change in 
response to external stimuli. Moreover, at the time of commencement of 
this project, the human neutrophil transcriptome had yet to be quantified 
by RNA-Seq despite similar studies on other cell types 117,170–172 There are 
several benefits offered by RNA-Seq over more established technologies 
such as micro-arrays and quantitative PCR as a method of quantifying the 
gene expression profile of a cell (as discussed in section 1.5.2). 
The past 20 years has seen an exponential increase in sequencing 
technologies. Both sequencing speed and accuracy have increased 
dramatically, whilst the financial cost of the instruments and reagents has 
decreased. These improvements can largely be attributed to the efforts of 
the human genome project, which brought about the collaboration of 
several research institutes in an attempt to comprehensively sequence the 
human genome using the best available technology at the time. The 
success of the 13 year project has led the way for further improvements 
and greater decreases in costs of sequencing. By way of example, Fig 3.1 
shows how the cost of sequencing a genome has decreased by over 4 
orders of magnitude in the space of a decade. These costs declined 
modestly over the first 5 years, but more rapidly post-2008, via the 
introduction of the then-called “next generation sequencing” (NGS) 
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technology, which consisted of Applied Biosystem’s SOLiD™ platform, 
Roche’s 454 pyrosequencer technology and Illumina’s Genome analyser 
system 173.  
 
 
Fig	  3.1	  The	  cost	  of	  sequencing	  a	  genome	  from	  2003-­‐2013.	  The	  cost	  of	  sequencing	  has	  
decreased	  by	  more	  than	  4	  orders	  of	  magnitude	   in	   the	  space	  of	   10	  years.	  The	  current	  
cost	   (Jan	   2014)	   is	   approximately	   £2300.	   	   Adapted	   from,	   Wetterstrand	   KA.	   DNA	  
Sequencing	  Costs:	  Data	  from	  the	  NHGRI	  Genome	  Sequencing	  Program	  (GSP)	  Available	  
at:	  www.genome.gov/sequencingcosts.	  Accessed	  [23-­‐5-­‐14].	  
 
In addition to a decrease in sequencing costs, the digital output of a 
sequencing run has equally accelerated exponentially during the last 
decade. The rate of development (or fall in cost) of many technological 
platforms can often be shown to correlate well with Moore’s law, which 
states that on average, the number of transistors in an integrated circuit 
doubles every 24 months. One such area of technology that has fallen in 
line with Moore’s law is that of data storage. However, the increase seen in 
NGS capacity for data production far outstrips that predicted by Moore’s 
law 174. This disparity in cost between storage and production of NGS data 
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could ultimately lead to sequence data being more expensive to store than 
to produce 175. 
Whilst the relative improvements in sequencing technologies compared to 
other technological fields is of interest (and concern), perhaps of greater 
importance is the disproportionate improvements in sequencing 
technologies with sequencing data analysis software. As the cost of 
sequencing decreased to accessible levels, the data analysis software 
available to analyse the raw data remained largely either inadequate, too 
technical to operate, or unfeasibly expensive for small-scale studies by 
scientists.  
More recently, a large number of open-access software programs have 
been developed for biology- users who have basic informatics skills. These 
allow free distribution and adaptation of programs that are designed to be 
compatible with the major sequencing platforms and raw data formats, but 
require the user to be familiar with a basic command line interface and 
non-standard operating systems, such as Linux or Unix. Additionally, 
software development of this kind is often small-scale and with limited 
features. Consequently, there are now a large number of open-source 
bioinformatic analysis software packages offering a range of utilities, 
advantages and features over other software packages. While these may 
not have the breadth of features available or ease of use to appeal to a 
dedicated bioinformatics research lab, they are usable to researchers with 
modest bioinformatic skills.  
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Perhaps unsurprisingly, many of the more successful and popular software 
packages are those developed by large commercial companies such as the 
CLCbio Genomics Workbench by Qiagen, or ERGO™ by igenbio, which 
are software suites offering all the most popular features of other software 
packages (such as read-mapping, annotation and differential analysis) in 
one software suite, with the added benefit of offering full user support and 
guidance on how best to utilise the software and extensive troubleshooting 
documentation. Software suites of this kind are an attempt to standardise 
the process of quantifying large datasets but they do so at fairly high cost. 
Whilst the intuitive graphical interface, full support, and industry-wide 
recognition is of great importance for large research centres, the often high 
commercial-licence cost (and annual subscription costs) can price out the 
smaller laboratories. Consequently, there is little agreement within the NGS 
community as to what is considered to be ‘best practice’ when it comes to 
data annotation and analysis 176. 
In summary, It is clear that a global approach to studying neutrophil gene 
expression by RNA-Seq is both potentially achievable, and of great 
interest. It will allow the accurate measurement of transcriptional changes 
in neutrophils under tightly controlled conditions and could ultimately lead 
to the development of a predictive model to determine the functional 
consequences of these changes. Whilst the available high-throughput 
sequencing technology is both adequate and affordable to undergo a large 
scale study into gene expression, the necessary software and parameters 
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required are poorly defined. The data presented here aim to define a 
robust pipeline of software packages, protocols and methods that can be 
employed to quantify the neutrophil transcriptome under conditions of 
stimulated inflammation. 
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3.2 Aims 
The overall aims of this Chapter were to establish a pipeline for the analysis 
of transcriptome data obtained by RNA-Seq of neutrophils stimulated in 
vitro by inflammatory activators. The specific aims were: 
 
1. To define a pipeline of methods, software programs and settings for 
compilation and analysis of RNA-Seq data. 
 
2. To determine if changes in gene expression are consistently 
detectable and if they correlate with a change in phenotype, as 
measured by laboratory based functional assays. 
 
3. To define a set of downstream analysis techniques to further analyse 
RNA-Seq gene expression data. 
 
  
106	  
	  
3.3 Methods 
The data herein describe the optimisation of a bioinformatics pipeline (of 
protocols and software packages) to define the neutrophil transcriptome 
under stimulated conditions of inflammation (in vitro). The data is 
presented in such a way as to be informative and clear to an interested 
reader of the best methods to adopt in addition to various pit-falls to 
avoid. The pipeline described here will form the basis of bioinformatic 
analysis undertaken in later Chapters. For the sake of brevity, many of the 
comparative and optimisation analyses carried out could not be included, 
hence much of the results described represent the optimal settings for 
each software program under comparison. 
 
3.3.1 Sample preparation 
Neutrophils were isolated by Polymorphprep™ from healthy donors (as 
described in section 2.2.2.2). Neutrophil RNA was extracted by TRIzol®-
chloroform precipitation and analysed by RNA-Seq using paired-end 
sequencing on the SOLiD™ 4.0 platform or single-end sequencing using 
the Illumina HiSeq 2000 platform, as indicated in the text. 
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3.3.2 Computational processing 
All of the bioinformatic software discussed in this Chapter can be run on a 
stand-alone desktop computer using a Unix/Linux or Mac OS operating 
system providing there is adequate processing power and random access 
memory (RAM) available. Technical specifications of the processing unit 
used (analysis-Mac) in the bioinformatics analysis can be found in Appendix 
Table A.2. 
For bioinformatic analyses using multiple data sets, to allow multiple 
analyses to be run simultaneously and in a shorter time than using analysis-
Mac, it was necessary to utilise a high-powered multi-core processing 
cluster provided by the University of Liverpool Computer Services 
Department (CSD). Consequently all mapping, annotation and differential-
expression testing processing was carried out using a Gigabit Ethernet 
cluster (44-core, per core; 2.2 GHz AMD core, 8GB RAM, 72GB disk space, 
Linux 9.3 SuSE). This cluster was accessed via the analysis-Mac through the 
University intranet. Raw data was firstly uploaded to cluster servers and 
bioinformatic analysis software was run via a short command script (.txt file).  
Software commands listed in this Chapter only include the basic commands 
(and optimised parameters) needed to run the software, and file paths are 
summarised. An example of the additional scripting required for cluster-
based analyses is provided in Appendix Fig A.1. 
Raw data from cluster-run analyses was backed up both internally and 
manually using University of Liverpool CSD backup storage facility.  
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3.4 Results 
3.4.1 RNA quantity and quality 
3.4.1.1 Quantity 
RNA-Seq technology requires high integrity RNA, with minimal 
contamination by genomic DNA. Typically, sequencing service providers 
require a minimum of 5 μg total RNA (per sample) for library construction 
(which also provides enough material for a second attempt at library 
construction). The numbers of neutrophils isolated from peripheral blood is 
donor-dependent and can vary between 1x106-5x106/mL blood 177. 
Furthermore, neutrophils contain considerably less RNA than other 
leukocytes such as peripheral blood mononuclear cells (PBMCs) 178. 
Following extraction by TRIzol®-chloroform precipitation, total RNA from 
106 and 107 neutrophils (isolated by Polymorphprep™)  and 106 PBMCs 
(isolated by Lymphoprep™)  was measured from 4 separate donors using a 
nanodrop spectrophotometer (Thermo Fisher scientific, Gloucestershire, 
UK) (Fig 3.2). Mean level of RNA from 106 neutrophils = 139.5 ng/mL ± 
15.75, 107 neutrophils =1797.8 ng/mL ± 91.75 and 106 PBMCs = 807.0 
ng/mL ± 117.43. These data suggest that PBMCs have approximately 5-
times more RNA than neutrophils on a cell basis, and that a minimum of 
30x106 neutrophils is required to achieve the recommended 5 μg of total 
RNA necessary for sequencing. 
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Fig	   3.2	   Amounts	   of	   RNA	   extracted	   from	   106	   and	   107	   neutrophils	   (PMN)	   and	   106	  
peripheral	   blood	   mononuclear	   cells	   (PBMC).	   Bars	   represent	   mean	   of	   4	   separate	  
experiments.	  Error	  bars	  represent	  SEM.	  
 
3.4.1.2 Quality 
i) RNA integrity 
The lengthy isolation process required for purifying neutrophils from whole 
blood (60-90 min) can often affect the quality of the final purified RNA. 
While the contamination of neutrophil preparations by other leukocytes 
must be considered, the greater number of steps required to isolate highly-
pure neutrophils can lead to longer isolation times and opportunities to 
inadvertently activate neutrophils or compromise the quality of RNA that is 
recovered. 
The overall integrity of an RNA sample is such a crucial determinant of the 
eventual success of an RNA-Seq experiment that sequencing service-
providers often request that all samples be accompanied by an accurate 
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measurement of integrity. Furthermore, an additional measurement of 
integrity is often made just prior to the samples being sequenced. A 
common method of measuring RNA integrity (RIN) is using the Agilent 
BioAnalyser 179,180. RNA integrity is measured on a scale of 1-10 where 1 
refers to RNA with the lowest integrity and 10 indicating no degradation of 
RNA. By way of example, output from the Agilent Bioanalyser relating to a 
low, and high-integrity RNA sample is shown in appendix Fig A.2. 
RNA from 106 PBMCs and 107 neutrophils was extracted by TRIzol®-
chloroform precipitation and RNA integrity was measured by Agilent 2100 
BioAnalyser (Fig 3.3). Levels of integrity were consistently measured 
between 7.0 – 8.6 RIN. The mean values across 4 samples were identical in 
PBMCs and neutrophils (7.9 RIN). 
 
 
 
Fig	   3.3	   RNA	   integrity	   number	   (RIN)	   values	   for	   RNA	   samples	   from	   PBMCs	   and	  
neutrophils	   (PMN).	   Horizontal	   bars	   represent	   mean	   value	   from	   4	   separate	  
experiments/Donors.	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ii) RNA purity 
RNA purity is of upmost importance for RNA-Seq. Residual solvent from 
extraction protocols or contaminating genomic DNA can have a significant 
effect on the success and accuracy of the resulting RNA-Seq experiment. 
Neutrophil RNA extraction performed in the previous experiments was 
using TRIzol®-chloroform precipitation, followed by on-column cleanup by 
Qiagen RNeasy kit including a 15 min the DNase digest step. The 
efficiency of TRIzol®-chloroform extraction and DNase digestion step was 
compared to an on-column extraction method using a Qiagen column, with 
or without a DNase digestion step. RNA from TRIzol®-chloroform 
extraction and Qiagen on-column extraction was converted to cDNA using 
the Superscript III first strand cDNA synthesis kit. Primers for MCL-1 (full 
length) were used to amplify cDNA by PCR. Amplified cDNA from each 
extraction method was analysed on an agarose gel to assess levels of 
contamination by genomic DNA. Samples prepared by on-column 
extraction were found to contain higher levels of contaminating genomic 
DNA than samples extracted by TRIzol-cholorform precipitation. 
Additionally, where contaminating genomic DNA was present, a 15 min 
DNAse digest step was sufficient to eliminate any genomic DNA signal (see 
Appendix Fig A.3). 
These data suggest that neutrophil isolation by Polymorphprep™ and RNA 
extraction by TRIzol-chloroform precipitation, plus RNA cleanup and DNase 
digestion steps, provides an appropriate method for RNA sample 
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preparation with high integrity (> 8.0 RIN) and low contamination by 
genomic DNA, which are suitable for RNA-Seq experiments. 
 
3.4.2 Sample preparation 
Several stimuli are known to induce de novo gene expression in 
neutrophils, such as low oxygen tension (hypoxia), immune complexes and 
cytokine stimulation. Of these stimuli, the effects of cytokines on neutrophil 
gene expression are perhaps the most widely studied and established 
(often by micro-arrays and qPCR), and so these agonists were used to 
validate transcriptome analysis by RNA-Seq. 
 
3.4.3 Cytokine stimulation and time point selection 
Both GM-CSF and TNFα are commonly-used neutrophil priming agents 
that regulate neutrophil gene expression in vitro 181,182. Neutrophils 
incubated with previously established priming concentrations of GM-CSF (5 
ng/mL) and TNFα (10 ng/mL) 182–184 were prepared as previously described 
(Methods section 2.2.9) for RNA-Seq analysis.   
Priming of neutrophils with either GM-CSF or TNFα has previously been 
shown to rapidly increase transcription of several genes, such as IL-8 and 
IL-1β 10,185,186. First, it was necessary to determine the time course of 
activation of gene expression following addition of these cytokines. Fig 3.4 
shows the relative expression of IL-8, IL-1β, CCL3 and ICAM1 over 2 h 
following neutrophil incubation with (or without) GM-CSF measured by 
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qPCR. Time points beyond 2 h were not considered due to the likelihood 
of de novo cytokine production leading to autocrine signalling 186–189. 
 
 
 
Fig	   3.4	   Relative	   expression	   of	   mRNA	   following	   stimulation	   with	   GM-­‐CSF	   (GM)	   (5	  
ng/mL)	   (black	   bars),	   or	   remaining	   untreated	   (UT)(white	   bars)	   over	   2	   h	  measured	   by	  
qPCR.	   Target	   gene	   expression	   was	   normalised	   to	   B2M	   housekeeping	   gene167	   and	   is	  
expressed	  as	  fold	  increase	  compared	  to	  levels	  of	  expression	  at	  0h.	  
 
Levels of expression were highest at 1 h for ICAM1 and IL-1β, levels of 
CCL3 were highest at 30 min whilst levels of IL-8 remained high for entire 2 
h time course. Whilst it is impossible to have a single time point for RNA-
Seq analysis which is optimal for all genes in the transcriptome, these data 
suggest that a 1 h time point is adequate to identify rapid changes in gene 
expression following neutrophil stimulation whilst also avoiding any risk of 
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measuring secondary activation of neutrophils by autocrine signalling 
following de novo synthesis of cytokines. 
3.4.4 RNA-Seq pipeline development 
3.4.4.1 Platform selection 
The most popular platforms for NGS share many similarities, such as 
sensitivity, capacity and accuracy, but differ in a number of parameters such 
as read length, output data format, speed and cost (described in more 
detail in sections 1.5.4-1.5.6) The choice of a suitable platform must 
consider each of these factors, in addition to availability and access.  
At the outset of this project, the Centre for Genomic Research (CGR) 
located in-house at the University of Liverpool provided next generation 
sequencing of RNA by both Roche’s 454, and Applied Biosystems SOLiD™ 
4.0 platforms. In addition, sequencing by the SOLiD™ platform could be 
carried out using single- (50 bp) or paired-end (50 + 35 bp) reads. The 
short reads and deep coverage of the SOLiD platform is better suited to 
gene expression studies of a well annotated genome (e.g. the human 
genome), than the 454 platform which utilises much larger read lengths 
and is more appropriate for de novo assembly of non-sequenced genomes 
(or transcriptomes) where a reference sequence is not available. 
Furthermore, the ability to carry out paired-end sequencing on the SOLiD 
platform can increase the amount of raw data produced from a single 
sequencing run by approximately 70% whilst also improving the accuracy 
of read mapping. Consequently, neutrophil RNA samples were initially 
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sequenced by paired-end technology on the SOLiD 4.0 platform at the 
CGR. 
3.4.4.2 SOLiD™ 4.0 paired-end sequencing 
Whole blood from a healthy donor was prepared by Polymorphprep™. 
Neutrophils (3x107/sample) were incubated at 37 °C for 1 h with (or 
without) GM-CSF (5 ng/mL) or TNFα (10 ng/mL). RNA was extracted as 
previously described. RNA integrity was analysed by Agilent bioanalyser 
2100 and measured at 8.5, 7.5 and 7.0 RIN for the untreated, GM-CSF and 
TNF samples respectively.  
Total RNA was enriched for mRNA transcripts by terminator exonuclease 
treatment at the CGR (as described in section 1.5.3.2.a). Enriched samples 
were processed for paired-end sequencing which produced upwards of  
6x107 50 bp 5’à3’ forward (F3) and  paired 35 bp 3’à5’ reverse (F5) 
transcripts per sample (see section 1.5.8 for details of paired end 
sequencing, and Appendix Table A.4 for number of raw reads per sample). 
 
3.4.4.3 Quality control analysis of paired end sequence data 
For each sample sequenced on the SOLiD™ 4.0 platform, 2 data files are 
produced; a raw data file (filtered to remove adapter sequences and 
fragment reads) in .csfasta file format (i.e. a fasta sequence file with the 
data in colorspace, rather than base space), and an accompanying quality 
file (.qual) which provides a Phred quality score for each base in each read. 
The Phred score refers to the likelihood that the base calling at each base 
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position is correct. For example, a Phred score of 40 indicates that there is 
a 99.99% chance that at that position the sequencing software has correctly 
called the base nucleotide whereas a score of 10 indicates that there is a 
90% chance that the base nucleotide has been called correctly 190. Quality 
scores can be used to assess the success of a sequencing run and can be 
included in the mapping software protocols to improve read mapping 
rates. 
Raw reads were analysed by the Java program Quality Assessment 191 to 
quantify the number of reads in each data set that had a mean Phred score 
of >20 (i.e < 1 incorrectly called base per 100 bases). In each sample, less 
than 50% of reads had a mean Phred quality score of >20, with the smaller 
F5 reverse-fragments consistently having a lower score than the F3 
forward-fragments (Fig 3.5). These values are lower than expected and 
could impact on successful mapping due to the low quality of the data. 
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Fig	  3.5	  Total	  number	  of	  reads	  (open	  bars)	  and	  number	  of	  reads	  with	  >20	  Phred	  quality	  
score	   (black	  bars)	   in	   untreated	   (UT),	  GM-­‐CSF	   (GM)	   and	  TNFα	   (TNF)	   treated	   samples,	  
for	   forward	   (F3)	   and	   reverse	   (F5)	   fragments	   of	   paired-­‐end	   raw	   SOLiD	   sequencing	  
reads.	  Reads	  quantified	  by	  Quality	  Assessment	  software	  191.	  
	  
3.4.4.4 High throughput mapping of paired-end sequence data by 
Bowtie/Tophat 
The high throughput mapper Bowtie is an ultra-fast, short sequence-read 
aligner that can operate on modest computational hardware utilising a 
heavily indexed (Burrows-Wheeler compression† 192) reference sequence 
and multi-core processing (where available) to map upwards of 25x106 
reads per hour 151. Bowtie can take single- or paired-end reads in either 
base space or colorspace as input, such that it can process raw data from 
any of the 3 major sequencing platforms (454, SOLiD or Illumina). However, 
Bowtie cannot map reads that span splice junctions. 
The closely-related software package Tophat 155 utilises the basic mapping 
features of Bowtie, while applying an additional mapping algorithm to 
unmapped reads to enable the accurate mapping of reads that span splice 
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†Burrows-Wheeler compression is a method of indexing large amounts of data.  It is 
particularly  useful  for data with large portions of repetition (such as genomic data), and is 
a lso a reversib le form of compression without the need for addit ional data.   
 
118	  
	  
junction sites that would otherwise be unmapped by Bowtie (covered in 
more detail in section 1.6.2). Initiation of Tophat first uses Bowtie to map 
reads not spanning splice junctions, subsequently, Tophat attempts to map 
remaining reads. Provision of a .gtf file (see Abreviations Table Ab.1 for 
details)  to Tophat can improve mapping rates by providing a list of known 
splice junctions within the reference sequence. 
Several different parameters and settings options exist for both software 
programs which affect how read-data are processed and handled, prior to, 
or during the mapping process. For example, reads may be trimmed to 
eliminate areas of low quality prior to mapping. Alternatively, if a read can 
be aligned to multiple locations in the reference sequence, settings within 
the Bowtie program determine if the read is eventually positioned at the 
highest-quality location, spread amongst all sites equally, or removed from 
the mapping process entirely since no definitive mapping location can be 
determined. These features exist to enable the user to improve rates of 
mapping, while also improving the quality of mapping by a decrease in the 
number of false positives, false negatives or sequencing/mapping artefacts. 
A summary of the most important parameters are found in Table 3.1, which 
also highlights the parameters that were altered from default settings 
during the mapping process to achieve optimal mapping rates. 
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Table	   3.1	   Summary	   of	   Bowtie	   options	   and	   parameters	   available.	   <int>	   refers	   to	  
additional	   parameter	   required	   as	   an	   integer.	   Settings	   shaded	   grey	  were	   assigned	   in	  
neutrophil	  sequencing	  pipeline.	  
 
Bowtie	  settings	   Function	  
Input	  options	   	  
-­‐q	   Input	  file	  is	  in	  FASTQ	  format	  
-­‐f	   Input	  file	  is	  in	  FASTA	  format	  
-­‐r	   Input	  file	  is	  in	  RAW	  format	  
-­‐c	   Input	  via	  command	  line	  
-­‐C/-­‐-­‐color	   Input	  is	  interpreted	  in	  colorspace	  
-­‐Q/-­‐-­‐qual	   Input	  file	  is	  a	  quality	  file	  	  
-­‐s/-­‐-­‐skip	  <int>	   Skip	  <int>	  no.	  of	  reads	  from	  input	  
-­‐-­‐solexa1.3-­‐quals	   Input	  quals	  are	  in	  ASCII	  format,	  appropriate	  for	  
Illumina	  pipeline	  version	  >	  1.3	  
Alignment	   	  
-­‐v	  <int>	   Report	   alignments	  with	  no	  greater	   than	  <int>	  
mismatches	  
-­‐e	  <int>	   Maximum	  permitted	   total	  of	  quality	  values	  of	  
all	   mismatched	   read	   positions	   throughout	  
entire	  read	  alignment	  
-­‐l	  <int>	   Seed	  length,	  i.e	  the	  number	  of	  reads	  from	  the	  
high	  quality	  end	  used	  to	  begin	  alignment	  
-­‐n	  <int>	   Number	   of	   mismatches	   permitted	   in	   the	  
“seed”	  (0-­‐3,	  default:	  2)	  
-­‐I/-­‐-­‐minins	  <int>	   Minimum	   length	   of	   reads+insert	   for	   paired	  
end	  reads	  
-­‐X/-­‐-­‐maxins	  <int>	   Maximum	   length	   of	   reads+insert	   for	   paired	  
end	  reads	  
-­‐-­‐fr/-­‐-­‐rf/-­‐-­‐ff	   The	   upstream/downstream	   orientation	   of	  
paired-­‐end	   reads	   relative	   to	   the	   forward	  
reference	  strand	  
-­‐-­‐chunkmbs	  <int>	   The	   amount	   of	  memory	   (in	  Mbs)	   assigned	   to	  
read	  alignment	  per	  thread	  (default:	  64)	  
Reporting	   	  
-­‐k	   Report	  up	  to	  <int>	  no.	  of	  alignments	  per	  read	  
(or	  read	  pair)	  
-­‐a/-­‐-­‐all	   Report	   all	   valid	   alignments	   per	   read	   (or	   read	  
pair)	  (default:	  off)	  
-­‐m	  <int>	   Suppress	   all	   subsequent	   alignments	   if	   a	   read	  
has	   more	   than	   <int>	   possible	   alignment	  
locations	  
-­‐M	  <int>	  	   As	  with	   –m	   ,	   supress	   alignments	  with	   greater	  
than	   <int>	   valid	   locations,	   but	   assign	   read	   to	  
one	  location	  at	  random	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-­‐-­‐best	   Where	   multiple	   alignments	   for	   a	   single	   read	  
occur,	  use	  number	  of	  mismatches	  and	  quality	  
of	   reads	   to	   assign	   to	   best	   alignment	   location,	  
or	   where	   multiple	   alignments	   are	   permitted,	  
list	  alignments	  in	  order	  of	  best	  to	  worst	  
-­‐-­‐strata	   As	   with	   –best,	   where	   multiple	   alignment	  
locations	  occur	  that	  fall	   into	  multiple	  stratum,	  
only	   use	   alignments	   from	   the	   best	   strata.	  
(Redundant	  in	  later	  versions	  of	  Bowtie)	  
Output	   	  
-­‐t/-­‐-­‐time	   Print	   the	   amount	   of	   time	   taken	   to	   complete	  
each	  phase	  of	  mapping	  
-­‐-­‐quiet	   No	  update	  text	  whilst	  software	  is	  running,	  only	  
output	  alignments	  
-­‐-­‐al	  <filename>	   Output	  all	   reads	   that	   successfully	  aligned	   into	  
a	   new	   <filename>	   as	   they	   appear	   in	   the	   raw	  
input	  file	  
-­‐-­‐un	  <filename>	  	   Output	  all	  reads	  that	  failed	  to	  align	  into	  a	  new	  
<filename>	  as	  they	  appear	  in	  the	  raw	  input	  file	  
-­‐-­‐max	  <filename>	   Output	   all	   reads	   that	   failed	   to	   align	   due	   to	  
exceeding	   limit	   of	   alignment	   locations	   into	   a	  
new	   <filename>	   as	   they	   appear	   in	   the	   raw	  
input	  file	  
-­‐-­‐suppress	  <int>	   Suppress	  column	  no.	  <int>	  from	  the	  output	  file	  	  
-­‐S/-­‐-­‐sam	   Output	  in	  SAM	  format	  
Performance	   	  
-­‐p/-­‐-­‐threads	  <int>	  	   Run	   alignment	   in	   parallel	   on	   <int>	   no.	   of	  
processors/cores	  
	  
 
3.4.4.5 Optimisation of Bowtie/Tophat settings  
Settings such as seed length, number of alignment threshold and read 
trimming were optimised to increase rates of mapping without increasing 
the amount of non-specific alignments (see Table 3.1 for explanation of 
each parameter). Due to the low quality values for F5 paired fragments in 
each of the SOLiD sequenced samples, F5 reads were omitted from the 
mapping stage. Furthermore, low quality 3’ ends of the F3 fragments were 
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trimmed (by 8 bases) by Bowtie prior to alignment, as this improved overall 
rates of mapping. 
Due to a software design feature, several of the Bowtie parameters were 
not available when initiating mapping by Bowtie through running Tophat. 
Consequently, mapping was completed via a three-stage process. Firstly, 
reads were mapped to the genome using Bowtie and unaligned reads were 
outputted into a separate file, using the command:  
 
bowtie	  -­‐p	  8	  -­‐S	  -­‐C	  -­‐l	  20	  -­‐-­‐trim3	  8	  -­‐e	  100	  -­‐-­‐un	  unaligned	  -­‐-­‐chunkmbs	  4000	  -­‐k	  1	  -­‐m	  1	  -­‐-­‐
best	  -­‐-­‐strata	  /path/to/Bowtie/reference/genome	  –f	  path/to/raw/reads_data	  –q	  
path/to/raw/quality/values	  >	  output.sam	  
 
 
 Secondly, unaligned reads were inputted into Tophat and realigned to the 
reference  sequence (human reference hg19), using the command: 
 
tophat	  -­‐p	  8	  -­‐-­‐color	  -­‐-­‐quals	  -­‐r	  200	  -­‐-­‐mate-­‐std-­‐dev	  30	  -­‐a	  5	  -­‐-­‐library-­‐type	  fr-­‐
secondstrand	  -­‐-­‐segment-­‐length	  20	  –bowtie-­‐n	  -­‐-­‐max-­‐multihits	  1	  -­‐G	  
/path/to/reference/annotation_file.gtf	  /path/to/Bowtie/reference/genome	  	  
/path/to/unaligned_reads	  –q	  path/to/unaligned_reads/quality/values	  
 
 
Finally, all aligned reads were merged into a single output file (.Bam) and 
sorted by the java program Picard 193, using the commands: 
 
java	  -­‐Xmx2g	  -­‐jar/path/to/picard-­‐
merge.jar	  INPUT=bowtie.bam	  INPUT=tophat.bam	  OUTPUT=merged.bam	  SORT
_ORDER=coordinate”	  	  	  
	  
“java	  -­‐Xmx2g	  -­‐jar	  /path/to/Picard-­‐sort.jar	  INPUT=/path/to/merged.bam	  
OUTPUT=merged-­‐sort.bam	  REFERENCE=/path/to/reference/hg19.fa	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Fig 3.6 summarises the mapping strategy used to map reads to human 
hg19 genome, using Bowtie and Tophat and output files merged with 
Picard. 
 
 
	  
Fig	  3.6	  Flow	  chart	  of	  mapping	  process	  using	  the	  high	  throughput	  aligners	  Bowtie	  and	  
Tophat.	  Output	  files	  were	  merged	  using	  Picard	  software	  193.	  
 
 
3.4.4.6 Mapping results of SOLiD data 
Table 3.2 list the maximal mapping percentages achieved using the 
optimised mapping pipeline shown in Fig 3.6. Mapping rates could not be 
increased above 35% in any samples. This was likely due to the low quality 
scores for reads across all samples, as seen in Fig 3.5. 
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Table	  3.2	  Percentage	  reads	  mapped	  for	  each	  dataset	  using	  optimal	  mapping	  strategy	  
summarised	  in	  Fig	  3.6	  
	  
Dataset	   Reads	  mapped	  
(%)	  
Untreated	   34.9	  
GM-­‐CSF	   32.7	  
TNFα	   31.0	  
	  
	  
	  
To evaluate the quality of reads that were successfully mapped by 
Bowtie/Tophat the final .Sam file was analysed using the software program 
FastQC 194.  FastQC is a Java based program that takes .Bam/.Sam 
mapping files as input and performs a series of quality control tests on the 
raw data. Among the output is a mean quality score (Phred value) for each 
base position among all reads that were successfully mapped. Fig 3.7 
shows the FastQC output for the untreated neutrophil dataset. Mapped 
reads were found to have highest quality values at the 5’ end (base 
positions 1-10) but quality values consistently decreased towards the 3’ 
end, such that the mean values for position 49 was approximately half of 
the mean value for base position 1 (base position 1 – mean Phred score- 
60; base position 49 – mean Phred score – 31). The variability in quality 
scores (i.e. the inter quartile range 25-75 percentile) also increased towards 
the 3’ end of mapped reads. Similar results were obtained for GM-CSF and 
TNFα treated samples.  
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Fig	  3.7	  FastQC194	   analysis	  of	  Bowtie/Tophat	  mapped	  reads	   from	  neutrophil	  untreated	  
dataset.	   Graph	   shows	   the	  mean	   quality	   values	   (Phred	   score)	   (y-­‐axis),	   for	   each	   base	  
position	  within	   the	  mapped	   reads	   (x-­‐axis).	   Scores	   are	   represented	  by:	   inner	  quartile	  
range	   (25-­‐75	   percentile)	   (Yellow	   boxes);	  median	   Phred	   score	   (Red	   line);	  mean	   value	  
(Blue	  line);	  and	  10-­‐90	  percentile	  (whisker	  plots).	  
	  
	  
These data reveal that only the highest quality reads were able to be 
mapped (30-35%). Furthermore the quality of mapped-reads was poor at 
the 3’ end and reveals why removing the 8-bases from the 3’ end (by using 
the trimming command in bowtie) improved mapping rates. It is likely that 
the poor percentage of mapped reads and the average quality of reads 
which successfully mapped will impact on the quantification of data in 
downstream analyses. 
3.4.5 I l lumina HiSeq2000 – Single end sequencing 
Due to low quality scores for raw data and low mapping rates obtained 
from the SOLiD paired end sequencing run, further neutrophil samples 
(untreated, GM-CSF and TNFα, N=1) were subsequently sequenced using 
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single-end sequencing (50bp) on the Illumina HiSeq2000 platform, by BGI 
International (Hong Kong). RNA was extracted and prepared using identical 
methods and couriered on dry ice to BGI. Sample processing was subject 
to identical QC analysis and any variation in sequencing protocols were 
due to platform-specific requirements. Quality control analysis (as provided 
by BGI International) of sequenced reads revealed that > 98% of reads 
exhibited a Phred score of > 20 (data not shown), representing a marked 
improvement in read quality over SOLiD datasets. 
Downstream analysis of SOLiD platform data (annotation and 
quantification) was performed using the methods described below and 
results are later used in validation and comparison analysis vs Illumina 
platform and qPCR results included in this chapter, (as indicated in the 
text). 
3.4.5.1 Illumina mapping strategy 
Due to higher quality values in raw data from the Illumina platform, it was 
not necessary to trim the 3’ end of the reads prior to mapping. In addition, 
improvements to the Tophat software (release version 1.4), meant that the 
Illumina reads could be mapped in a single-step process by Tophat using 
the command: 
tophat	  -­‐p	  8	  -­‐-­‐solexa1.3-­‐quals	  -­‐-­‐max-­‐multihits	  1	  -­‐o	  ./_output_with_gtf	  \	  
-­‐-­‐transcriptome-­‐index=/path/to/transcriptome/index	  \	  
/path/to/reference/genome	  path/to/raw.data	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Improved read quality and mapping strategy resulted in an increase in the 
percentage reads that mapped to reference sequence. Mapping 
percentages for Illumina sequenced datasets are listed in Table 3.3. 
Mapping rates were determined by TopHat version 1.4. 
 
Table	   3.3	   Percentage	   reads	   mapped	   for	   Illumina	   sequenced	   datasets,	   following	  
mapping	   with	   Tophat	   1.4.	   Percentage	   mapped	   reads	   calculated	   by	   Tophat	   during	  
processing.	  	  
	  
Dataset	   Reads	  mapped	  
(%)	  
Untreated	   94.5	  
GM-­‐CSF	   94.7	  
TNFα	   94.9	  
	  
 
3.4.5.2 Illumina read quality of mapped reads	  
To assess the quality of the 94% mapped reads from Illumina sequenced 
datasets, output files from Tophat (.Bam files) were analysed by FastQC 
(Fig 3.8). Reads had a markedly higher Phred score than those assessed 
form the SOLiD platform. Values were > 30 throughout the entire length of 
reads with an increase at the 3’ end. The inner quartile range was also 
much lower than with previous SOLiD samples. These data verify the high 
percentage mapping achieved with Illumina sequenced data and confirm 
that Illumina sequencing-platform (and sequencing by BGI International) is 
sufficient to produce high quality datasets of neutrophil RNA when 
mapped using Tophat. 
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Fig	  3.8	  FastQC	   194	  analysis	  of	  Bowtie/Tophat	  mapped	  reads	  from	  neutrophil	  untreated	  
datasets	   sequenced	   on	   the	   Illumina	   platform.	   Graph	   shows	   the	  mean	   quality	   values	  
(Phred	  score)	  (y-­‐axis),	  for	  each	  base	  position	  within	  the	  mapped	  reads	  (x-­‐axis).	  Scores	  
are	   represented	   by:	   inner	   quartile	   range	   (25-­‐75	   percentile)	   (Yellow	   boxes);	   median	  
Phred	  score	  (Red	  line);	  mean	  value	  (Blue	  line);	  and	  10-­‐90	  percentile	  (whisker	  plots).	  
 
3.4.5.3 Mapping-annotation and quantification 
Several programs are available for annotating and quantifying NGS data 
against a reference sequence. Broadly speaking software packages differ in 
the way they quantify gene expression and model variation within the 
population, relying on either an absolute count of reads mapping to a 
specific loci (in the case of edgeR and DESeq) or using a normalised metric 
for gene expression RPKM (in the case of Cufflinks) (covered in more detail 
in section 1.6.4). To evaluate the relative effectiveness of  annotation 
software, 3 widely-used, open source software packages (Cuffdiff- a 
subroutine of the Cufflinks package; DESeq; and edgeR) were compared 
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for their ability to quantify genes that are significantly differentially 
expressed (DE) between neutrophil samples incubated with either GM-CSF,  
TNFα, or untreated (Fig 3.9). DESeq and edgeR were run through the R 
software environment using a bespoke runscript adapted from the standard 
operating vignette 159,160. Cuffdiff was run with default settings providing 
both a reference genome (.fa file) and reference transcriptome (.gft file) to 
improve annotation accuracy. A significance value of q< 0.05 (applying a 
5% FDR) was applied in all 3 software packages. 
Of the three software packages used, Cuffdiff was found to be the most 
conservative in calling significantly differentially-expressed (DE) genes 
(UT:GM-CSF=110, UT:TNFα=82, GM-CSF:TNFα=151), whereas DESeq 
identified a similar number of genes as significantly DE (UT:GM-CSF=167, 
UT:TNFα=74, GM-CSF:TNFα=201). However, edgeR was the least 
conservative when calculating significantly DE genes, consistently 
quantifying approximately 3 times as many genes as the other two software 
programs (UT:GM-CSF=407, UT:TNFα=234, GM-CSF:TNFα=538) (Fig 3.9). 
The increased number of significant genes following DESeq and edgeR 
analysis is likely due to the poisson distribution utilised by these software 
packages. Poisson distribution of gene expression data is known to 
increase the number of false positives discovered by virtue of the fact that 
biological variation is not sufficiently estimated within the population 149,163. 
Determination of gene expression by Cufflinks/Cuffdiff provides an added 
benefit of several downstream software packages which are compatible 
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with the output format of Cufflinks. For example, cummeRbund 168 – an R 
based program specifically designed to perform downstream analyses and 
produce graphical output using Cufflinks/Cuffdiff data. In summary, 
Cufflinks was determined as the most suitable annotation and 
quantification software of neutrophil RNA-Seq data and was utilised in all 
subsequent analyses of datasets. 
 
 
Fig	  3.9	  Venn	  diagrams	  showing	  the	  number	  of	  differentially-­‐expressed	  genes	  between	  
neutrophil	   samples	   incubated	  with	  GM-­‐CSF	   (5	  ng/mL),	   TNFα	   (10	  ng/mL)	  or	  untreated	  
(UT)	   for	   1	   h.	   Determination	   of	   significance	   calculated	   using	   quantification	   software;	  
DESeq	  (orange),	  Cuffdiff	  (green)	  or	  edgeR	  (blue),	  q<0.05	  (5%	  FDR)	  N=3.	  
  
3.4.6 Analysis of platform, Donor and experimental variation 
To assess the level of variation between platforms, donors and also within a 
single experiment, RPKM levels of a subset of genes were analysed for 
correlation (Fig 3.10). To measure the levels of variation seen between 
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sequencing platforms, biological donors and sample replicates, correlation 
of the top 1000 most expressed genes between untreated neutrophil 
samples from several different experiments were compared. Firstly, two 
datasets of RNA samples from the same donor but sequenced on either 
the SOLiD or Illumina platforms were compared: this analysis would identify 
any differences in gene expression due to the different technology 
platforms (Fig 3.10A). Secondly, samples from 2 different donors, both 
sequenced on the Illumina platform were compared with each other (Fig 
3.10B): this analysis will give insights into donor variability and patterns of 
neutrophil gene expression. Thirdly, two samples from a single donor 
(prepared on separate days) sequenced on Illumina platform were 
compared to each other (Fig 3.10C). This would inform on the intra-donor 
variability in gene expression. Finally, data from a single experiment on the 
Illumina platform (but sequenced on different lanes of the sequencing flow 
cell) were compared to each other to measure the level of intra-
experimental variation (Fig 3.10D). 
Samples from the same donor sequenced on different platforms (SOLiD 
and Illumina) (Fig 3.10A), showed a much lower correlation than samples 
from the same donor sequenced on the same platform (Fig 3.10C), 
rs=0.656 and rs=0.9188 respectively. Indeed, levels of correlation between 
donors on the Illumina platform were equally high rs=0.9204 (Fig 3.10B). 
Intra-experimental (technical variation) correlation was extremely high 
(rs=0.9993) (Fig 3.10D).  
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Fig	   3.10	   Correlation	   of	   gene	   expression	   values	   (RPKM)	   between	   RNA-­‐Seq	   samples.	  
Gene	  expression	  values	  were	  compared	  between	  (A)	  SOLiD	  and	  Illumina	  platforms,	  (B)	  
2	  biological	  replicates	  (on	  Illumina	  platform)	  (C)	  2	  technical	  replicates	  (same	  Donor	  on	  
Illumina	   platform)	   and	   (D)	   2	   lanes	   from	   a	   single	   sequencing	   experiment	   on	   Illumina	  
platform.	   In	   each	   analysis	   1000	   genes	   with	   the	   highest	   expression	   were	   used	   in	  
correlation	  analysis	  (Spearman	  correlation	  	  metric	  (rs)	  p<0.0001).	  
	  
3.4.7 Validation of RNA-Seq data by comparison to qPCR  
RNA-Seq analysis methodologies are still regarded as a relatively new 
technique. As with any new assay or protocol, the most important measure 
of success, accuracy and applicability is how well the results correlate with 
the currently used “gold-standard” technique. In the case of gene 
expression studies the most established techniques remain either micro-
array or quantitative PCR (qPCR). RNA-Seq expression values for a selection 
of genes from 3 Donors measured by both SOLiD and Illumina platforms 
were compared with those obtained from qPCR for validation. A sample set 
of genes was selected that included genes that had high levels (>3000 
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RPKM) of expression: Interleukin-8 (IL-8), nicotinamide 
phosphoribosyltransferase (NAMPT), and suppressor of cytokine signalling-
3 (SOCS3); median levels (50-3000 RPKM) of expression: FBJ murine 
Osteosarcoma viral oncogene homolog (FOS), intercellular adhesion 
molecule-1 (ICAM1), and interleukin-1β (IL-1β); and low levels (<50 RPKM) 
of expression: Fas-associated via death domain (FADD), Jun proto-
oncogene (JUN), and TNFα. 
Firstly, absolute values of gene expression (RPKM) were compared 
between SOLiD samples and 3 biological replicates sequenced by Illumina 
(Fig 3.11A-C). As seen previously, gene expression levels were most similar 
in samples from the Illumina platform but values from SOLiD sequenced 
samples were also largely in line with the Illlumina sample replicates. 
Secondly, the fold change in gene expression for each gene was compared 
between the SOLiD samples, Illumina samples and qPCR data (Fig 3.12A-
B). Here, the fold change in gene expression for each gene was highly 
similar across all 3 platforms. This suggests that while the absolute values 
can vary between platforms (and replicates) the relative change in gene 
expression correlate well between independent platforms and validation 
methods.  
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Fig	   3.11	   Comparison	   of	   gene	   expression	   levels	   (RPKM)	   between	   RNA-­‐Seq	   platforms.	  
Expression	   levels	   of	   9	   genes	   expressed	   in	   neutrophils	   following	   1h	   incubation	   in	   (A)	  
absence,	   or	   presence	   of	   (B)	   GM-­‐CSF	   (5	   ng/mL)	   or	   (C)	   TNFα	   (10	   ng/mL).	   Expression	  
levels	   measured	   by	   SOLiD	   (¯)	   or	   by	   Illumina	   (p¢)	   sequencing	   platform	   and	  
calculated	  by	  Cufflinks.	  (SOLiD	  n=1,	  Illumina	  n=3).	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Fig	   3.12	   Fold	   change	   in	   expression	   of	   genes	   in	   (A)	   GM-­‐CSF	   and	   (B)	   TNF-­‐α-­‐treated	  
neutrophils	   compared	   to	   unstimulated	   cells,	   measured	   by	   qPCR	   (black	   bars,	   n	   =	   3),	  
SOLiD	  sequencing	   (grey	  bars,	  n	  =	   1)	  or	   Illumina	  sequencing	   (white	  bars,	  n	  =	  3).	  Error	  
bars	  represent	  SEM.	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Whilst it is important with any new technique to validate results with more 
established methods of measurement it is equally important to realise the 
limitations of the established technique. When comparing data from RNA-
Seq and qPCR experiments, there are several factors that need to be 
considered. Firstly, RNA sample preparation should be consistent between 
quantification techniques.  Secondly, PCR primers should be designed to 
amplify all variants of the gene under analysis and not miss out alternative 
splice variants, since RNA-Seq experiments can provide a quantification of 
all variants of a gene. Most importantly, the effect of normalisation method 
used for qPCR data must be appreciated. 
Quantification of transcript abundance from qPCR data is calculated using 
the number of PCR cycles required for transcripts to achieve exponential 
amplification (Ct value). This value can be transformed into a mean 
normalised expression (MNE) by normalising these values against a 
housekeeping gene 167,195. For neutrophil studies, a variety of housekeeping 
genes can be used, but Standford et al 196 have previously shown many of 
the commonly-used housekeeping genes used in other cell types vary in 
expression in neutrophils. This can lead to differences in the calculated 
relative expression values for a gene of interest, depending on which 
housekeeping gene is used to normalise the data. By comparison, RNA-
Seq data can be normalised to the entire size of the read library and the 
length of each gene independently (RPKM), and so does not necessitate 
normalisation to a pre-selected gene or set of genes 116. 
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3.4.9 Comparison of normalisation method in RNA-Seq and 
qPCR  
mRNA levels of TNFα are known to increase rapidly in neutrophils following 
stimulation with TNFα 183. RNA from untreated and TNFα treated 
neutrophils (10 ng/mL) was prepared and mRNA expression of TNFα was 
measured using qPCR. Threshold (Ct) values for TNFα mRNA were 
normalised against several different housekeeping genes that are often 
used in neutrophil gene expression; β-2microglobulin (B2M), 
glyceraldehyde-3-phosphate dehyrodgenase (GAPDH), β-actin (ACTB) and  
hypoxanthine phosphoribosyltransferase 1 (HPRT1) 196. In parallel, the fold 
change in TNFα expression for untreated neutrophils versus TNFα treated 
neutrophils was measured by RNA-Seq and RPKM values calculated by 
Cufflinks. RNA was prepared using identical RNA preparation methods and 
neutrophils from the same donor.  
The fold changes in expression levels in the TNFα stimulated cells versus 
the control varied from 10-fold to 22-fold, dependent on which 
housekeeping gene was selected for normalisation (Fig 3.13). The RNA-Seq 
value was found to correlate well with qPCR data normalised to GAPDH or 
B2M, but not to values normalised to ACTB or HPRT1. This highlights the 
care needed when analysing and interpreting qPCR data, and suggests that 
consideration should be given to the use of multiple housekeeping genes 
for normalisation of qPCR data, especially in cells such as neutrophils where 
the expression of genes used to normalise the data may be subject to 
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regulation during neutrophil activation. These data suggest that RPKM 
values are a more suitable and accurate metric for use in gene expression 
analysis and that this method of quantitation can be compared to 
appropriately controlled qPCR data.  
 
 
 
Fig	  3.13	  Fold	  change	  in	  expression	  of	  TNFα	  mRNA	  measured	  by	  qPCR	  (open	  bars)	  and	  
RNA-­‐Seq	   (black	   bar).	   qPCR	   Ct	   values	   for	   TNFα	   expression	   normalised	   to	   values	   for	  
commonly-­‐used	   housekeeping	   genes;	   β-­‐microglobulin	   (B2M),	   glyceraldehyde-­‐3-­‐
phosphate	   dehydrogenase	   (GAPDH),	   β-­‐actin	   (ACTB),	   	   hypoxanthine	  
phosphoribosyltransferase	   1	   (HPRT1).	   RNA-­‐Seq	   value	   normalised	   to	   read-­‐library	   size	  
and	  gene	  length	  (RPKM).	  
	  
 
3.4.10 Correlation of qPCR Ct values with RNA-Seq RPKM 
values 
Accurate detection of low-abundance transcripts in samples if often difficult 
to distinguish from experimental noise and DNA contamination. It is 
generally considered that a transcript requiring >30 cycles for detection in 
a qPCR experiment (Ct value > 30,) is likely to be a false positive. Likewise, 
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care must be taken when setting a RPKM threshold for gene expression in 
order to balance the number of false positives with the number of false 
negatives.  A study by Ramskold et al 197, attempted to characterise 
transcriptomes across different tissue types in both humans and mice  and 
determined that an RPKM value of 0.3 was an appropriate threshold, above 
which it can be concluded that the transcript is genuinely expressed.   
To confirm these findings and ascertain whether 0.3 RPKM was an 
appropriate threshold for neutrophil studies, RNA was extracted (as 
previously described) from 1 h untreated neutrophils and assayed using 
qPCR to determine the Ct value of 84 genes which had a range of 
expression levels. Values were compared to RNA-Seq data from 1h 
untreated neutrophils from the same biological donor.  Ct and RPKM 
values were found to significantly negatively correlate (rS=-0.91, p<0.0001, 
Spearman correlation). Importantly, data convergence was observed at 30-
cycles in qPCR and 0.3 RPKM in RNA-Seq (Fig 3.14). These data confirm 
that the pre-defined threshold of 0.3 RPKM is entirely appropriate and 
adequate to determine whether a transcript is expressed in neutrophils. 
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Fig	  3.14	  Correlation	  of	  gene	  expression	  values	  measured	  by	  qPCR	  and	  RNA-­‐Seq.	  RNA	  
from	  untreated	  neutrophils	   from	  the	  same	  biological	  donor	  was	  assayed	  using	  qPCR	  
and	   RNA-­‐Seq.	   Cycle	   threshold	   (Ct)	   values	   for	   qPCR	   were	   found	   to	   correlate	  
significantly	   with	   RPKM	   gene	   expression	   values	   (r=-­‐0.91,	   p<0.0001,	   Spearman	  
correlation).	  qPCR	  data	  collected	  by	  Dr	  C.	  Lam	  and	  analysed	  and	  reproduced	  here	  with	  
permission.	  
 
3.4.11 Downstream analysis of RNA-Seq data 
The above methods describe the software and protocols necessary to 
produce accurate gene expression data from a starting sample of total 
RNA. This pipeline can be utilised to produce normalised absolute-values 
(RPKM) of gene expression using Cufflinks, or a list of DE genes between 
multiple samples via Cuffdiff. These data are of great use and can be 
manually curated to extract information on genes of interest. However, to 
analyse larger portions of the data, (or compare entire datasets with each 
other) further downstream bioinformatic techniques are required. In 
general, bioinformatic analysis of gene expression data aims to simplify 
large amounts of data by identifying smaller gene-sets with similar 
expression patterns, or quantify levels of dissimilarity between whole 
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datasets/samples. This can be achieved in a variety of ways. A selection of 
software and bioinformatic analyses for downstream analysis of RNA-Seq 
data are described below. These methods complement the above 
bioinformatic RNA-Seq pipeline to form a comprehensive set of 
bioinformatic techniques which form the complete bioinformatic pipeline 
used in future results chapters (Chapters 4-6). Further details of specific 
downstream analysis are provided in the results sections of Chapters where 
they are employed. 
3.4.11.1 cummeRbund 
cummeRbund is a software package developed by the Cufflinks group 
(Trapnell et al) 168. It utilises the output files of Cufflinks and runs in the R 
software environment to produce several graphical representations of the 
gene expression data. These include: global visualisation of data in terms 
of quality, dispersion, or gene expression distribution; multi-dimensional 
scaling (MSA) for 2-dimensional representation of whole data sets; and 
gene clustering via heat maps 168. 
3.4.11.2 Ingenuity Pathway Analysis (IPA) 
The most powerful method of extracting meaningful data from large data 
sets is to model the data against large databases of canonical biological 
data. These are provided by a variety of online resources such as the Kyoto 
encyclopaedia of genes and genomes (KEGG) 198 or CLCbio by Qiagen. By 
far the most comprehensive database of biological pathways and 
interactions is held by Ingenuity systems 199. The Ingenuity pathway analysis 
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(IPA) software is a licensed online resource which allows the uploading of 
large datasets of NGS data, the data can then be modelled against their 
database of canonical pathways and referenced biological interactions. 
Subsequent analysis of the data can then be carried out to identify 
pathways or networks of genes which are significantly enriched with DE 
genes. Additionally, since the database of signalling pathways is so 
comprehensive, the software can be employed to identify upstream 
regulators and transcription factors based on the gene expression values 
provided. This is a powerful technique for predicting activation of signalling 
pathways and associated networks of genes from raw RNA-Seq gene 
expression values. 
3.4.11.3 Gene ontology 
An alternative method of summarising large gene lists is by Gene Ontology 
analysis. Genes are categorised by their universal gene ontology 
annotation (as defined by the Gene Ontology consortium 200). This provides 
a method of identifying sets of DE genes which share a common biological 
process, molecular function or cellular component, and identifying 
relationships between genes that would otherwise be impossible to 
achieve using a manual approach. 
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3.4.12 Final bioinformatic pipeline for neutrophil gene 
expression studies 
By way of summary, the components and work flow of the final 
bioinformatic pipeline developed for neutrophil gene expression analyses 
is shown in Fig 3.15. This represents a complete workflow for the 
production, quantification and analysis of neutrophil RNA-Seq data. 
 
Fig	  3.15	  Bioinformatic	  pipeline	  for	  production	  quantification	  and	  analysis	  of	  neutrophil	  
RNA-­‐Seq	   data.	   Flow	   diagram	   of	   sample	   preparation	   processes	   and	   software	  
incorporated	   into	   complete	   bioinformatic	   pipeline.	   Processes	   in	   white	   box	   were	  
completed	  by	  3rd	  party	  (BGI	  International).	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3.5 Summary 
Modern sequencing technology provide a method of accurately 
sequencing millions of DNA or RNA fragments on a massively parallel scale 
producing huge amounts of raw data. Whilst the efficiency and usability of 
sequencing technology has improved in recent years, the same cannot be 
said of NGS analysis software (in particular software that is open source). 
The bioinformatic community is saturated with various kinds of analysis 
software, each offering specific benefits over each other with respect to 
different aspects of the analysis process. Furthermore, there is no 
community wide agreement on best practices when it comes to analysing 
NGS data. The eclectic nature of bioinformatic methods in the literature 
attests to this. Hence before undertaking a study into neutrophil gene 
expression, it was first necessary to compile a robust set of software and 
protocols to accurately analyse the raw data produced by RNA-Seq. This 
pipeline could then be implemented for further studies into neutrophil 
gene expression. 
Neutrophils naturally express less mRNA than other leukocytes 178, thus it 
was necessary to quantify the amount of total RNA that could be extracted 
from a whole blood sample, whilst also assessing the integrity and quality 
of RNA following neutrophil isolation, RNA extraction and cleanup. 
Standard isolation of 30x106 neutrophils by Polymorphprep™ and 
extraction using TRIzol® (including a DNA digest step) was found to be 
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sufficient to produce 5 µg of high integrity (>8 RIN) purified RNA, which is 
often a prerequisite of 3rd party sequencing service providers. 
Sequencing of neutrophil RNA was carried out on 2 of the most popular 
sequencing platforms, SOLiD and Illumina. The paired-end sequencing on 
the SOLiD platform suffered from poor read quality values such that the 
shorter paired fragment could not be used in the mapping stage, the 
remaining reads mapped poorly to a reference sequence (<35 %) . Whilst 
paired-end sequencing is a useful method of increasing the total amount of 
read data from a single experiment, the library preparation protocols are 
more complex than single-end protocols and thus more likely to suffer 
experimental error. Furthermore, the ability of paired-end sequencing to 
improve mapping rates by removing mapping-location ambiguity is less 
relevant when dealing with samples where a complete and comprehensive 
reference sequence is available (such as with human samples). In contrast, 
sequencing carried out on Illumina platform by single-end sequencing was 
of a much higher quality and consequently resulted in extremely high 
mapping rates (>94%). Annotation and quantification of mapped reads was 
carried out by count-based (edgeR and DESeq) and gene normalisation 
(Cufflinks) techniques. These two approaches are frequently used in RNA-
Seq studies. Indeed, rather than one technique becoming preferred or 
optimal, it is likely that studies in the future will start to incorporate a 
combination of both approaches 201, for example a count based 
quantification for absolute gene expression values and a normalised 
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expression (RPKM) approach for transcript-level quantification. An added 
advantage of RNA-Seq data is that once reads are mapped adequately, 
data can subsequently be re-analysed or re-quantified using a different 
approach without the need for producing new samples.  
Following quantification, data were validated against results gained by 
qPCR.  
Despite numerous publications using RNA-Seq as the primary method of 
gene expression analysis, it is still common for research articles to include 
comparative qPCR results as validation of the accuracy of the primary RNA-
Seq data 202,203. Neutrophil RNA-Seq data from both platforms (SOLiD and 
Illumina) showed good correlation with results from qPCR, in particular 
when comparing fold change in gene expression rather than absolute 
values. In addition, correlation between datasets from the Illumina platform 
(either from a single donor or two donors) was extremely high (r > 9.1). This 
highlights the robust and reproducible nature of RNA-Seq data as a 
method of analysing large amounts of data.  
Two aspects of gene expression analyses that hinder studies using micro-
arrays or PCR are signal to noise ratios and normalisation of data 107,196,204. 
During the development of this bioinformatic pipeline the normalisations 
techniques and threshold value for positive expression were assessed in 
RNA-Seq by comparison to traditional qPCR methods. It was found that the 
normalised metric of RPKM was comparable to results gained by qPCR and 
since it relies on a defined value of gene length, is less variable than results 
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gained using multiple reference genes by qPCR. Moreover, it was 
confirmed that a previously defined 197 value of 0.3 RPKM is an appropriate  
cut-off value for gene expression and correlates well with a Ct value of 30 in 
qPCR. 
Since analysis of RNA-Seq is often (by virtue of the different software 
programs required) a multi-step process, compatibility of data with 
downstream analysis software is of crucial importance. The work flow within 
the bioinformatic pipeline benefits from being fully compatible at all 
stages, such that the output files from the annotation steps using cufflinks 
can seamlessly be inputted into each of the downstream analysis programs, 
for example cummeRbund or IPA. The greatest benefit of this inter-
compatibility is the usability and lack of informatic experience needed to 
carry out a RNA-Seq experiment using the above described software and 
settings. Improvements in software during the course of this study (Tophat 
alone received 12 iterative upgrades between 2010 and 2012) led to both 
improved performance and streamlining of the pipeline, for example, the 
ability to map all reads in a single Tophat command was not possible until 
the release of version 1.4.  
In summary the processes described above form a robust and user-friendly 
pipeline of analyses that can accurately measure the gene expression 
profile of neutrophils under different conditions. This pipeline will be 
utilised in subsequent chapters to further define the transcriptional profile 
of neutrophils in conditions of simulated inflammation. 
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Chapter 4: RNA-Seq analysis 
of neutrophil priming by 
GM-CSF and TNFα 
Bioinformatic analyses presented within this chapter were included in a 
publication in which I was co-lead author. 
 
Wright	  HL†,	  Thomas	  HB†,	  Moots	  RJ,	  Edwards	  SW	  (2013)	  RNA-­‐Seq	  Reveals	  
Activation	  of	  Both	  Common	  and	  Cytokine-­‐Specific	  Pathways	  following	  
Neutrophil	  Priming.	  PLoS	  ONE	  8(3):	  e58598.	  doi:10.1371/journal.pone.0058598	  
 
4.1 Introduction 
Neutrophil function in vivo is regulated by “priming” by inflammatory 
signals generated during an inflammatory response. Priming induces 
several rapid (<1 h) functional changes such as the mobilisation of internal 
granules (containing pre-formed receptors) to the cell surface, 
phosphorylation of key signalling proteins, and assembly of the NADPH 
oxidase leading to increased respiratory burst in response to a secondary 
activating signal 3. 
Several agents are able to prime neutrophils, including: lipid mediators 
such as leukotriene B4 and platelet activating factor (PAF); hormones and 
growth factors, such as melatonin and substance P; bacterial products, such 
as lipopolysaccharide (LPS); and numerous cytokines and chemokines, such 
as IL-1, -3, -8, G-CSF, IFNγ, GM-CSF and TNFα	   205,206. Stimulation of 
neutrophils by these agents in vitro induces a similar, “primed” phenotype 
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resulting from the short-term, rapid molecular changes described above. 
Consequently, priming agents are sometimes used interchangeably in 
neutrophil studies on the assumption that priming occurs via common 
mechanisms 207,208. Furthermore, it is well established that cytokines and 
other priming agents are able to regulate gene expression in neutrophils 
11,181,183,209,210 but few studies have examined the global gene expression 
profile in neutrophils following priming, and none to date have directly 
compared the patterns of gene expression induced by different priming 
agents.  
Although regarded as a prerequisite for neutrophil activation, priming also 
serves an important role as a regulatory mechanism. By requiring a second 
stimulus for transition from a quiescent neutrophil (for example in 
peripheral blood), to an activated neutrophil (for example at the site of 
inflammation), neutrophils are able to regulate their activation state much 
more specifically. Ultimately, this decreases the possibility of inappropriate 
or excessive neutrophil activation leading to damage to host tissue from 
the release of ROS and proteases. Despite this, neutrophil dysfunction and 
inappropriate activation is often a hallmark of inflammatory and 
autoimmune diseases. In many cases, the mechanisms leading to initial 
inappropriate activation of the immune system are poorly understood, but 
it is clear that elevated levels of inflammatory cytokines are fundamental to 
the progression and exacerbation of these conditions 2,3,32,211.   
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The importance of inflammatory cytokines in inflammatory diseases is 
highlighted by the success of the successful application of anti-cytokine (or 
cytokine-receptor) drug therapy. Drugs such as Anakinra (IL-1R antagonist), 
Tocilizumab (anti-IL-6R), Milivimumab (anti-GM-CSFR), secukinumab (anti-
IL17) and Belimumab (anti-B-cell activating factor (BAFF)) are routinely used 
in a variety of inflammatory diseases such as gout, SLE, psoriasis, Crohn’s 
and RA 3,211,212 (See table 1.1 for a more complete list of cytokine-targeting 
therapies). However, the most successful target for treatment of 
inflammatory disease is TNFα. Several drugs, such as Infliximab, 
Adalimumab, Cerolizumab-pegol, Golimumab and Etanercept are 
considered the front line treatment for conditions such as RA, COPD, 
Ankylosing spondylitis and Crohn’s disease. However, an important feature 
of these drugs is the varying degree to which patients respond. For 
example, it is estimated that approximately 30% of patients with RA who 
are prescribed anti-TNF will not respond 213. These patients will often have 
to switch therapies a number of times to alternative anti-TNF drugs, or to 
drugs such as Rituximab (anti B-cell) or Abatacept (anti-T-cell), before 
adequate disease control is achieved and maintained.  This highlights the 
heterogeneity that exists in inflammatory diseases such as RA and suggests 
that different cytokines may be responsible for driving inflammation in 
different patients. Whilst treating inflammatory diseases using a single anti-
cytokine drug is of merit, a comprehensive understanding of the molecular 
changes induced by inflammatory cytokines in health and disease, and how 
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this regulation differs between cytokines and individuals, is important to 
understand immune regulation, but could also lead to a more rationale-
based approach to drug treatment. 
 
4.2 Aims 
The aims of this chapter were: 
 
1. To utilise the previously-described pipeline of methods and 
bioinformatic techniques (Chapter 3) to quantify the neutrophil 
transcriptome following priming with GM-CSF and TNFα 
 
2. To compare the molecular changes in neutrophils induced by 
priming and identify genes and signalling pathways that are either 
common or specific to each priming agent.  
 
3. To determine if predictions made by bioinformatic analyses can be 
validated by functional assays. 
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4.3 Results 
4.3.1 Effect of GM-CSF and TNFα on neutrophil function 
Several cytokines are commonly used as priming agents for in vitro studies 
of neutrophil function. To assess whether priming by different agents had 
any effect on neutrophil function, priming of respiratory burst and levels of 
apoptosis after overnight incubation were compared in neutrophils treated 
with either GM-CSF or TNFα.  
4.3.1.1 Ability of GM-CSF and TNFα to prime the respiratory burst 
Neutrophils were treated for 30 min in the presence or absence of priming 
concentrations of GM-CSF (5 ng/mL) or TNFα (10 ng/mL). Following 
incubation, neutrophils were stimulated with fMLP (1 µM) in the presence of 
luminol (10 µM) and immediately measured every 24 s over a 25 min time 
course using a plate reader (see Methods, section 2.2.8). Both GM-CSF and 
TNFα primed neutrophils for an enhanced respiratory burst, peaking at 
approximately 1 min.  This first peak represents extracellular release of ROS 
214. A second peak at 5 min was seen in both primed samples, which 
corresponds to a delayed intra-cellular activation of reactive oxygen 
species (ROS), as previously described 214.  
The primed response of ROS production was slightly higher in GM-CSF 
primed samples compared to TNFα primed samples (GM-CSF; 32,2316 
relative luminescence units (RLU) p=0.0022, TNFα; 28,5858 RLU p=0.0077, 
N=4). Unprimed neutrophils exhibited a modest increase in 
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chemiluminescence compared to unstimulated cells (negative control) (Fig 
4.1A-B). 
 
 
 
 
 
Fig	  4.1	  GM-­‐CSF	   (GM)	  and	  TNFα	   (TNF)	  have	  similar	  effects	  on	  neutrophil	   function.	   (A)	  
Neutrophils	   were	   primed	   with	   either	   GM-­‐CSF	   (5	   ng/mL)	   or	   TNFα	   (10	   ng/mL),	   or	  
untreated	  (UT)	  for	  30	  min.	  The	  respiratory	  burst	  was	  stimulated	  with	  fMLP	  (1	  µM)	   in	  
the	   presence	   of	   luminol	   (10	   µM).	   Primed:	   black	   line;	   	   unprimed:	   grey	   line;	  	  
unstimulated:	  dotted	  line.	  Graph	  shows	  representative	  trace	  of	  relative	  luminescence	  
units	  (RLU).	  (B)	  Results	  of	  4	  separate	  chemiluminescence	  experiments	  calculating	  the	  
RLU	  by	  quantifying	  area	  under	  curve	  in	  each	  condition.	  Error	  bars	  represent	  ±	  SEM.	  (**	  
p<0.01,	   Student’s	   t-­‐test).	   (C)	   Neutrophils	   were	   incubated	   overnight	   (18	   h)	   in	   the	  
absence	   (UT)	   or	   presence	   of	   GM-­‐CSF	   (5	   ng/mL)	   or	   TNFα	   (10	   ng/mL),	   and	   percentage	  
apoptosis	   was	   quantified	   by	   annexin-­‐V/propidium	   iodide	   staining	   and	   measured	   by	  
flow	  cytometry.	  N=7.	  Error	  bars	  represent	  SEM.	  (***	  p<0.001,	  Student’s	  t-­‐test).	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4.3.1.2 Effect of GM-CSF and TNFα on neutrophil apoptosis 
To assess the effect of priming  neutrophils with GM-CSF and TNFα on 
levels of apoptosis, neutrophils were incubated at 37 °C + 5% CO2 for 18 h 
in the absence or presence of GM-CSF (5 ng/mL) or TNFα (10 ng/mL). 
Apoptosis was quantified by Annexin V/propidium iodide staining and flow 
cytometry (see Methods section 2.2.5).  Levels of apoptosis were 
significantly lower in both GM-CSF and TNFα treated samples compared to 
controls (p<0.01, paired Student’s t-test: untreated 66.5 % ±2.08 %; GM-
CSF 38.6 % ±2.55 %; TNFα 56.9 % ±2.61 %).  
Taken together, these data indicate that both GM-CSF and TNFα are able 
to prime neutrophils leading to: elevated respiratory burst (upon 
stimulation); and delayed apoptosis. However, these effects are not 
identical between priming agents, suggesting that GM-CSF and TNFα may 
induce subtle differences in neutrophil signalling during the priming 
response. 
 
4.3.2 Whole transcriptome sequencing of primed neutrophils 
To investigate the molecular changes in neutrophils following priming with 
GM-CSF and TNFα, whole transcriptome sequencing by RNA-Seq was 
carried out on mRNA from neutrophils incubated for 1 h with either GM-
CSF (designated as GM), TNFα (designated as TNF) or without stimulation 
(designated as UT). 
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RNA was extracted by TRIzol®/chloroform precipitation (see Methods 
section 2.2.9) and sequenced on the Illumina HiSeq 2000 platform 
(summarised in 1.5.5) using upwards of 40x106 single end reads (see 
Appendix table A.5 for total no. of reads). Reads where mapped to the 
human genome (hg 19) by Tophat and annotated using Cufflinks (as 
previously described in Chapter 3). 
 
4.3.3 RNA-Seq analysis of primed neutrophils  
4.3.3.1 Analysis of gene expression by Cufflinks.  
Following mapping and annotation (as previously described in Chapter 3), 
Cufflinks analysis was carried out to determine the number of genes 
expressed in each of the 3 sample conditions (UT, GM and TNF). Fig 4.2A 
details the number of genes which are either treatment specific, expressed 
under multiple conditions, or not expressed in neutrophils in any of the 3 
conditions (using a cut-off RPKM of  0.3). In total, 11,201 out of a possible 
23,283 genes were expressed in neutrophils in any of the 3 conditions. Of 
these, 10,056 (89.8%) were expressed in all conditions. Interestingly, some 
genes were only expressed under certain conditions (condition-specific).  
GM treatment resulted in the expression of the most condition-specific 
genes (229), with marginally less in UT (220) and TNF (193). A total of 
12,082 genes were not expressed in any condition, suggesting that under 
the conditions studied, neutrophils express approximately half of the 
human transcriptome. This number broadly agrees with previous micro-
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array-based studies into neutrophil transcript expression of peripheral 
blood neutrophils 181,215,216 (Fig 4.2A). If a threshold of expression of RPKM 
of 10 is applied to the data, to remove genes with low abundance from 
quantification analysis, the total number of genes expressed (≥ RPKM 10) 
decreases from 11,201 to 3,574, with the vast majority of filtered genes 
being those expressed in all conditions (RPKM ≥0.3 – 10,056 genes, RPKM≥ 
10 – 2,829 genes). Conversely, filtering out low abundance genes has a 
lesser effect on the number of condition-specific gene changes. For 
example, the number of GM-CSF-specific genes decreases from 229 to 
187, while TNFα-specific genes decreases from 193 to 109 (Fig 4.2B). 
These data reveal that neutrophils express almost half of the human 
transcriptome and that 90% of these genes are expressed irrespective of 
GM-CSF or TNFα treatment. However, a large number of these 
constitutively-expressed genes (a total of 7225 genes) are present at low 
abundance (< RPKM 10) whereas the majority of condition-specific genes 
are expressed at a higher abundance (> RPKM 10). 
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Fig	   4.2	   (A)	   Venn	   diagram	   showing	   the	   number	   of	   genes	   expressed	   (RPKM	   ≥	   0.3)	   in	  
untreated	   (UT),	   GM-­‐CSF	   primed	   (GM),	   TNFα	   primed	   (TNF)	   neutrophils,	   or	   not	  
expressed	  in	  any	  condition.	  (B)	  Increasing	  the	  expression	  threshold	  to	  an	  RPKM	  of	  10	  
to	   filter-­‐out	   low-­‐expression	   genes	   decreases	   the	   number	   of	   expressed	   genes	   in	   all	  
conditions.	  	  	  RPKM	  values	  of	  genes	  were	  calculated	  by	  Cuffdiff.	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4.3.3.2 Hierarchical clustering of highly expressed genes in UT, GM and 
TNF 
To better visualise and identify genes which are either common or specific 
to neutrophil priming conditions, hierarchical clustering of all genes with an 
RPKM ≥ 10 (in at least one of the 3 datasets) was performed using Multiple 
experiment Viewer (MeV)217(Fig 4.3). An expanded heatmap of the (150) 
highest expressed genes is also shown in Fig 4.3. These genes are 
associated with a number of functions and can be broadly categorised as: 
cell surface receptors; cytokines/chemokines; Interferon-induced genes; 
Major Histocompatibility Complex (MHC) proteins; calcium-binding 
proteins; adhesion molecules and apoptosis regulators. 
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Fig	  4.3	  Hierarchical	  clustering	  of	  genes	  expressed	  (≥	  RPKM	  10)	  in	  untreated	  neutrophils	  
(UNTR)	  or	   	  following	  priming	  by	  GM-­‐CSF	  or	  TNFα.	  RPKM	  values	  are	  represented	  on	  a	  
log10	  scale	  where	  green	  represents	   low	  expression,	  black	  median	  expression	  and	  red	  
high	  expression.	  Right	  hand	  column	  shows	  expanded	  heatmap	  of	  the	  150	  most	  highly	  
expressed	  genes.	  Several	  of	  the	  most	  highly	  expressed	  genes	  can	  be	  categorised	  into	  
functional	   groups,	   such	   as:	   cell	   surface	   receptors;	   cytokines/chemokines;	   Interferon-­‐
induced	   genes;	   Major	   Histocompatibility	   Complex	   (MHC)	   proteins;	   Calcium	   binding	  
proteins;	  adhesion	  molecules	  and	  apoptosis	  regulators.	  
	  
	  
4.3.3.3 Analysis of differentially expressed genes by Cuffdiff 
Following quantification of neutrophil genes expressed in each condition 
by Cufflinks, Cuffdiff analysis was applied to the data to quantify the 
number of genes which were significantly differentially expressed (DE) 
between sample conditions (q< 0.05, 5% FDR). This identifies the genes 
most affected during neutrophil priming and also identifies which genes 
were DE in neutrophils during priming by either GM-CSF or TNFα.  
 
	  	  
Fig	   4.4	   Number	   of	   significantly	   differentially	   expressed	   genes	   between	   neutrophils	  
treated	  with	  GM-­‐CSF	   (GM),	  TNFα	   (TNF)	  or	  untreated	   (UT).	  Significance	   calculated	  by	  
Cuffdiff	  (q<0.05,	  FDR	  5%).	  
 
Cuffdiff analysis revealed that neutrophil priming by GM-CSF significantly 
regulated the expression of 505 genes compared to untreated control. 
Likewise, priming by TNFα resulted in 250 differentially expressed genes. 
Surprisingly, the greatest number of DE genes was found to be between 
TNF 
UT GM 
505 
580 250 
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GM-CSF and TNFα (580 genes) (Fig 4.4). It could be hypothesised that 
since GM-CSF and TNFα exert similar effects on neutrophils phenotypically 
(as seen in Fig 4.1) their gene expression profile would be similar. However, 
these RNA-Seq data suggest that there are a greater number of genes 
differentially expressed between GM-CSF and TNFα than between either 
GM-CSF or TNFα and untreated controls. These 580 genes are further 
analysed in a later section (see section 4.3.3.6). 
 
Of the 755 genes which were DE between either GM-CSF or TNFα and UT 
(UT vs GM, 505 genes; UT vs TNF, 250 genes), 40 genes were up-regulated 
by at least 10-fold by either GM-CSF or TNFα. These genes are listed in 
Table 4.1. Interestingly, several genes relating to cytokines/chemokines 
were differently expressed by the two treatments. For example: Chemokine 
(C-C motif) ligand 3 (CCL3), CCL4 and the TNFα-gene (TNF) were only 
significantly upregulated by TNFα treatment, whereas oncostatin M (OSM) 
was only significantly upregulated by GM-CSF treatment. CXCL1 (also 
known as Chemokine (C-X-C Motif) Ligand 1) was upregulated 
approximately 3-fold greater by GM-CSF compared to TNFα (GM, 10.4-
fold; TNF, 3.6-fold), whereas CXCL2 was upregulated 6-fold greater by 
TNF than by GM (TNF,29-fold; GM,4.7-fold). The cytokines interleukin-1A 
(IL1A), IL-1β and interleukin receptor agonist (IL1RN) were the only genes 
that were significantly upregulated by more than 10-fold by both 
treatments (Table 4.1). 
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Table	   4.1	   Genes	   significantly	   up-­‐regulated	   at	   least	   10-­‐fold	   in	   either	   GM-­‐CSF	   or	   TNFα	  
treated	   neutrophil	   samples	   compared	   to	   untreated	   sample.	   Values	   represent	   fold	  
change	   in	   expression	   relative	   to	   control.	   	   All	   values	   are	   significant,	   as	   calculated	   by	  
Cuffdiff	  (q<0.05,	  5%	  FDR)	  unless	  stated	  (NS	  =	  not	  significant). 
 
Gene	   GM-­‐CSF	   TNFα 	  
CCL3	   NS	   41.5	  
CCL4	   NS	   99.6	  
CD69	   57.5	   NS	  
CISH	   102.1	   NS	  
CXCL1	   10.4	   3.6	  
CXCL2	   4.7	   29.0	  
DUSP2	   NS	   12.1	  
EDN1	   16.5	   NS	  
EGR1	   57.9	   NS	  
EGR2	   21.5	   NS	  
GADD45B	   NS	   15.8	  
GPR84	   NS	   74.9	  
HBEGF	   33.2	   NS	  
HCAR2	   12.1	   NS	  
HCAR3	   12.2	   NS	  
HRH4	   32.3	   NS	  
ICAM1	   10.6	   7.7	  
IL1A	   35.3	   67.0	  
IL1B	   22.8	   13.8	  
IL1RN	   12.4	   31.4	  
KCNJ2	   NS	   16.6	  
MFSD2A	   -­‐1.6	   11.9	  
NFKBIA	   NS	   11.9	  
NFKBIE	   NS	   15.8	  
OLR1	   NS	   3.2	  
OSM	   15.0	   NS	  
PDE4B	   11.8	   NS	  
PLAU	   5.8	   13.9	  
PNPLA1	   -­‐2.1	   10.2	  
PPP1R15A	   3.6	   10.2	  
RHOH	   26.3	   NS	  
SLC35B2	   NS	   10.4	  
SOCS3	   90.2	   NS	  
TARP	   13.5	   NS	  
TIFA	   6.7	   17.7	  
TNF	   NS	   25.8	  
TNFAIP3	   2.7	   16.1	  
TNFAIP6	   NS	   10.6	  
TRAF1	   NS	   11.6	  
ZFP36	   11.4	   4.7	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4.3.3.4 Gene ontology analysis of genes with differential expression in 
either GM-CSF or TNFα  
Following identification of a subset of genes showing differential 
expression during neutrophil priming with GM-CSF or TNFα, further 
characterisation of these genes was performed by Gene Ontology (GO) 
analysis. GO analysis is a method of gene annotation used to collate and 
categorise large lists of genes (of the type often produced during large 
genetic studies such as RNA-Seq analyses) on the basis of known functional 
associations. Genes are assigned to GO terms based on their known 
function or functional association. GO terms are broadly categorised into 3 
hierarchical classes: biological process; molecular function or cellular 
component 200. Within each class, additional GO terms are structured in a 
hierarchical manner such that “high level” (or broadly descriptive) terms 
would include terms such as “signal transduction” or “cell growth and 
maintenance”. Whereas, more specific “low level” GO terms would include 
terms such as “pyrimidine metabolism” or “cAMP synthesis” 218. This allows 
the summarising of large sets of genes and the identification of common 
functional properties within groups of co-expressed genes. 
Gene Ontology analysis using the online software DAVID 219 revealed that 
genes DE by either GM-CSF or TNFα led to enrichment of GO terms that 
were cytokine-specific and common to both treatments (Table 4.2). High 
level GO categories, such as “inflammatory response” or “response to 
wounding” were represented in both GM-CSF and TNFα samples, whereas 
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more specific low level GO categories were represented in only one 
treatment sample. For example, “regulation of I-kappaB kinase/NF-kappaB 
cascade” and was only represented in TNFα samples, whilst “positive 
regulation of nitric oxide biosynthetic process” was only represented in 
GM-CSF samples (Table 4.2). 
4.3.3.5 Pathway analysis of genes with differential expression in either GM-
CSF or TNFα 
GO analysis is a useful bioinformatic approach to describe biological 
functions or cellular processes and to discover functional relationships 
within in a set of genes. However, the process is not sufficiently powerful to 
accurately predict activation of specific signalling pathways or identify 
upstream regulation of transcription factors. Therefore, further analyses 
were carried out on the genes DE by either GM-CSF or TNFα  using 
Ingenuity Pathway Analysis software (IPA) 220 to identify if the genes 
expressed during neutrophil priming by each priming agent activated 
common or different signalling pathways and transcription factors.  
IPA analysis identified that neutrophils primed with TNFα or GM-CSF 
significantly regulated a number of intracellular signalling pathways. For 
example, genes DE following TNFα treatment were found to regulate 
pathways associated with: TNF- and death-receptor activation; apoptosis; 
and APRIL (A Proliferation-Inducing Ligand) signalling (Fig 4.5A).  
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Table	   4.2	  Gene	  Ontology	   analysis	   of	   genes	  with	  DE	  during	  priming	  with	   TNFα	   (TNF)	  
and	  GM-­‐CSF	  (GM).	  *	  represents	  which	  dataset	  GO-­‐terms	  were	  found	  to	  be	  significantly	  
enriched	  	  (compared	  to	  untreated	  control	  dataset).	  
 
GO	  Term	   GO	  Category	   GM	   TNF	  
GO:0006954	   Inflammatory	  response	   *	   *	  
GO:0009611	   Response	  to	  wounding	   *	   *	  
GO:0006955	   Immune	  response	   *	   *	  
GO:0042981	   Regulation	  of	  apoptosis	   *	   *	  
GO:0006952	   Defense	  response	   	   *	  
GO:0006935	   Chemotaxis	   	   *	  
GO:0043122	   Regulation	  of	  I-­‐kappaB	  kinase/NF-­‐kappaB	  cascade	   	   *	  
GO:0007243	   Protein	  kinase	  cascade	   	   *	  
GO:0031328	   Positive	  regulation	  of	  cellular	  biosynthetic	  
process	  
*	   	  
GO:0010557	   Positive	  regulation	  of	  macromolecule	  
biosynthetic	  process	  
*	   	  
GO:0010628	   Positive	  regulation	  of	  gene	  expression	   *	   	  
GO:0045321	   Leukocyte	  activation	   *	   	  
GO:0010604	   Positive	  regulation	  of	  macromolecule	  metabolic	  
process	  
*	   	  
GO:0001775	   Cell	  activation	   *	   	  
GO:0045766	   Positive	  regulation	  of	  angiogenesis	   *	   	  
GO:0051789	   Response	  to	  protein	  stimulus	   *	   	  
GO:0008285	   Negative	  regulation	  of	  cell	  proliferation	   *	   	  
GO:0051174	   Regulation	  of	  phosphorus	  metabolic	  process	   *	   	  
GO:0019220	   Regulation	  of	  phosphate	  metabolic	  process	   *	   	  
GO:0032570	   Response	  to	  progesterone	  stimulus	   *	   	  
GO:0042325	   Regulation	  of	  phosphorylation	   *	   	  
GO:0045429	   Positive	  regulation	  of	  nitric	  oxide	  biosynthetic	  
process	  
*	   	  
GO:0006350	   Transcription	   *	   	  
GO:0045893	   Positive	  regulation	  of	  transcription,	  DNA-­‐
dependent	  
*	   	  
GO:0051254	   Positive	  regulation	  of	  RNA	  metabolic	  process	   *	   	  
GO:0045859	   Regulation	  of	  protein	  kinase	  activity	   *	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However, genes DE by GM-CSF treatment were found to regulate: p38 
mitogen-activated protein kinase (MAPK) signalling; JAK/STAT signalling; 
and protein ubiquitination pathways (Fig 4.5B). The NF-κB pathway was 
found to be regulated by both GM-CSF and TNFα; however whereas TNFα 
positively regulated the NF-κB pathway, GM-CSF negatively regulated this 
(Fig 4.5C-D). IPA analysis reports signalling pathways whose components 
(genes) have been significantly up- or down-regulated by treatment. The 
software calculates the significance of pathway regulation based on the 
proportion of a canonical pathway which is enriched with DE genes. For 
example, if 18/24 genes in a signalling pathway are DE (versus control) then 
that pathway is more likely to be defined as significantly regulated than if 
only 2/24 genes are DE. However, the analysis does not distinguish if the 
signalling pathway has been (on the whole), up- or down-regulated. To 
further elucidate the specific regulation within a signalling pathway, the up- 
or down-regulation of each gene within a signalling pathway can be colour-
coded and visualised to identify which portions of the pathway are 
regulated, and in what way. For example, genes which have increased 
expression (compared to control) are coloured red, genes whose 
expression is lower than in control are coloured green), genes with no 
change are shaded grey and those genes with no data are unshaded 
(white) (Fig 4.5C-D). 
Having identified the NF-κB pathway as being significantly-regulated by 
both GM-CSF and TNFα, further analysis was carried out to determine if 
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similar genes within the pathway were regulated in a similar fashion.  Fig 
4.5C reveals that following TNFα priming, the majority of genes within the 
NF-κB pathway were upregulated (compared to untreated sample). 
Conversely, priming with GM-CSF led to a down-regulation of several 
genes within the NF-κB pathway (Fig 4.5D). This highlights an important 
difference between the molecular changes induced by both priming agents 
that would otherwise be overlooked if simply looking at signalling pathways 
that were significantly regulated.  
4.3.3.6 Analysis of genes that are differentially-expressed between GM-CSF 
and TNFα  
Cuffdiff analysis identified 580 genes that were DE between GM-CSF and 
TNFα treated neutrophils (Fig 4.4). These genes therefore represent those 
that reflect the greatest differences regulated by the two priming agents. 
Further analysis was carried out on these genes to identify their functional 
associations. 
GO analysis revealed that 44 GO-terms were significantly enriched (see 
Appendix Table A.6 for full list of enriched GO-terms). Of the 44 GO-terms, 
11 were directly related to cell death and/or apoptosis, including the most 
represented GO-term “Regulation of apoptosis” (containing 58 genes from 
the dataset). A similar result was obtained by IPA analysis of the 580 genes 
that identified “Apoptosis” as the cellular function with the greatest 
differential regulation between the two treatments (p= 6.78E-23). Table 4.3 
lists the RPKM values for each of the 58 genes found to be DE between 
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GM-CSF and TNFα. IPA analysis was carried out to identify upstream 
transcription factor activation. A total of 36/58 genes were more highly-
expressed in TNFα	   treated samples, and of these, IPA analysis predicted 
that 23 were regulated by the NF-κB system (p=5.77E-21) (Fig 4.5E). 
Conversely, a total of 22/58 genes had higher expression in GM-CSF 
samples, of which, 15 where predicted by IPA analysis to be regulated by 
the STAT family of transcription factors (p=2.73E-12), in particular STAT3 and 
STAT5 (Fig 4.5E). 
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Fig	  4.5	  Analysis	  of	  signalling	  pathways	  in	  TNFα	  and	  GM-­‐CSF	  primed	  neutrophils.	  (A-­‐B)	  	  
Bar	   graphs	   show	   the	   canonical	   pathways	  with	   the	  most	   significant	   regulation	   in	   (A)	  
TNFα-­‐	   or	   (B)	   GM-­‐CSF-­‐	   treated	   neutrophils	   compared	   to	   untreated	   control.	   Bars	  
represent	  the	  probability	  (p-­‐value)	  that	  the	  enrichment	  of	  significant	  genes	  within	  the	  
canonical	  pathway	  is	  due	  to	  chance	  alone.	  Orange	  line	  represents	  the	  ratio	  of	  number	  
of	   genes	   that	   are	   enriched	   in	   the	   pathway	   to	   the	   total	   number	   of	   genes	   in	   the	  
pathway.	  (C-­‐D)	  NF-­‐κB	  pathway	  was	  identified	  as	  being	  significantly	  regulated	  in	  both	  
(C)	  TNFα-­‐	  or	  (D)	  GM-­‐CSF-­‐	  treated	  neutrophils	  compared	  to	  control;	  genes	  significantly	  
up-­‐regulated	   are	   coloured	   in	   red,	   down-­‐regulated	   in	   green	   and	   genes	   with	   no	  
significant	   change	   are	   shaded	   in	   grey.	   Genes	   where	   no	   data	   is	   available	   are	   have	  
orange	  boxes.	   (E-­‐F)	   IPA	  analysis	  of	  58	  apoptosis-­‐regulating	  genes	  with	  significant	  DE	  
between	  TNFα	  and	  GM-­‐CSF	  treated	  neutrophils.	  (E)	  NF-­‐κB	  activation	  was	  predicted	  in	  
TNFα-­‐	   treated	  neutrophils	   (p=9.04E-­‐11),	  whereas	  STAT	  activation	   (F)	  was	  predicted	   in	  
GM-­‐CSF-­‐treated	   neutrophils	   (p=2.26E-­‐05).	   The	   RPKM	   values	   of	   individual	   genes	   are	  
represented	  by	  increasing	  intensity	  of	  red. 
 
 
Table	  4.3	  Gene	  expression	  value	  (RPKM)	  of	  58	  apoptosis-­‐related	  genes	  significantly	  DE	  
in	  neutrophils	  treated	  with	  GM-­‐CSF	  or	  TNFα.	  RPKM	  values	  calculated	  by	  Cufflinks	  and	  
significance	  of	  DE	  calculated	  by	  Cuffdiff	  (q<0.05	  5%FDR).	  
 
Gene	   GM-­‐CSF	   TNFα 	  
ANXA1	   231.73	   82.28	  
APAF1	   20.50	   24.50	  
BBC3	   3.58	   15.43	  
BCL3	   323.05	   764.80	  
BID	   66.72	   192.62	  
BIRC3	   14.36	   107.60	  
CARD16	   68.22	   114.51	  
CARD6	   12.14	   2.73	  
CASP1	   65.68	   87.50	  
CDKN1A	   44.49	   16.55	  
CDKN2C	   0.37	   1.09	  
CHST11	   61.81	   79.18	  
CLCF1	   0.95	   6.73	  
CREB1	   8.22	   13.50	  
DDIT3	   240.01	   109.21	  
F3	   0.80	   2.98	  
FAS	   33.88	   62.78	  
GCH1	   12.90	   31.89	  
GHRL	   6.28	   12.84	  
HSPD1	   20.84	   8.29	  
ID3	   2.01	   <0.3	  
INPP5D	   68.32	   88.53	  
MAEA	   27.03	   57.98	  
NET1	   5.76	   0.60	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NFKB1	   21.19	   42.05	  
NFKBIA	   225.87	   3901.19	  
NLRP3	   16.81	   49.76	  
NR4A1	   2.02	   21.41	  
NR4A2	   18.14	   50.14	  
NUAK2	   5.25	   24.99	  
PIM1	   98.05	   11.26	  
PIM2	   36.66	   260.17	  
PIM3	   74.97	   246.79	  
PLAGL2	   4.81	   33.72	  
PPIF	   1352.77	   488.80	  
PRNP	   17.15	   4.24	  
PROK2	   582.65	   210.88	  
PSEN1	   39.99	   69.94	  
RIPK2	   92.35	   36.63	  
RRM2B	   7.70	   16.15	  
SERPINB9	   13.36	   37.09	  
SLC11A2	   0.78	   1.82	  
SMPD2	   2.04	   9.13	  
SOCS2	   23.61	   2.96	  
SOCS3	   4060.71	   36.45	  
SOD2	   2696.87	   4619.77	  
SQSTM1	   114.89	   280.27	  
TGM2	   4.84	   0.68	  
THBS1	   13.16	   52.91	  
TICAM1	   9.98	   47.41	  
TNFAIP3	   244.30	   1451.80	  
TNFRSF10D	   12.54	   1.09	  
TNFSF14	   41.61	   85.44	  
TNFSF15	   3.59	   0.77	  
TNFSF8	   19.93	   5.93	  
TPT1	   3025.26	   1310.06	  
UTP11L	   5.02	   1.39	  
ZAK	   1.40	   0.51	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4.3.4 Regulation of neutrophil apoptosis by GM-CSF and TNFα 
v ia activation of different transcription factors  
The above bioinformatic analyses revealed that whilst priming of 
neutrophils with either GM-CSF or TNFα	  results in expression of apoptosis-
regulating genes, they do so via different signalling pathways and by 
activation of different transcription factors. Further functional assays were 
employed to validate these findings, as detailed below. 
4.3.4.1 Levels of apoptosis in neutrophils following addition of inhibitors of 
signalling pathways 
Neutrophils were incubated overnight (18 h) with GM-CSF (5 ng/mL) or 
TNFα (10 ng/mL) in the presence of chemical inhibitors of NF-κB 
(wedeloactone, 50 µM) and JAK/STAT (JAK inhibitor-1, 10 µM). Levels of 
apoptosis were measured following annexin-V/PI staining by flow cytometry 
(see Methods section 2.2.5). Levels of apoptosis in GM-CSF and TNFα 
treated neutrophils were in-line with previously described experiments (see 
section 4.3.1.2) (untreated 60.35% ± 6.98%; GM-CSF 36.96% ± 6.56%; 
TNFα 50.07% ± 5.89%). Inhibition of NF-κB by wedeloactone abrogated 
the anti-apoptotic effect of TNFα (p<0.05, Student’s t-test), but had no 
effect on GM-CSF-delayed apoptosis. Conversely, inhibition of STAT using 
JAK inhibitor-1 abrogated GM-CSF-delayed apoptosis (P<0.05, Student’s t-
test), and only partially attenuated TNFα-delayed apoptosis (although this 
was not significant p>0.05) (Fig 4.6A). 
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4.3.4.2 Western blot analysis of neutrophils following addition of signalling 
inhibitors  
Next, activation-states of NF-κB and JAK/STAT pathways were determined 
by western blotting for phospho-STAT3, phospho-NF-κB and IκB-α. 
Neutrophils were pre-incubated for 1 h with wedeloactone or JAK inhibitor-
1 before addition of GM-CSF (5 ng/mL) or TNFα (10 ng/mL). Following 15 
min incubation, protein lysates were made using boiling Laemmli buffer 
containing a phosphatase inhibitor cocktail (see Methods section 2.2.6). 
Activation of NF-κB and degradation of IκB-α was seen in TNFα-­‐ treated 
samples, which was abrogated by wedeloactone but not by JAK inhibitor-
1. Conversely, GM-CSF treatment did not activate NF-κB but was able to 
activate STAT3, which was inhibited by JAK inhibitor-1 (Fig 4.6B). These 
data confirm the predictions made by the bioinformatic analyses: 
regulation of neutrophil apoptosis by GM-CSF and TNFα is achieved via 
differential activation of transcription factors. 
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Fig	   4.6	   Delayed	   neutrophil	   apoptosis	   in	   GM-­‐CSF-­‐	   and	   TNFα-­‐	   treated	   neutrophils	   is	  
regulated	   by	   different	   transcription	   factors.	   (A)	   Overnight	   (18	   h)	   incubation	   of	  
neutrophils	  with	  GM-­‐CSF	  or	  TNFα	  significantly	  delayed	  apoptosis	  (†	  p<0.05,	  Student’s	  t-­‐
test)	  compared	  to	  untreated	  (UNTR).	  Inhibition	  of	  STAT	  signalling	  with	  JAK	  inhibitor-­‐1	  
(JAK1,	   10	  µM)	  abrogated	   the	  effect	  of	  GM-­‐CSF	  on	  neutrophil	  apoptosis	   (*p<0.05)	  but	  
did	   not	   affect	   TNFα-­‐delayed	   apoptosis.	   Inhibition	   of	   NF-­‐κB	   with	   wedelolactone	  
(WEDEL,	   50	   µM)	   abrogated	   the	   effect	   of	   TNFα	   (*p<0.05),	   but	   not	   GM-­‐CSF,	   on	  
neutrophil	  apoptosis.	  (B)	  Western	  blot	  of	  NF-­‐κB	  and	  STAT3	  activation	  in	  GM-­‐CSF-­‐	  and	  
TNFα-­‐	   treated	   neutrophils.	   TNFα	   induced	   rapid	   phosphorylation	   of	   NF-­‐κB	   and	  
degradation	   of	   IκBα,	  which	  was	   inhibited	   by	  wedelolactone.	   GM-­‐CSF	   did	   not	   induce	  
phosphorylation	   of	   NF-­‐κB	   or	   degradation	   of	   IκBα,	   but	   did	   induce	   STAT3	  
phosphorylation	  which	  was	  inhibited	  by	  JAK	  inhibitor-­‐1.	  TNFα	  did	  not	  activate	  STAT3	  in	  
neutrophils.	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4.4 Discussion 
Priming is an important process to regulate neutrophil activation. 
Appropriate priming ensures that neutrophils arrive at the site of 
inflammation suitably prepared for their anti-microbial roles. Priming also 
ensures that neutrophils do not become non-specifically activated at non-
inflammatory sites, such as in the bloodstream. The rapid changes induced 
by priming are well established, but the longer term molecular changes, 
such as de novo gene expression, are poorly defined. Moreover, the 
specific effects of individual priming agents on gene expression in 
neutrophils is limited to a few studies 181,182,221,222, and no studies have 
directly compared the effects of two cytokines using RNA-Seq. 
This chapter set out to characterise the molecular changes induced by two 
inflammatory cytokines, GM-CSF and TNFα. Although both cytokines are 
known neutrophil-priming agents, and are elevated during inflammation 
and in inflammatory disease, little was known of any differences that may 
exist during priming with these cytokines. 
Neutrophils were treated with priming concentrations of GM-CSF and 
TNFα and analysed by RNA-Seq to quantify the global changes in gene 
expression induced during neutrophil priming. Functional experiments 
using GM-CSF and TNFα revealed that both agents were able to rapidly 
prime the respiratory burst and delay apoptosis over the course of 18 h. 
While GM-CSF was a stronger inducer of these anti-apoptotic effects, the 
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effects of both priming agents were significantly different when compared 
to unprimed controls (p<0.01).  
RNA-Seq and bioinformatic analysis of primed and unprimed neutrophils 
revealed that approximately half of the human transcriptome was 
transcribed under the conditions analysed, with the majority of genes being 
transcribed in all 3 conditions. However, several hundred genes were found 
to be expressed uniquely in each of the 3 conditions. Analysis of the most 
highly expressed genes, identified transcripts associated with several 
functional categories such as cell surface receptors, adhesion molecules 
and cytokines/chemokines. This suggests that although a large proportion 
of the human transcriptome is actively transcribed in both primed and 
unprimed neutrophils, the levels of expression of the majority of these 
genes are very low and most likely do not play an important role in 
neutrophil function under the conditions analyses. The identification of 
specific genes that are only expressed under certain conditions, (the 
majority of which had expression levels (RPKM) >10), suggest that not only 
is the neutrophil transcriptome dynamically-regulated, but that the global 
gene expression profile of primed neutrophils is regulated by the initial 
priming agent. It is therefore likely that the subsequent phenotype of a 
primed neutrophil is governed by the priming agent. Importantly, among 
the most highly-expressed genes in both GM-CSF and TNFα-treated 
neutrophils were cytokine/chemokine genes. For example, TNFα treatment 
led to a more than 10-fold increase in expression of TNF, CCL3 CCL4 and 
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CXCL2. Whereas GM-CSF treatment resulted in a >10-fold expression of 
CXCL1 and OSM, both treatments upregulated expression of IL1A, IL1B, 
and IL1RN. Thus, cytokine/chemokine production appears to be 
differentially-expressed by these two inflammatory cytokines. These 
findings have important implications for inflammatory disease where high 
levels of inflammatory cytokines are common, such as TNFα in RA 223 or 
psoriasis 90. 
It is well established that both GM-CSF and TNFα delay neutrophil 
apoptosis 178,183,184,224,225. However, RNA-Seq analysis of neutrophils has 
revealed that the genes regulating apoptosis are DE during priming with 
these two cytokines. Pathway analysis of 58 apoptosis-related genes found 
to be DE between cytokine treatments predicted differential activation of 
two independent transcription factors families. NF-κB was predicted to be 
activated following TNFα treatment, whereas STAT activation was 
predicted following GM-CSF treatment.  
RNA-Seq followed by bioinformatic analysis is a powerful way to 
characterise the molecular changes induced by different stimuli or 
inflammatory conditions. The scale of data produced and the 
comprehensive databases of canonical biological processes allow accurate 
predictions of functional mechanisms from the expression profile of 
associated genes. Nevertheless, where possible, bioinformatic predictions 
should always be verified by functional assays.  
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Bioinformatic predictions of differential activation of transcription factors in 
neutrophils was verified using functional assays measuring neutrophil 
apoptosis and pathway activation in the presence and absence of specific 
inhibitors of signalling pathways. Inhibition of NF-κB abrogated the anti-
apoptotic effect of TNFα and inhibited TNFα-induced phosphorylation of 
NF-κB. Conversely, STAT inhibition abrogated the anti-apoptotic effect of 
GM-CSF and inhibited the GM-CSF-induced phosphorylation of STAT3. 
Neither wedeloactone nor JAK inhibitor-1 had any significant effects on 
GM-CSF or TNFα-induced function, respectively. Whilst activation of NF-κB 
by TNFα and STAT by GM-CSF has previously been shown in neutrophils, 
their involvement in cytokine-delayed apoptosis is less well studied. 
During inflammation, it is likely that neutrophils are exposed to a variety of 
cytokines at sites of inflammation (including both GM-CSF and TNFα). 
Therefore, for apoptotic pathways at least, there is a level of redundancy of 
processes capable of maintaining neutrophil survival. These discrete 
signalling pathways may allow the effects of each cytokine to act additively 
to increase the anti-apoptotic effect in situations where multiple cytokines 
are present.  
 
Among the genes with highest expression following treatment with either 
cytokine, were several genes associated with suppression or inhibition of 
signalling. For example, TNFα treatment induced expression of NFkBIA, 
NFKBIE and TNFAIP3 – inhibitors of NF-κB signalling. Similarly, GM-CSF 
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increased expression of gene associated with suppression of STAT 
signalling (CISH and SOCS3). This suggests that in addition to activating 
different transcription families, priming by GM-CSF and TNFα also induces 
expression of inhibitors of these transcription factors. This mechanism thus 
provides a way of controlling the signalling by provision of a negative 
feedback loop.	  	  
In summary, these data suggest that the nature of the initial priming agent 
during neutrophil priming is crucial in determining the subsequent 
phenotype and functional capacity of the primed and/or activated 
neutrophil. The molecular differences that exist between neutrophils 
primed by different agents have successfully been characterised using a 
systems-based approach of RNA-Seq technology and current bioinformatic 
software, and have successfully been validated post hoc by traditional 
laboratory functional assays. 
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Chapter	  5:	   	  Activation	  of	  gene	  
expression	   by	   pro-­‐
inflammatory	  cytokines	  
Bioinformatic analyses presented within this chapter (section 5.4.2.5) were 
included in a publication in which I was second author. 
 
Wright,	  H.L.,	  Thomas,	  H.B.,	  Edwards,	  S.W.,	  Moots,	  R.J.	   (2015)	   Interferon	  gene	  
expression	   signature	   in	   RA	   neutrophils	   predicts	   response	   to	   anti-­‐TNF	  
therapy.	  Rheumatology,	  Vol	  54	  (1):	  188-­‐193	  
5.1 Introduction 
In the previous chapter, neutrophil gene expression was analysed by RNA-
Seq following stimulation with two inflammatory cytokines capable of 
priming neutrophils (GM-CSF and TNFα). Whilst these cytokines are often 
found at the site of inflammation at high concentrations, neutrophils are 
unlikely to be exposed to these cytokines alone during an inflammatory 
response. Epithelial cells and other surrounding activated leukocytes 
express and release a variety of inflammatory signals during inflammation, 
each playing a role in regulating and propagating the immune response 5.  
Details of how inflammatory signals affect neutrophil function, either 
individually or in combination are poorly-defined. Indeed, for studies using 
human neutrophils, there is still contention around whether neutrophils can 
respond directly to certain cytokines such as IL-6 206,226 and IL-17 227. Thus, a 
greater understanding of the molecular consequences of stimulation by 
different inflammatory mediators will provide a means to identify the genes 
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and proteins most commonly-associated with a particular stimulus (or 
group of stimuli). 
In this chapter, neutrophils were treated with cytokines/chemokines 
commonly-associated with either sterile or pathogen-driven inflammation, 
and changes in gene expression were analysed using the bioinformatic 
pipeline previously described (Chapter 3). Neutrophils were stimulated for 
1 h with one of 5 cytokine/chemokines (G-CSF, IFNγ, IL-1β, IL-8, IL-6). In 
addition, neutrophils were stimulated with GM-CSF and TNFα (dual-
treated) to analyse the effects of multiple cytokines compared to activation 
by these agents used singly. 
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5.2 Aims 
The aims of this chapter were: 
 
1. To utilise a previously-described pipeline of methods and 
bioinformatic techniques (Chapter 3) to quantify the neutrophil 
transcriptome following stimulation with a variety of inflammatory 
mediators (G-CSF, IFNγ, IL-1β, IL-8, IL-6, GM-CSF+TNFα). 
 
2. To identify treatment-specific changes in gene expression and 
activation of signalling pathways /transcription factors. 
 
3. To analyse whether dual stimulation of neutrophils by GM-CSF and 
TNFα induces expression of a discrete set of genes when compared 
to individually treated neutrophils (i.e. GM-CSF alone, TNFα-alone). 
 
4. To validate any treatment-specific findings by functional assays. 
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5.3 Methods 
Neutrophils were stimulated for 1 h in the absence or presence of one or 
more cytokine/chemokines (Table 5.1).  The optimal concentration of each 
cytokine was previously determined using a range of functional assays (data 
not shown). 
 
Table	   5.1	   List	   of	   cytokine/chemokine	   treatments	   and	   concentrations,	   and	   number	   of	  
biological	  repeats	  per	  sample.	  
	  
Inflammatory	  stimulus	   Concentration	   No.	  of	  biological	  replicates	  
G-­‐CSF	   10	  ng/mL	   3	  
IFNγ	   10	  ng/mL	   3	  
IL-­‐1β	   10	  ng/mL	   3	  
IL-­‐8	   100	  ng/mL	   3	  
GM-­‐CSF+TNFα	   5	  ng/mL	  +	  10	  ng/mL	   3	  
IL-­‐6	   10	  ng/mL	   1	  
 
Following 1 h incubation, RNA was extracted and purified as previously 
described (Section 2.2.9). RNA was sequenced on the Illumina platform 
(50bp, single-end reads) and analysed using the methods described in 
Chapter 3. For a list of RNA concentrations, integrity values and number of 
reads produced per sample library, see Appendix Table A.5. 
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5.4 Results 
5.4.1 Effects of cytokines on neutrophil apoptosis 
Activation or priming of neutrophils often results in a delay in neutrophil 
apoptosis. This mechanism allows neutrophils to carry out their anti-
microbial role in inflammatory situations. Consequently, several 
inflammatory mediators are known to extend the lifespan of neutrophils. 
Neutrophils were incubated overnight (21 h) in the presence or absence of 
several inflammatory stimuli (either alone or in combination). Levels of 
neutrophil apoptosis were analysed by annexin V/PI staining and 
measurement by flow cytometry (as described in section 2.2.5) (Fig 5.1).  
Levels of apoptosis varied considerably between stimuli compared to 
controls (UT, 69.04%). As previously reported in this thesis, GM-CSF (41.6% 
p<0.0001) and TNFα (56.4% p<0.05) significantly delayed neutrophil 
apoptosis. Similarly, stimulation with IFNγ (55.3% p<0.01), G-CSF (34.1% 
p<0.001), IL-8 (55.2% p<0.01) or dual stimulation with GM-CSF and TNFα 
(45.2% p<0.01), all significantly delayed neutrophil apoptosis. Conversely, 
stimulation by IL-1β (66.12% p>0.05) and IL-6 (66.81% p>0.05) had no 
effect on neutrophil apoptosis. This suggests that different 
cytokines/chemokines greatly affect neutrophil function in vitro and implies 
that this difference in phenotype may be explained by the de novo gene 
expression profile induced by each stimulus. 
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Fig	   5.1	   Neutrophil	   apoptosis	   following	   overnight	   (21	   h)	   incubation	   with	   several	  
inflammatory	   cytokines/chemokines.	   Apoptosis	   was	   quantified	   by	   annexin-­‐V/PI	  
staining	  and	  measured	  by	  flow	  cytometry.	  N=4.	  Error	  bars	  represent	  SEM.	  Significance	  
(***	  p<0.001,	  **	  p<0.01,	  *	  p<0.05,	  NS=	  not	  significant,	  p>0.05)	  calculated	  by	  Student’s	  t-­‐
test	   versus	   untreated	   neutrophils	   (UT,	   black	   bar).	   Dotted	   horizontal	   line	   represents	  
level	  of	  apoptosis	  in	  untreated	  samples.	  	  
 
 
5.4.2 Bioinformatic analysis of neutrophils fol lowing incubation 
with inflammatory st imuli  
Having identified that levels of neutrophil apoptosis vary depending on the 
specific inflammatory stimuli, neutrophils were next analysed by RNA-Seq 
and bioinformatic pipeline software to identify any changes in gene 
expression between stimuli.  
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5.4.2.1 Multidimensional scaling of cytokine-induced gene expression 
profiles. 
Following quantification of neutrophil transcriptomes by Cufflinks, the 
downstream R-based software cummeRbund 168 was utilised to produce 
multi-dimensional scaling (MDS) plots of each dataset in relation to each 
other (Fig 5.2). MDS is a method for visualising the relative differences and 
similarities between samples in a 2-dimensional form. Thus, similar datasets 
(in terms of their RPKM values across all genes) will be spatially close to 
each other, whereas datasets with the greatest dissimilarity will be further 
apart in both spatial dimensions. Nine neutrophil datasets were plotted in 
2-dimensional space following MDS (Fig 5.2). 
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Fig	   5.2	   Multi-­‐dimensional	   scaling	   plot	   showing	   the	   2-­‐dimensional	   association	   of	   9	  
neutrophil	   transcriptomes	   under	   different	   inflammatory	   conditions:	   untreated	   (UT);	  
IL-­‐6	   (IL6);	   IL-­‐1β	   (IL1B);	   TNFα	   (TNF);	   G-­‐CSF	   (GCSF);	   IFNγ	   (IFNg);	   IL-­‐8	   (IL8);	   GM-­‐CSF	  
(GMCSF);	   and	   GM-­‐CSF+TNFα	   dual	   treatment	   (GM+TNF).	   MDS	   carried	   out	   by	  
cummeRbund168.	   Colouring	   of	   datasets	   was	   arbitrarily	   applied	   post	   hoc	   to	   highlight	  
dataset	  groupings.	  	  
 
Datasets most similar were untreated and IL-6, with TNFα and IL-1β 
forming a closely related pair. G-CSF and IFNγ datasets grouped together 
whilst IL-8, GM-CSF and GM-CSF+TNFα dual treatment were the most 
dissimilar data sets. Interestingly, despite GM-CSF and dual treatment GM-
CSF+TNFα sharing a common stimulus, their respective datasets were 
among the two most dissimilar datasets. This suggests that dual stimulation 
induces expression of discrete gene sets or differential expression of genes 
that are not explained by a combination of GM-CSF and TNFα expression. 
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5.4.2.2 Analysis of neutrophil genes significantly DE genes following 
cytokine/chemokine treatment. 
Cuffdiff analysis was used to calculate the number of significantly (q<0.05, 
5% FDR) DE genes in each treatment compared to control (Table 5.2). 
 
Table	  5.2	  Number	  of	  significantly	  DE	  genes	   (vs	  untreated).	  Significance	  calculated	  by	  
Cuffdiff	  (q<0.05,	  FDR	  5%).	  
	  
Treatment	   No.	  of	  DE	  genes	  
GM-­‐CSF	   110	  
TNFα	   81	  
GM+TNFα	   151	  
IFNγ	   110	  
G-­‐CSF	   95	  
IL-­‐1β	   6	  
IL-­‐8	   5	  
IL-­‐6	   0	  
	  
	  
	  
Similarly to the apoptosis results previously, analysis of DE genes identified 
a wide range in the number of DE genes following cytokine stimulation. IL-
1B, IL-8 and IL-6 treatment resulted in only 6, 5 and 0 genes DE, 
respectively. Interestingly, these 3 treatments also resulted in the lowest 
inhibition of neutrophil apoptosis. Moreover, the stimuli that induced the 
greatest delay in apoptosis also resulted in the greatest number of DE 
genes. This suggests a correlation between apoptosis levels and number of 
genes DE. This was confirmed by comparing the number of DE genes with 
the percentage delay in apoptosis induced by each treatment (r= 0.719, 
p<0.05, Pearson correlation coefficient) (Fig 5.2).  
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Fig	  5.3	  Linear	  regression	  of	  the	  number	  of	  DE	  genes	   in	  8	  conditions	  vs	  the	  %	  delay	   in	  
apoptosis.	  Line	  represents	  best	  fit.	  r=	  0.719,	  p<0.05,	  (Pearson	  correlation	  coefficient).	  
 
5.4.2.2 Analysis of gene and protein expression in dual stimulated 
neutrophils 
The greatest number of DE genes was seen following dual stimulation with 
GM-CSF and TNFα, as might be predicted since previous results (Chapter 
4) revealed that each cytokine activated independent transcription factors. 
Thus, the number of DE genes might represent a combination of both 
cytokines resulting in the expression of discrete sets of genes. However, 
further analysis of the genes DE following dual stimulation revealed that 
only 16 genes were DE in the dual treatment samples and both of the 
single treatments, with a further 79 genes expressed in dual treatment and 
one of the single treatments (Fig 5.4). Thus, 56 genes were uniquely DE 
after GM-CSF/TNFα dual stimulation. The top 30 genes (with the greatest 
difference in RPKM to untreated samples) of the 56 genes unique to dual 
treatment are listed in Table 5.3. Genes uniquely DE in dual-treated 
No. of DE genes
%
de
la
y
in
ap
op
to
si
s
0 50 100 150
0
10
20
30
40
189	  
	  
neutrophils include several genes which are poorly characterised, for 
instance: Guanylate binding proteins (GBP) GBP1, GBP3, and GBP1P1; G-
protein coupled receptor 132 (GPR132); the heme-binding protein 
Cytochrome B5 Domain Containing 1 (CYB5D1) and transmembrane 
coupled receptor 170B (TMEM170B). The gene with the greatest difference 
in RPKM to untreated is immediate early response-3 (IER3) which is an 
“anti-death” protein that protects from FASL- or TNFα-induced apoptosis 
and inhibits ERK dephosphorylation 228. Conversely, dual treatment also 
induces expression of dual specificity phosphatase 5 (DUSP5), which is 
involved in negative regulation of the MAPK/ERK pathway 229.  
 
 
Fig	  5.4	  Venn	  diagram	  showing	  the	  number	  of	  DE	  genes	  in	  neutrophils	  following	  single,	  
or	  dual	   stimulation	  with	  GM-­‐CSF	   (GM)	  and/or	  TNFα	   (TNF).	   Significance	   calculated	  by	  
Cuffdiff	  (q<0.05,	  5%FDR).	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Table	  5.3	  The	  30	  genes	  with	  the	  greatest	  difference	   in	  RPKM	  compared	  to	  untreated	  
(UT)	  samples	  from	  genes	  that	  are	  uniquely	  DE	  in	  GM+TNFα	  treated	  samples.7	  
 
Gene	  name	   UT	   GM+TNF	   ΔRPKM	  
IER3	   108.47	   1147.56	   1039.09	  
GBP1	   22.38	   183.91	   161.53	  
CYB5D1	   7.55	   106.26	   98.72	  
GPR132	   10.51	   50.44	   39.93	  
TMEM170B	   28.01	   3.51	   -­‐24.50	  
DUSP5	   4.14	   24.20	   20.05	  
MRPS24	   1.16	   16.85	   15.69	  
LOC100506229	   0.72	   15.97	   15.25	  
GBP1P1	   1.73	   14.66	   12.93	  
GBP3	   2.65	   15.12	   12.47	  
LOC257358	   1.75	   14.17	   12.42	  
KLHDC8B	   15.07	   2.76	   -­‐12.32	  
C5orf58	   2.27	   14.36	   12.09	  
HELB	   0.75	   9.80	   9.05	  
BATF2	   1.40	   10.36	   8.96	  
TMEM54	   0.39	   7.96	   7.58	  
PLEKHG2	   1.08	   8.29	   7.22	  
APLP1	   0.88	   7.85	   6.97	  
KIRREL2	   0.04	   6.63	   6.58	  
CCDC85B	   0.86	   7.33	   6.47	  
LINC00309	   0.21	   5.98	   5.76	  
LDLR	   0.77	   6.30	   5.53	  
SPHK1	   0.24	   5.29	   5.05	  
CAHM	   0.76	   5.21	   4.45	  
MTVR2	   0.61	   4.99	   4.38	  
TKTL1	   4.08	   0.48	   -­‐3.61	  
ENO3	   0.14	   2.48	   2.34	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TGM2	   0.18	   2.48	   2.30	  
PRDM7	   0.12	   2.28	   2.16	  
	  
 
Expression of IL-1β was DE in all 3 treatment conditions. However, levels of 
expression following dual treatment were almost double the combined 
expression of both individual treatment (GM-CSF 6410 RPKM, TNF 3614 
RPKM, GM-CSF + TNFα 17,647) (Fig 5.5). To investigate whether this 
increased expression resulted in a corresponding high protein expression, 
expression of IL-1β was assessed by western blot over a 6h period (Fig 5.6). 
Levels of IL-1β were elevated in all 3 treatment conditions compared to 
control. Levels were highest in dual treated neutrophils, although the 
magnitude of the expression in dual treatment was approximately equal to 
the combined expression of each individual treatment, for example, at 2 h:  
GM-CSF = 106; TNF = 132; and GM-CSF + TNFα = 207 (arbitrary unit of 
band intensity, normalised to actin) (Fig 5.5). However, despite protein 
expression peaking at 2 h in all treatment conditions, individual treatment 
with either GM-CSF or TNFα resulted in a significant decrease in expression 
by 4 h which decreased further by 6 h. In contrast, dual treatment resulted 
in much lower decrease in protein expression, with levels of IL-1β protein 
being maintained over the 6 h time period. Differential protein expression 
dynamics were also seen when analysing expression of NFκBIA (also known 
as IκBA) in dual- and single-stimulated neutrophils (data not shown). 
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Fig	  5.5	  Neutrophil	  gene	  expression	  values	  (RPKM)	  for	  IL-­‐1β	  following	  stimulation	  with	  
GM-­‐CSF,	   TNFα	   or	   dual	   treatment	  with	   GM-­‐CSF	   and	   TNFα	   and	  measurement	   by	   RNA-­‐
Seq.	  
 
Taken together, these data suggest that dual treatment of neutrophils with 
GM-CSF and TNFα results in the differential expression of discrete genes 
not otherwise differentially expressed by individual treatments. However, 
these genes are poorly characterised and provide few clues to their effect 
on neutrophil phenotype. Additionally, dual stimulation of neutrophils 
results in different protein-expression dynamics over 6 h. 
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Fig	  5.6	  Western	  blot	  analysis	  of	  IL-­‐1β	  in	  neutrophils	  following	  stimulation	  with:	  GM-­‐CSF	  
(grey	   bars);	   TNFα,	   (black	   bars);	   GM-­‐CSF	   and	   TNFα	   (striped-­‐bars);	   or	   no	   stimulation	  
(white	  bars)	  and	  representative	  blot/housekeeping	  blot.	  Band	  intensity	  normalised	  to	  
housekeeping	  control	  (Actin)	  N=2.	  
 
5.4.2.3 Analysis of signal pathway activation in cytokine/chemokine 
stimulated neutrophils 
To assess whether the differential expression of genes by different 
cytokines/chemokines resulted from differential activation/regulation of 
signalling pathways, data was analysed by IPA to predict which upstream 
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regulators (transcription factors) regulated gene expression in neutrophils 
incubated under these different conditions.  
In order to validate the IPA predictions, neutrophils were stimulated with 
each of the 9 conditions for 15 min and analysed by western blot for 
activation of several key signalling pathways: STAT (STAT1/3); NFκB 
(NFκB); PI3K (Akt); MAPK (ERK1/p38) (Fig 5.7). Results were then compared 
to those predicted by IPA (Table 5.4). 
 
	  
Fig	   5.7	   Western	   blot	   analysis	   of	   phospho-­‐proteins	   in	   neutrophils	   treated	   with	  
inflammatory	  cytokines/chemokines.	  Data	  representative	  of	  3	  separate	  experiments.	  	  
 
Western blot analysis identified differential activation of signalling pathways 
in each of the conditions analysed. For example, STAT activation was seen 
in GM-CSF, IFNγ and G-CSF stimulated samples, whereas ERK activation 
was only seen in GM-CSF stimulated samples (Fig 5.7). IPA analysis of 
upstream regulators confirmed the results of western blot analysis. Each of 
the signalling pathways identified by western blot were predicted to be 
active by IPA analysis (p<0.05) (Table 5.4). Interestingly, none of the 
signalling pathways analysed were activated by IL-1β, although IPA 
predicted several upstream regulators from the RNA-Seq data; these 
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include the zinc-finger proteins: CCCTC-binding factor (CTCF) (p=1.58 e-05) 
and GATA-binding protein (GATA4) (p=1.58 e-03). Taken together, these 
data highlight the predictive power of bioinformatic software and its ability 
to confirm and complement traditional western blot analysis of signalling 
pathway activation, which together have identified the differential 
activation of signalling pathways in neutrophils by different 
cytokines/chemokines. 
	  
Table	  5.4	  Signalling	  pathway	  activation	  states	   in	  neutrophils	  stimulated	  with	  a	  range	  
of	  cytokines/chemokines.	  Table	  shows	  results	  of	  western	  blotting	  and	  corresponding	  
p-­‐value	  as	  calculated	  by	  IPA	  using	  RNA-­‐Seq	  data	  to	  predict	  up-­‐stream	  activation. 
 
Cytokine/chemokine	  
stimulus	  
Pathway	  
activation	  
(Western	  
blot)	  
IPA	  
prediction	  
p-­‐value	  
GM-­‐CSF	  
ERK	   6.52	  e-­‐07	  
p38	   4.85	  e-­‐05	  
STAT3	   2.31e-­‐03	  
STAT1	   1.49	  e-­‐02	  
AKT	   2.81	  e-­‐02	  
TNFα	  
NFκB	   4.56	  e-­‐09	  
AKT	   3.59	  e-­‐03	  
P38	   7.75	  e-­‐03	  
GM+TNF	  
NFκB	   9.29	  e-­‐14	  
ERK	   2.89	  e-­‐07	  
STAT3	   1.48	  e-­‐05	  
P38	   5.56	  e-­‐05	  
AKT	   9.66	  e-­‐05	  
STAT1	   3.59	  e-­‐03	  
IFNγ	   STAT3	   2.24	  
e-­‐04	  
STAT1	   8.65	  e-­‐04	  
G-­‐CSF	  
STAT3	   3.57	  e-­‐04	  
STAT1	   4.07	  e-­‐02	  
AKT	   4.65	  e-­‐02	  
IL-­‐1B	   n/a	   n/a	  
IL-­‐8	   AKT	   1.42	  e-­‐02	  
IL-­‐6	   STAT3	   2.33	  e-­‐02	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5.4.2.4 Analysis of cytokine/chemokine expression in cytokine/chemokine 
stimulated neutrophils  
In addition to differential activation of signalling pathways, neutrophils also 
exhibited differential expression of several cytokine/chemokines associated 
with the inflammatory response. 
A gene list was compiled which included all genes defined as a “cytokine” 
or “chemokine” by their inclusion in the Gene Ontology groups “cytokine 
activity” (GO-term accession GO:0005125) or “chemokine activity” (GO-
term accession GO:0008009). The RPKM values for each gene in all 
conditions were extracted from the Cufflinks output files and their fold 
change relative to untreated sample was calculated. The 25 genes with the 
highest expression were analysed by hierarchical clustering. A heatmap 
highlighting the differential expression of the cytokine/chemokine genes is 
shown in Fig 5.8. Samples treated with GM-CSF, TNFα, IL-1β or dual 
treatment with GM-CSF + TNFα showed the greatest expression of 
cytokines/chemokines and clustered together.  Conversely IFNγ, G-CSF, IL-
8 and IL-6 treatment had low expression of these genes, but had the 
highest expression of CXCL9. The only genes that showed high expression 
in all conditions (except IL-6) were IL-1B and IL-1RN. Interestingly, IL-1A 
was only upregulated by GM-CSF, TNFα and dual stimulation, whereas IL-
1B was upregulated by all conditions, except IL-6. A table showing the raw 
RPKM values for each gene is shown in Appendix Table A.7. 
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These data highlight the ability of neutrophils to express different sets of 
cytokines/chemokines in response to different stimuli. 
 
	  
	  
Fig	  5.8	  Heatmap	  showing	  hierarchical	  clustering	  of	  25	  cytokine/chemokine	  associated	  
genes	   in	   neutrophils	   following	   stimulation	   with	   a	   range	   of	   cytokines/chemokines.	  
Green=	  low,	  black	  =	  median,	  red	  high	  values	  (log2	  fold	  change	  vs	  untreated	  samples).	  	  
Raw	  values	  presented	  in	  Appendix	  Table	  A.7. 
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5.4.2.5 Modelling of in vitro gene expression data by comparison to ex vivo 
patient data 
[All	  data	  in	  this	  section	  relating	  to	  patients	  were	  collected	  and	  analysed	  by	  Dr	  
Helen	  Wright	  and	  reproduced	  here	  with	  permission]	  
 
An important benefit of producing large quantities of digital data such as 
those produced by an RNA-Seq experiment is the ability to easily compare 
and model the data against other datasets. This allows the identification of 
common features and gene sets within a large amount of data, which 
would otherwise be impractical and implausible by manual curation.  
RNA-Seq analysis of in vitro stimulated samples provides a robust set of 
data that are highly specific to the treatment conditions and exhibit low 
variance between samples. Thus, gene expression profiles from in vitro 
stimulated samples can be modelled against less well defined datasets, 
such as those from patients with inflammatory disease, in an attempt to 
extrapolate meaningful similarities and patterns of association. 
To this end in vitro stimulated neutrophil datasets were compared to 
neutrophil gene expression profiles of patients with RA (Fig 5.9). 
Neutrophils from 20 RA patients and 6 healthy controls were analysed by 
RNA-Seq and gene expression profiles produced using the bioinformatic 
techniques described in Chapter 3. Gene expression analysis of patient 
data identified high expression of IFN-genes which correlated with the 
degree of response of patients to anti-TNF (TNFi) treatment (r=0.51 
Pearson’s correlation, p=0.02) 230.  Data for 59 interferon-response genes 
199	  
	  
from patient and healthy control datasets were then modelled against in 
vitro stimulated neutrophil datasets (for IFNγ and IFNα) and visualised by 
heatmap (Fig 5.9). 
Hierarchical clustering of in vitro and ex vivo sample datasets identified that 
gene expression of the 59 interferon-response genes clustered into two 
main patient sub-groups: IFN-high (associated with INFγ signalling); and 
IFN-low (associated with IFNα signalling). Datasets relating to healthy 
controls clustered into a single group within the IFN-low cluster.  IFNα is a 
type-I interferon which signals via the IFNα receptor complex, whilst IFNγ is 
a type-II which acts through the IFNγ receptor.  These two IFN receptors 
activate different downstream Janus kinase (JAK)/STAT signalling 
pathways. For instance, IFN type-I signalling involves the activation of 
tyrosine kinase 2 (TYK2) and JAK1 leading to STAT1/STAT2 hetero-
dimerisation and activation of interferon-stimulated response element 
(ISRE) transcription factor. In contrast, IFN type-II signalling involves 
JAK1/JAK2 activation leading to STAT1 homo-dimerisation ultimately 
resulting in activation of the transcription factor interferon-γ-activated site 
(GAS) 231.  Thus, the patient cohort can be further sub divided into two 
groups based on their hierarchical association with type-I and type-II gene 
expression profiles.  
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Fig	   5.9	  Heatmap	   showing	   the	  expression	  of	   59	   IFN-­‐regulated	  genes	   in	   20	  RA	   (purple	  
bars),	  6	  healthy	  control	  (yellow	  bar),	  IFNα-­‐treated	  (orange	  bar)	  and	  IFNγ-­‐treated	  (blue	  
bar)	  neutrophils.	  (Expression	  level:	  green=low,	  black=median,	  red=high.)	  Patient	  data	  
collected	  and	  analysed	  by	  Dr	  Helen	  Wright.	  Figure	  adapted	  from	  230.	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Healthy controls 
IFNα IFNγ 
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5.5 Discussion 
The aim of this chapter was to measure the global changes in gene 
expression profiles of neutrophils stimulated with a variety of inflammatory 
cytokines.  Neutrophils were stimulated for 1 h with a range of 
cytokines/chemokines commonly associated with inflammation and often 
found at sites of inflammation, those being: G-CSF; IFNγ; IL-1β; IL-8; and 
IL-6. In addition, neutrophils were dual stimulated with GM-CSF+TNFα to 
analyse the effects of multiple cytokine stimulation on neutrophils by 
comparison to data collected in the previous chapter on neutrophils 
stimulated by single cytokines. Neutrophil RNA was subsequently 
sequenced by RNA-Seq and analysed using the previously-described 
bioinformatic pipeline. 
 Analysis of the effects of cytokine/chemokine stimulation on neutrophil 
apoptosis revealed that these agents acted significantly differently to each 
other. G-CSF had the strongest anti-apoptotic effect, whereas IL-6 and IL-
1β had no effect on neutrophil apoptosis. Similarly, the number of DE 
genes induced by each cytokine correlated with the anti-apoptotic effect of 
each stimulus. Since neutrophils have a much shorter life span than other 
leukocytes, regulation of neutrophil apoptosis is an important biological 
process. This delay in neutrophil apoptosis may be critically linked to 
activation of gene expression. Cytokine activation of neutrophils leads to 
the enhanced expression of other chemokines and cytokines, as well as 
other key molecules such as adhesion molecules. Therefore, neutrophil 
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extended neutrophil lifespan is essential for these newly-expressed 
molecules to be expressed and affect the progress of an inflammatory 
response. These up-regulated genes may themselves be directly involved 
in apoptosis delay, although it must be  pointed out that some regulation 
of apoptosis is achieved by stabilisation of anti-apoptotic proteins such as 
Mcl-1, without the requirement of de novo gene expression 232.  
In the previous chapter, the effects of stimulation with either GM-CSF alone 
or TNFα alone on neutrophil gene expression profiles were evaluated. In 
this chapter, the effects of dual stimulation with both cytokines were 
investigated. Given that previous results showed independent activation of 
transcription factors and different gene sets by both GM-CSF and TNFα, it 
may have been predicted that dual stimulation would result in increased 
DE gene expression and that these genes would be representative of the 
gene lists seen from both single-stimulation conditions (i.e. additive 
effects). In addition, since the apoptosis pathway was found to be 
regulated differentially by both cytokines, it may also have been predicted 
that dual stimulation would further delay neutrophil apoptosis beyond that 
achieved by either single cytokine alone. However, neutrophil apoptosis 
following dual stimulation was lower than TNFα-stimulation levels but 
higher than GM-CSF-stimulation levels. Dual stimulation also affected the 
protein expression dynamics of IL-1β and NκFBIA, resulting in an increased 
magnitude and maintained expression over 6 h. interestingly, over one 
third of the DE genes following dual stimulation (56 genes from a total of 
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151 DE genes) were not DE after either individual treatment conditions. 
Although several of these genes are poorly characterised, in particular their 
role in neutrophil biology, this raises important questions as to the effects 
of multiple stimulants by inflammatory mediators on neutrophil function. 
This is of considerable importance when considering neutrophil function in 
disease, since elevation of multiple cytokines at inflammatory sites is a 
hallmark of several inflammatory or auto-immune conditions 3,77,78,211,233.	  
Analysis of signalling pathway activation revealed that neutrophil 
stimulation with different inflammatory cytokines/chemokines resulted in 
differential activation of a range of signalling pathways. Whilst the 
activation of these pathways by particular cytokines/chemokines is fairly 
well-documented 230,232,234,235, the ability to also predict such events using 
RNA-Seq data highlights the powerful predictive nature of RNA-Seq data.  
Additionally, it is a powerful way of revealing the expression level of each 
gene within a particular pathway, thus providing a way of estimating the 
contribution of each gene to the overall activation state of a specific 
pathway. For example, RNA-Seq data could identify if a particular signalling 
pathway is activated by up-regulation of cell surface receptors or through 
the increased actions of a transcription factor. 
Analysis of cytokine/chemokine expression by neutrophils is less well 
defined. The importance of neutrophil-derived molecules during 
inflammation has long been overlooked in favour of cells from the adaptive 
immune response (B-cells, and T-cells). Indeed, much of the current 
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knowledge on neutrophil-derived products is based on studies from non-
human species (often mice), such that their production by human 
neutrophils remains controversial 5,6. Bioinformatic analysis of 
cytokine/chemokine genes revealed both similarities and differences in the 
expression profiles of neutrophils stimulated with different 
cytokines/chemokines. Perhaps unsurprisingly, conditions which had 
exhibited greatest ability to delay apoptosis also showed a similar pattern 
of cytokine expression, especially GM-CSF-stimulation, TNFα-stimulation 
and dual stimulation. However, several genes showed decreased 
expression following IFNγ compared to control, for instance, CXCL1, CCL3, 
CCL4 and CXC12, while IL-6 stimulated neutrophils showed no DE of 
cytokine/chemokine genes compared to control. Furthermore, of the 6 
genes that were identified as having DE following IL-1β treatment, 3 relate 
to chemokines: CCL3; CCL4; and CCL4L1.  
Although, not directly confirmed by data presented here, it is likely that the 
differential expression of cytokine/chemokine related mRNA under 
different inflammatory conditions would lead to differential protein 
translation and cytokine release by neutrophils. This highlights not only the 
ability of neutrophils to propagate and maintain the immune response by 
direct activation/signalling with surrounding cells by release of de novo 
inflammatory mediators, but it also reveals the importance of the nature of 
the stimulating signal to define the phenotype of activated neutrophils. 
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Among the most unexpected findings during this analysis was the effect of 
IL-6 on neutrophil function and gene expression. IL-6 is a crucial mediator 
of inflammation that is produced by several immune cells and can influence 
numerous cell types with multiple biological actions, such that it is often 
regarded as a pleiotropic cytokine 83. It is often found at high 
concentrations at inflammatory sites such as synovial fluid 236. Indeed, the 
importance of IL-6 to the inflammatory response is best highlighted by the 
success of therapeutic inhibition of IL-6R by Tocilizumab, which is used to 
treat conditions such as vasculitis, inflammatory bowel disease, RA and 
cancer 83. Interestingly, IL-6 can behave as both a pro- and anti-
inflammatory regulator, dependent on whether signalling occurs via the 
membrane bound IL-6R, known as classical signalling, or via trans 
signalling, involving soluble IL-6R (sIL-6) and the ubiquitously expressed 
gp130 receptor, respectively 237.  The effect of IL-6 on neutrophils is less 
well-defined. For example, previous studies on the effect of IL-6 stimulation 
on neutrophil apoptosis are conflicting, with anti-apoptotic, pro-apoptotic 
and no effect on apoptosis all previously reported 238–241. Under the 
conditions studied here (10ng/ mL, for 21 h) IL-6 had no effect on 
neutrophil apoptosis. Moreover, IL-6 did not significantly differentially 
regulate the expression of any genes in neutrophils. However, the 
concentration of IL-6 used (10 ng/mL) was found to be biologically 
functional by the demonstration that it could induce the rapid 
phosphorylation of STAT3 (<15 min).  
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Several reasons could explain the lack of differential gene expression 
following IL-6 treatment, in spite of STAT3 activation. Firstly, the actions of 
IL-6 on immune cells may be limited to non-neutrophil cells, thus limiting 
the activation state of neutrophils at sites of inflammation where levels of 
IL-6 are elevated. Secondly, de novo gene expression may be delayed 
beyond 1 h, and any such changes would not have been measured by the 
current studies. Finally, full activation of neutrophils by IL-6 may require a 
secondary signal 242 or epigenetic changes 243 as has been demonstrated 
for IL-10 signalling in neutrophils. 
The modelling of RNA-Seq data against other sources of biological data 
enables the identification of patterns of expression in genes that would 
otherwise be difficult to identify. This systems biology approach using 
RNA-Seq data from in vitro stimulated neutrophils to model against data 
from RA neutrophils has revealed that sub-populations of patients exist 
within a cohort of RA patients, relating to either a type-I or type-II IFN 
phenotype. Whilst modern predictive bioinformatic software is capable of 
identifying these changes based on patient data alone, the comparison 
with well-defined in vitro samples provides an additional level of data 
validation, ultimately increasing confidence of results.  
In summary, analysis of neutrophils under different conditions of simulated 
inflammation (by cytokine stimulation) using RNA-Seq has revealed that 
neutrophils express discrete sets of genes in response to different stimuli. 
Additionally, stimulation by multiple cytokines induces expression of further 
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unique gene-sets. Analysis of the nature of the genes expressed reveals 
that several signalling pathways are differentially activated, which is 
confirmed by western blot analysis. Among the genes expressed are genes 
relating to cytokines/chemokines which show differential expression among 
treatment conditions. These data reveal the plasticity of neutrophils under 
conditions of inflammation and highlight the importance of surrounding 
signals on the developing phenotype of a neutrophil during different forms 
of activation. 
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Chapter	   6:	   The	   effects	   of	  
isolation	   method	   and	   purity	  
on	   neutrophil	   gene	  
expression	  and	  function	  
6.1 Introduction 
In recent times there has been a growing appreciation of the ability of 
neutrophils to respond to, and influence, immune signalling between 
several different cell types, acting as a signalling bridge between the innate 
and adaptive immune systems 5. Neutrophils are now known to activate 
monocytes, dendritic cells and T and B-cells, either through direct 
interactions or via secreted products 4. But perhaps more importantly, 
neutrophils can respond to a variety of signals that affect their function and 
behaviour at the site of inflammation. For example, neutrophils can be 
activated by a range of stimuli such as, chemokines, ROS, DAMPs and 
PAMPs. In response, they release a variety of molecules such as pro- and 
anti-inflammatory cytokines, angiogenic factors and colony-stimulating 
factors 5. Neutrophils can also modulate their function in response to 
different concentrations of apoptotic neutrophils. Contact with, or uptake 
of, apoptotic neutrophils, by neutrophils, can lead to inhibition of the 
respiratory burst and decreased release of the pro-inflammatory cytokines 
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TNFα and CXCL10, whilst also increasing their secretion of IL-8 and CXCL1 
68. 
It is therefore clear that activated neutrophils do not merely localise to the 
site of infection, clear any pathological insult, and then rapidly undergo 
apoptosis: they are capable of more sophisticated and complex immune 
regulation. Indeed, they are central to the progression of the immune 
response and can shape the outcome of inflammation or infection in 
response to the signals they receive from the local environment 3. 
Given the growing appreciation of intercellular signalling in neutrophil 
function and activity, it is perhaps somewhat paradoxical that the majority 
of research on human neutrophil activation and function has been achieved 
by in vitro studies, using purified blood neutrophil preparations. Although 
minimally-contaminated with other types of immune cells, the contribution 
of such contaminating cells to the overall assay output is often ignored. 
Moreover, whilst it is now appreciated that surrounding immune- and 
tissue-cells affect neutrophil function at the site of inflammation, in vitro 
studies of purified neutrophils attempt to remove the influence of such 
interacting cells.  
An extra consideration when isolating neutrophils is their relative sensitivity 
to physical stimuli that may promote apoptosis in the absence of 
stimulating factors.  Neutrophils are easily activated by shear forces or 
over-agitation, further complicating isolation methods. It is often of equal 
importance that the suspension of neutrophils resulting from a purification 
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protocol contains both high numbers of viable cells and low numbers of 
contaminating cells. 
A variety of neutrophil isolation techniques are in current use, which 
generally achieve a final neutrophil purity of >95% and viability of >97%. 
Until recently, all isolation methods exploited the differing size and density 
of different blood cells to separate cells into distinct populations. These 
methods require multiple centrifugation steps and overall isolation times of 
60-90 min. More recently, several new cell-sorting techniques, often 
offering higher sensitivity and specificity, have been developed. For 
example, Fluorescent Activated Cell Sorting (FACS) and Magnetic 
Activated Cell Sorting (MACS) techniques provide methods for sorting cells 
following attachment of a fluorescently-conjugated or magnetic particle-
tagged antibody respectively, that bind to particular immune cell-specific 
surface markers. The use of surface markers to immuno-select mixtures of 
cells is often less perturbing and a more specific method of cell purification. 
Both the FACS and MACS approaches dramatically decrease the number 
of centrifugation steps required and achieve a higher final purity of cells, 
often in a similar time frame to density-gradient techniques. However, the 
higher purity afforded by these techniques usually comes at a greater 
financial cost and often a lower yield 244,245.  
An additional concern when choosing an antibody-based isolation method 
is whether it utilises positive or negative selection. Neutrophils express 
high levels of receptors that bind immunoglobulins, and crosslinking of 
211	  
	  
these Ig-receptors can prime or even activate neutrophils 214. Isolation of 
neutrophils by positive selection requires binding of specific 
immunoglobulins to neutrophil-specific cell surface molecules, such as 
CD16b. The major disadvantage of this approach is the increased risk of 
priming or activating neutrophils during the isolation method, thus 
inadvertently changing their phenotype and most importantly, their 
functional capacity 246.  
Alternatively, negative selection approaches require a mixture of specific 
antibodies that recognise cell surface markers on other immune cell types, 
which can significantly increase the cost and efficiency of the methodology 
but leads to highly-pure, non-activated neutrophils. A summary of 3 
commonly-used neutrophil isolation methods is detailed below. 
 
6.1.1 Neutrophil Isolation methods 
6.1.1.1 Dextran ficoll-paque isolation  
Whole blood is mixed with dextran (average molecular mass 200-500 kDa), 
which causes the erythrocytes to aggregate and sediment more rapidly 
than other cell types (Fig 6.1A) 247. Following sedimentation under 1 g, the 
leukocyte-rich upper phase is removed and subsequently layered onto 
Ficoll-paque. The Ficoll-paque provides a discontinuous density gradient 
which facilitates the separation of the granulocytes (of which neutrophils 
are the most abundant) from the lymphocytes (B-cells, T-cells, NK cells) and 
monocytes, following high speed centrifugation (500-g for 30 min). The 
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monocytes and lymphocytes form a distinct band at the plasma/Ficoll-
paque interface, whereas the more dense granulocytes  (neutrophils, 
eosinophils and basophils, and any residual erythrocytes) form a pellet at 
the bottom of the tube (Fig 6.1B) 248. The remaining contaminating 
erythrocytes can subsequently be removed by hypotonic lysis. 
6.1.1.2 Polymorphprep™ isolation 
Polymorphprep™ is an endotoxin-free solution containing 13.8% (w/v) 
sodium diatrizoate and 8.0% (w/v) polysaccharide; it has a density of 1.113 
± 0.001 g/mL and an osmolality of 445 ± 15 mOsm 177. Polymorphprep™ 
solution incorporates a similar experimental approach to neutrophil 
isolation as the dextran/Ficoll-paque method (density separation of 
lymphocytes from granulocytes and the sedimentation of erythrocytes) but 
does so in a single, one-step centrifugation process (Fig 6.1C). Whole 
blood is layered onto Polymorphprep™ solution and centrifuged at 500-g 
for 35 min. As erythrocytes pass through Polymorphprep™ the higher 
osmotic pressure of Polymorphprep™ results in water being lost from the 
erythrocytes, this in turn dilutes the Polymorphprep™, thereby reducing its 
density. This produces a continuous density gradient and results in the 
formation of two distinct bands; an upper band containing lymphocytes 
and monocytes, and a lower band containing granulocytes. Non-nucleated 
platelets remain in the upper phase and erythrocytes sediment towards the 
bottom of the tube.  The PBMC band is carefully removed first to avoid 
cross-contamination with the neutrophil layer. The granulocyte layer is 
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subsequently carefully aspirated and washed. Any remaining erythrocytes 
in the granulocyte suspension are removed by hypotonic lysis. 
 
 
 
 
 
Fig	  6.1	  Treatment	  of	  whole	  blood	  prior	  to	  neutrophil	  isolation.	  A)	  Whole	  blood	  can	  be	  
depleted	   of	   erythrocytes	   prior	   to	   a	   density	   gradient	   separation	   by	   the	   addition	   of	  
dextran	   solution,	   causing	   erythrocytes	   to	   form	   aggregates	   and	   sediment.	   B)	   The	  
remaining	   nucleated	   cell	   fraction	   is	   layered	   over	   Ficoll-­‐paque	   and	   centrifuged,	  
separating	  the	  granulocytes	  from	  the	  peripheral	  blood	  mononucleated	  cells	  (PBMCs).	  
C)	  Alternatively,	  neutrophil	   isolation	  can	  be	  achieved	  by	  single-­‐step	  centrifugation	  of	  
whole	  blood	  over	  an	  equal	  volume	  of	  Polymorphprep™.	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 6.1.1.3 Neutrophil isolation by negative magnetic bead isolation 
Isolation of neutrophils using magnetic beads is usually carried out using 
smaller volumes of suspension (0.5 – 2 mL) and begins with a suspension of 
nucleated cells at a concentration of ≤ 5 x 107/mL. This is obtained by 
sedimentation of erythrocytes from whole blood at 1-g using a 
polysaccharide solution (HetaSep™) which has similar properties to 
dextran. Cells are then incubated with a cocktail mix of tetra-meric 
monoclonal antibodies (Fig 6.2). One portion of the antibody complex has 
specificity for dextran whilst the other portion is specific for one of seven 
cell-specific markers that are not expressed on neutrophils but are 
expressed on erythrocytes and other leukocytes (Table 3.1). 
 
Following incubation with this antibody cocktail, dextran-coated beads are 
incubated with cells before placing the cell suspension in a magnetic field.  
Antibody-bound cells are retained in the magnetic field whilst unbound 
neutrophils are decanted (Fig 6.3). 
 
 
Fig	   6.2	   Structure	   and	   specificity	   of	   tetrameric	   monoclonal	   antibody	   complexes.	  
Antibody	   complexes	   consist	   of	   two	   antibody	   molecules	   connected	   by	   a	   linker.	  
Antibody-­‐complexes	   possess	   dual	   specificity	   for	   dextran,	   and	   one	   of	   7	   different	   cell	  
surface	  antigens	  not	  expressed	  on	  neutrophils.	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Table	  6.1	  Specificity	  of	  antibodies	  recognising	  antigens	  on	  specific	  cell	  types,	  present	  
in	  a	  neutrophil	  magnetic	  bead	  isolation	  kit	  (StemCell®	  Genoble,	  France).	  	  
 
Antibody	  antigen	   Specificity	  
CD2	   T-­‐cells,	  NK	  cells	  
CD3	   T-­‐cells	  
CD9	   Eosinophils,	  Basophils	  
CD19	   B-­‐cells	  
CD36	   Monocytes	  
CD56	   NK-­‐cells	  
Glycophorin	  A	   Erythrocytes	  
Dextran	   Magnetic	  beads	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Fig	   6.3	   Summary	   of	   neutrophil	   isolation	   using	   magnetic	   beads.	   A	   mixture	   of	   cell-­‐
specific	   antibody	   complexes	   are	   added	   to	   a	   starting	   suspension	   of	   erythrocyte-­‐
depleted	   whole	   blood.	   Following	   incubation,	   dextran-­‐coated	   magnetic	   beads	   are	  
added	  and	  the	  suspension	  is	  placed	  in	  a	  magnetic	  field.	  Neutrophils	  are	  then	  decanted,	  
whilst	  other	  leukocytes	  are	  retained	  in	  the	  tube	  within	  the	  magnetic	  field	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6.1.2 Contaminating cells 
The small percentage (1-10%) of contaminating cells often found in 
neutrophil suspensions following density-gradient isolation methods, is 
often considered to be an acceptable level of contamination that has 
minimal effects on the behaviour of neutrophils in the preparations. 
However, more recently, the impact of contaminating leukocytes in 
neutrophil suspensions has been questioned. For example, Sabroe and 
colleagues demonstrated that ultra-pure neutrophils (>99%) behaved 
differently than those analysed with 5% PBMC contamination, namely that 
the anti-apoptotic effect of LPS on neutrophils was significantly decreased 
in the absence of contaminating PBMCs 249. Whilst it was suggested that 
monocytes in the PBMCs were responsible for these differences, it is often 
other granulocytes (in particular eosinophils) that constitute the largest 
proportion of non-neutrophil cells in most neutrophil preparations.  Since 
neutrophils, eosinophils and basophils have very similar size and density, it 
is not possible to separate them from each other using approaches based 
on density-gradient media. Consequently, the level of contamination by 
other granulocytes is usually donor-dependent, and the overall 
contamination is also reliant on the technical dexterity of the researcher. It 
was recently shown that the percentage of contaminating cells in a typical 
Polymorphprep™ neutrophil isolation can vary between 1-17% across 18 
individual blood isolations 177. This potential for contamination is of 
particular concern for high-sensitivity experiments such as qPCR, mass 
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spectrometry or RNA-Seq. Indeed, it has been suggested that eosinophils 
have a far greater transcriptional capacity than neutrophils, confounding 
experiments that quantify mRNA in neutrophil suspensions containing high 
and variable numbers of eosinophils 250.  
It is therefore clear that a greater understanding of the technical variations 
of different neutrophil isolation methods is required, both in terms of the 
effect of isolation methodologies on function and the contribution of 
contaminating cells on neutrophil function and gene expression. 
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6.2 Aims 
The aims of this chapter were: 
 
1. To compare the purity of neutrophils isolated by negative selection 
using antibody cocktails and magnetic beads (“ultra-pure 
neutrophils”) with those isolated by density gradient-centrifugation 
using Polymorphprep™. 
 
2. To quantify the differences in function and gene expression profiles 
of ultra-pure neutrophils compared to those of neutrophil 
preparations following Polymorphprep™ isolation, and evaluate 
the effects of contamination by non-neutrophil cells. 
 
3. To quantify the changes in function and gene expression profiles of 
ultra-pure neutrophils and Polymorphprep™ isolated neutrophils 
following stimulation with inflammatory cytokines. 
 
  
220	  
	  
6.3 Methods 
The RNA-Seq data in this chapter were collected using neutrophils from 2 
healthy donors of similar age. The donors were chosen on the basis of their 
consistently high or low levels of eosinophils in neutrophil suspensions 
following Polymorphprep™ isolation. Neutrophils from these two donors 
were isolated by both Polymorphprep™ and negative magnetic bead 
isolation (StemCell®).  For a full description of methods see section 2.2.2. 
Purified neutrophils (5 x 106/mL) were incubated at 37 °C in RPMI media (+ 
25 mM HEPES) and, where stated, treated with either 5 ng/mL of GM-CSF 
or 10 ng/mL of TNFα. Following 1h incubation, total RNA was extracted 
using Trizol/chloroform separation. RNA was further purified using a 
Qiagen on-column RNeasy cleanup-kit which included a DNAse digestion 
step (for more detailed methods see section 2.2.9). 
Total RNA was enriched for poly-A mRNA and sequenced using the 
Illumina Hi-Seq 2000 platform on a single lane producing upwards of 40 
million reads per sample (as previously described 251). For a list of raw reads 
produced per sample see Appendix Table A.5. All sequencing protocols 
were carried out by BGI International following shipment of purified total 
RNA on dry ice.  
Purity and integrity of RNA was determined prior to shipping and prior to 
sequencing using an Agilent bioanalyser (see Appendix, Table A.5 for full 
quality values and concentrations of all samples). All other methods were as 
previously described in Chapter 3.  
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6.4 Results 
For these studies, two healthy donors were selected, based on the levels of 
non-neutrophil leukocytes that consistently contaminated neutrophil 
preparations obtained following isolation on Polymorphprep™: Donor 1 
had consistently low levels of contaminating cells (~1-5%), whereas Donor 
2 had consistently high levels of contaminating cells (~10-18% by 
cytospins). Both donors were otherwise healthy and of similar age. 
Neutrophil preparations were obtained by Polymorphprep™ and negative 
selection, using the StemCell® negative selection technique. 
 
6.4.1 Quantif ication neutrophil purity by cytospin 
The levels of contamination of neutrophil preparations following 
Polymorphprep™ isolation or negative magnetic bead isolation of blood 
from Donors 1 and 2 were quantified by cytospins and flow cytometry. 
Cytospins were prepared and the mean number of neutrophils, monocytes, 
lymphocytes and eosinophils were quantified in 4 separate fields of view 
(x20 magnification). A minimum of 100 cells was counted in each field (Fig 
6.4).  
Quantification confirmed previous observations of different levels of 
contamination in these preparations between the two donors. Similar levels 
of lymphocyte and monocyte contamination were seen in both donors 
(Table3.2). However, the greatest differences between donors were 
detected in the number of eosinophils following Polymophprep™ isolation, 
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with Donor 1 having 1% eosinophils whereas Donor 2 had ~15% 
eosinophils (Table 6.2). The overall purity of neutrophils was higher 
following bead isolation than with Polymorphprep™ (Donor 1; 96% 
Polymorphprep™, 97.5% beads, Donor 2; 83% Polymorphprep™, 99% 
beads). Morphological analysis of levels of cell apoptosis immediately after 
isolation revealed that neither isolation method resulted in significant levels 
of apoptotic cells (<1%, data not shown).  
 
6.4.2 Quantif ication of neutrophil purity by f low cytometry 
Eosinophils are difficult to distinguish from neutrophils using a coulter 
counter 252 or by analysis of their forward-scatter and side-scatter profiles 
using flow cytometry 253 due to their similar sizes and granularity. However, 
they can be distinguished from neutrophils by flow cytometry based on 
their levels of auto-fluorescence or cell surface expression levels of CD16 
(FcγRIII). Eosinophils have a higher autofluorescence and express lower 
levels of CD16 on their cell surface then neutrophils.  
Following isolation of neutrophils by density-gradient or magnetic bead 
isolation, suspensions were stained with FITC-conjugated anti-CD16 
monoclonal antibody and analysed by flow cytometry. Cells were first 
gated on their forward- and side-scatter profiles so that subsequent 
measurements were made on granulocytic cells (see Appendix Fig A.6 for 
example of gating used). Gated cells were subsequently analysed by their 
forward-scatter and CD16 properties (Fig 6.5).  Two distinct populations 
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were detected: cells which were CD16bright ; and a lower population of cells 
of similar size that were CD16dim. These populations represent neutrophils 
and eosinophils, respectively (Fig 3.5). Quantification of the eosinophil 
population revealed that neutrophils isolated by density-gradient 
separation contained a higher proportion of eosinophils than neutrophils 
isolated by magnetic bead depletion. This analysis revealed that Donor 1 
exhibited 3.5% contamination following density gradient isolation, 
compared to 2.42% by magnetic bead isolation, whereas Donor 2 had 12% 
eosinophil contamination following density gradient separation, compared 
to 2.5% following magnetic bead isolation. These levels of eosinophil 
contamination correlate well with the levels of purity as assessed by 
cytospins (Table 6.2). 
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Fig	   6.4	   Representative	   cytospins	   of	   neutrophil	   preparations	   following	  
Polymorphprep™	  (left	  panels)	  	  or	  magnetic	  bead	  isolation	  (right	  panels)	  from	  Donor	  1	  
(top)	  and	  Donor	  2	  (bottom).	  White	  arrows	  highlight	  non-­‐neutrophil	  cells.	  All	  images	  at	  
x20	  magnification.	  Quantification	  of	  data	  is	  summarised	  in	  Table	  6.2.	  	  
	  
	  
	  
Table	   6.2	   Percentage	   of	   leukocytes	   in	   each	   preparation	   from	   each	   donor.	   Cells	  
quantified	   by	   cell	   morphology	   and	   staining	   properties	   using	   cytospins	   (calculated	  
from	  4	  separate	  fields	  of	  view,	  counting	  >	  100	  cells	  per	  field	  per	  donor).	  
 
Cell	  type	  
	  
Donor	  1	   Donor	  2	  
Isolation	  method	  
Poly	   Beads	   Poly	   Beads	  
Neutrophil	   96%	   97.5%	   83%	   99%	  
Eosinophil	  	   1%	   <1%	   15%	   <1%	  
Monocytes	  	  
/Lymphocytes	   3%	   2%	   2%	   <1%	  
 
	  
Do
no
r 1
 
Do
no
r 2
 
Poly Beads 
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Fig	   6.5	   Flow	   cytometry	   scatterplots	   of	   neutrophil	   preparations	   by	   Polymorphprep™	  
(top	  panels)	  or	  magnetic	  bead	   (bottom	  panels)	   isolation	  protocols.	  Plotted	  by	  green	  
fluorescence	  (CD16	  positive,	  X-­‐axis)	  and	  forward-­‐scatter	  (Y-­‐axis).	  Donor	  1	  (left	  panels)	  
and	  Donor	  2	  (right	  panels).	  Numbers	  shown	  are	  percentage	  of	  cells	  in	  each	  of	  the	  two	  
quadrants	  shown.	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6.4.3 Effect of neutrophil isolation method and population 
purity on neutrophil apoptosis 
Contaminating cells in neutrophil preparations have been implicated in 
affecting the behaviour of neutrophils in response to stimulation 225,249,254. 
Neutrophils prepared by both isolation methods were therefore incubated 
overnight (18 h) with (or without) GM-CSF (5 ng/mL) or TNFα (10 ng/mL). 
Levels of neutrophil apoptosis were subsequently measured by flow 
cytometric analysis of annexin V/PI staining (Fig 6.6). Mean levels of 
neutrophil apoptosis in suspensions from Donor 1 following 
Polymorphprep™ isolation were: untreated 81.5% ± 0.25%; GM-CSF 
51.7% ± 1%; TNF 53.4% ± 2.8%, which are in line with previously published 
data 251. Neutrophils from Donor 1 isolated by magnetic beads showed 
lower levels of apoptosis after GM-CSF treatment than control neutrophils: 
untreated 44.3% ± 1.5%; GM-CSF 32.1% ± 0.2%. However, neutrophils 
treated with TNFα exhibited a higher level of apoptosis than control 
neutrophils (TNF 57%, ± 2.9%), suggesting that under these conditions, 
TNFα is pro-apoptotic to neutrophils. Neutrophils from Donor 2 showed a 
similar pattern of apoptosis to Donor 1 for both the Polymorphprep™ 
isolated preparations (untreated 72.6% ± 0.62%, GM-CSF 45.7% ± 0.53%, 
TNF 53.1% ± 0.61%) and in the bead-isolated preparations (untreated 
27.7% ±0.1%, GM-CSF 10.8% ± 0.5%, TNF 54.7% ± 0.5%), including an 
increase in apoptosis following TNFα treatment of bead-isolated 
neutrophils. Increasing the number of biological replicates to N=4 resulted 
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in values for treated samples reaching significance (p <0.05) when 
compared to their paired, untreated sample (Fig 6.6). These data suggest 
that firstly, magnetic bead isolated neutrophils have lower levels of 
constitutive apoptosis than Polymorphprep™ isolated neutrophils, and 
secondly, that treatment of neutrophils with TNFα has opposing effects on 
apoptosis levels, dependent on neutrophil isolation method and/or 
preparation purity.  
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Fig	   6.6	   Levels	   of	   neutrophil	   apoptosis	   following	   overnight	   incubation	   (18	   h)	   with	  
inflammatory	  cytokines.	  Neutrophils	   isolated	  by	  Polymorphprep™	  (Poly)	  or	  magnetic	  
beads	   (Beads)	  were	   incubated	  overnight	   (18	  h)	   in	   the	  presence	   (or	   absence	   (UT))	   of	  
inflammatory	   cytokines	  GM-­‐CSF	   (GM)	   (5	  ng/mL)	  or	   TNFα	   (TNF)	   (10	  ng/mL).	   Levels	  of	  
apoptosis	  were	  measured	  by	  annexin	  V/PI	   staining.	  For	   (A)	  Donor	   1	  and	   (B)	  Donor	  2,	  
bars	   represent	  mean	   value	   of	   duplicate	  measurements	   (±	   SD),	   In	   (C)	   bars	   represent	  
mean	   value	   of	   4	   separate	   experiments	   from	   4	   donors,	   error-­‐bars	   represent	   SEM.	   *	  
Represents	  significance	  (p<0.05)	  as	  measured	  by	  a	  paired	  student’s	  t-­‐test.	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6.4.4 Cell surface markers of neutrophils prepared by different 
methods 
Appropriate cell surface markers can inform on the relative purity of cell 
preparations and the activation state of the cells. To assess levels of 
neutrophil purity and activation following Polymorphprep™ or bead 
isolation, freshly-isolated neutrophils were stained with FITC-conjugated-
monoclonal antibodies for CD16 (FcγIII), CD15, CD11b (ITGAM) and CD64 
(FcγRI) and relative fluorescence measured by flow-cytometry (Fig 6.7). 
Levels of CD16, CD15 and CD11b were slightly lower in neutrophils 
isolated by magnetic bead isolation whilst levels of CD64 were slightly 
lower in Polymorphprep™ isolated neutrophils. However, levels were not 
significantly different between neutrophils isolated using different methods 
(p>0.05 paired student’s t-test) suggesting that neutrophil isolation 
methods and preparation purity has only marginal effects on cell surface 
expression. 
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Fig	   6.7	   Levels	   of	   expression	   of	   cell	   surface	   markers	   in	   neutrophils	   isolated	   by	  
Polymorphprep™	  (Poly)	  or	  by	  magnetic	  beads	  (Beads).	  Geometric	  mean	  fluorescence	  
(GMF)	  of	  CD16	  (N=5),	  CD15	  (N=3),	  CD11b	  (N=3)	  and	  CD64	  (N=4)	  was	  measured	  by	  flow	  
cytometry	   and	   normalised	   to	   an	   appropriate	   isotype	   control.	   Error	   bars	   represent	  
SEM.	   No	   significant	   difference	   in	   expression	   found	   between	   isolation	   methods	  
(Student’s	  t-­‐test	  p>0.2).	  
	  
	  
6.4.5 Neutrophil yield from whole blood 
In addition to purity levels, different isolation methods result in different 
final yields of neutrophils from whole blood 244,245. To quantify differences 
between Polymorphprep™- and magnetic bead- isolated neutrophils, a 
sample of whole blood from a healthy donor was divided into two and 
neutrophils were isolated by Polymorphprep™ and magnetic beads in 
parallel. Final preparations of neutrophils were counted using a coulter 
counter and the number of neutrophils recovered per mL of whole blood 
was calculated (Fig 6.8). This process was repeated for 5 different donors. 
Mean levels of neutrophils after magnetic bead isolation were 
approximately 40% of those recovered after Polymorphprep™ isolation 
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using blood from the same donor (Polymorphprep™ 2.81x106 /mL whole 
blood ± 1.02; Beads 1.14x106 /mL whole blood ± 0.76). This suggests that 
a large proportion of whole blood neutrophils are lost during a magnetic 
bead isolation, and that this proportion would otherwise be retained using 
a Polymorphprep™ preparation. 
 
 
Fig	   6.8	   Comparison	   of	   neutrophil	   yield	   from	   whole	   blood	   following	   isolation	   by	  
Polymorphprep™	  (Poly)	  or	  magnetic	  beads	  (Beads).	  **	  p<0.01	  (paired	  student’s	  t-­‐test).	  
Paired	  data	  from	  5	  independent	  experiments.	  Error	  bars	  represent	  SEM.	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6.4.6 RNA-Seq analysis of neutrophils prepared by different 
methods 
Having shown that different donors and different neutrophil isolation 
procedures generate suspensions containing different numbers of 
contaminating cells, notably eosinophils, it was then necessary to 
determine how these contaminating cells and isolation techniques 
contribute to transcriptome studies. Neutrophil preparations isolated by 
two different methods  (Polymorphprep™ and Beads) from donors with 
high or low eosinophil contamination levels were incubated with (or 
without) inflammatory cytokines (GM-CSF or TNFα) for 1 h before total RNA 
was extracted and processed for high throughput sequencing by RNA-Seq 
(see Methods). For details of RNA integrity and number of raw reads per 
sample see Appendix Table A.5. 
 
6.4.7 Transcript levels of antigens targeted by antibodies in the 
bead kit protocol 
To quantify the efficiency of the magnetic bead isolation kit to deplete 
contaminating cells, transcripts for the cell-specific antigens utilised in the 
bead kit were analysed (transcripts for genes listed in Table 3.1). Of the 7 
antigens, only transcripts for CD9, CD36, CD2, and CD3 were detected in 
any samples, and these are expressed in eosinophils, monocytes, T-
cells/NK cells and T cells, respectively.  
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Transcripts for CD36, CD3 and CD2 were detected in all samples from both 
donors following Polymorphprep™ isolation, but were absent (or below the 
RPKM threshold of 0.3) from all samples isolated by magnetic beads (Fig 
6.9). CD9 transcripts (specific to eosinophils) showed the highest levels of 
expression of all 7 genes, with the highest levels seen in the untreated 
sample from Donor 2 following Polymorphprep™ isolation (RPKM=28.9). 
Samples processed by magnetic bead isolation showed much lower levels 
of CD9 expression than those isolated by Polymorphprep™.  However, 
unlike the other transcripts, levels of CD9 where not entirely absent in 
samples isolated by beads, and were at or around the 0.3 RPKM threshold 
(Fig 6.9). The high levels of CD9 in all samples from Donor 2 following 
Polymorphprep™ isolation confirmed the presence of significant levels of 
eosinophils, whilst the greatly decreased levels of CD9 transcripts in the 
samples isolated by magnetic beads confirmed the ability of the magnetic 
bead kit to effectively deplete eosinophils.  
Treatment of neutrophils from each preparation type and from both donors 
with GM-CSF or TNFα had no significant effect on any bead kit antigen 
transcripts compared with their corresponding untreated sample. However, 
it is noteworthy that the largest variation in values between treatments 
(untreated, GM-CSF and TNFα) was consistently seen in Donor 2 samples 
following Polymorphprep™ isolation (Fig 6.9), that is, the preparation with 
the highest levels of non-neutrophil leukocytes. 
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6.4.8 Expression of other non-neutrophil transcripts 
The levels of transcripts encoding each of the 7 bead kit antigen target 
antibodies correlate well with the overall levels of cellular contamination 
measured by cytospins and flow cytometry. However, whilst these gene 
products are known to be unique cell-surface markers on specific cell types, 
it is possible that they may also be transcribed in other leukocytes, but not 
translated and expressed. We therefore measured the expression levels of 
other transcripts, which, according to the literature, are only expressed in 
non-neutrophil leukocytes, in order to further elucidate the extent that 
contaminating cells contribute to the transcriptome profile of the 
neutrophil preparations. Figure 6.10 shows the RPKM levels for the T-and-
B-cell specific transcripts CD8a and CD5 (respectively), the monocyte-
specific transcripts Chemokine Ligand 2 (CCL2) and CD163, and the 
eosinophil transcripts, Interleukin 5 Receptor Alpha (IL5RA) and Charcot-
Leyden crystal galectin (CLC).  
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Fig	  6.9.	  RPKM	  values	  for	  non-­‐neutrophil	  genes	  of	  the	  antigen	  targets	  in	  the	  magnetic	  
bead	   isolation	  kit.	  The	  antigens	  not	  shown	  (CD19,	  CD56	  and	  glycophorin	  A)	  were	  not	  
expressed	  above	  the	  cut	  off	  RPKM	  values	  (0.3)	  under	  any	  conditions.	  Neutrophils	  were	  
either	  isolated	  by	  magnetic	  beads	  isolation	  (Bead)	  or	  by	  Polymorphprep™	  (Poly)	  from	  
Donor	   1	   (1)	  and	  Donor	  2	   (2)	   .	  Neutrophils	  were	   treated	  with	  5	  ng/mL	  GM-­‐CSF	   ( /¢),	  
10ng/mL	  of	  TNFα	  (¡ /¨)	  or	  untreated	  ( /¢)	  for	  1h.	  Horizontal	  dotted	  lines	  represent	  
RPKM	  expression	  threshold	  of	  0.3.	  Horizontal	  bars	  represent	  mean	  value.	  	  
	  
 
All 6 transcripts were present at very low levels in all samples (RPKM < 2), 
apart from the eosinophil specific transcript CLC in Polymorphprep™ 
prepared samples from Donor 2 (RPKM=249.5). As described previously for 
transcripts for cell-surface markers, the expression levels of transcripts for 
other cell-specific markers were higher in Polymorphprep™ preparations 
than in magnetic bead preparations from both donors. Furthermore, with 
the exception of CD163, all transcripts had highest expression levels in the 
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sample prepared by Polymorphprep™ from Donor 2. Importantly, where a 
transcript is expressed at a level >0.3 RPKM (that is, above the expression 
threshold) in the Polymorphprep™ preparations, the expression level in the 
paired bead isolation preparation was <0.3 RPKM (with the exception of 
CD163, RPKM = 0.36), suggesting that most contaminating cells have been 
removed.  The data in Fig 6.9 and 6.10 confirm that the major source of 
cellular contamination seen in the Polymorphprep™ preparations 
originates from eosinophils and that the magnetic bead isolation procedure 
is sufficient to remove this contamination. 
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Fig	  6.10	  RPKM	  values	   for	  non-­‐neutrophil	   specific	  genes	  associated	  with	  T	  and	  B	  cells	  
(top)	  monocytes	  (middle)	  and	  eosinophils	  (bottom).	  Neutrophils	  were	  either	  isolated	  
by	  magnetic	  beads	  isolation	  (Bead)	  or	  by	  Polymorphprep™	  (Poly)	  from	  Donor	  1	  (1)	  and	  
Donor	  2	  (2)	  .	  Neutrophils	  were	  treated	  with	  5	  ng/mL	  GM-­‐CSF	  ( /¢),	  10ng/mL	  of	  TNFα	  
(¡ /¨)	  or	  untreated	  ( /¢)	  for	  1h.	  Horizontal	  dotted	  lines	  represent	  RPKM	  expression	  
threshold	  of	  0.3.	  Horizontal	  bars	  represent	  mean	  value.	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6.4.9 Comparison of differential ly-expressed genes between 
isolation methods. 
Having analysed the expression levels of transcripts expressed by non-
neutrophil cell types, the open-source high-throughput annotation software 
Cufflinks 145 was used to perform differential expression tests on the raw 
data to identify all transcripts within the transcriptome that were DE 
between isolation methods. All samples from both isolation methods were 
initially compared with each other (all 6 samples prepared using 
Polymorphprep™ compared with all 6 bead-isolated samples) and then 
subsequently, samples were compared with only their paired-treatment 
sample, for example, untreated samples isolated by Polymorphprep™ 
(from Donor 1 and Donor 2) were compared with untreated samples 
prepared by magnetic bead isolation (from Donor 1 and Donor 2). This 
would determine two things, firstly, the effect of neutrophil isolation 
method (and typical levels of eosinophil contamination) on gene expression 
profiles, and secondly, it would identify transcripts that were DE (between 
isolation methods) following stimulation with inflammatory cytokines. 
6.4.9.1 Polymorphprep™ vs Magnetic bead isolation (all samples) 
Samples from both donors were analysed by RNA-Seq to identify changes 
in neutrophil gene expression following either Polymorphprep™ or 
negative magnetic bead isolation. When comparing all Polymorphprep™ 
samples against all bead samples from both donors (i.e. 6 
Polymorphprep™ samples (two donors, 3 treatments) vs 6 bead samples 
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(two donors, 3 treatments)). Cuffdiff identified only 16 genes (from a 
possible 24,934) that were significantly differentially-expressed between 
isolation methods (Table 6.3). All 16 genes showed a low expression value 
in the Polymorphprep™ samples (ranging from 0.708-20.548 RPKM) and 
were not detected in the bead samples (with the exception of ADP-
Ribosylation Factor-Like 4C (ARL4C) RPKM=0.471). This suggests that their 
detection is due to increased cell contamination in the Polymorphprep™ 
samples since several of the genes can be attributed to non-neutrophil 
cells, for example HBB and CD3 to erythrocytes and T cells, respectively. 
However, the absolute expression values of all 16 genes were low (< 21 
RPKM) and so contribute little to the overall transcriptome profiles of 
neutrophil suspensions prepared by Polymorphprep™. 
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Table	   6.3	   List	   of	   genes	   with	   significantly	   different	   expression	   levels	   in	   neutrophil	  
suspensions	   prepared	   by	   different	   isolation	   methods.	   Table	   shows	   all	   significantly	  
differentially	   expressed	   genes	   in	   order	   of	   the	   greatest	   change	   in	   RPKM	   values	  
(ΔRPKM)	   between	   neutrophils	   isolated	   using	   either	   Polymorphprep	   (poly)	   or	  
magnetic	   beads.	   Significance	   (q-­‐value)	   as	   calculated	   by	   Cuffdiff	   and	   adjusted	   for	   5%	  
false	   discovery	   rate	   by	   Benjamini-­‐Hochberg	   correction	   for	   multiple-­‐testing.	   Data	  
calculated	  from	  two	  biological	  replicate	  sets,	  as	  described	  in	  text.	  
 
Gene	  Name	   Poly	  
(RPKM)	  
Beads	  
(RPKM)	  
Fold	  
change	  
(log2)	  
q-­‐value	   ΔRPKM	  
HBA2	   20.548	   0.093	   -­‐7.786	   6.50E-­‐04	   20.454	  
THBS1	   12.944	   0.205	   -­‐5.981	   1.53E-­‐03	   12.739	  
HBB	   11.680	   0.080	   -­‐7.197	   3.83E-­‐03	   11.600	  
ARL4C	   10.754	   0.471	   -­‐4.513	   2.98E-­‐02	   10.283	  
ALOX15	   10.068	   0.041	   -­‐7.935	   3.12E-­‐06	   10.027	  
PRSS33	   7.281	   0.008	   -­‐9.806	   1.55E-­‐02	   7.273	  
IL7R	   5.736	   0.295	   -­‐4.282	   3.97E-­‐03	   5.441	  
EMR4P	   5.570	   0.158	   -­‐5.138	   6.64E-­‐03	   5.412	  
S1PR1	   4.115	   0.216	   -­‐4.250	   2.02E-­‐02	   3.899	  
CD3E	   3.867	   0.058	   -­‐6.054	   6.50E-­‐04	   3.809	  
SMPD3	   3.232	   0.049	   -­‐6.036	   8.79E-­‐04	   3.183	  
CCR7	   2.958	   0.154	   -­‐4.263	   1.71E-­‐02	   2.804	  
SIGLEC8	   2.263	   0.036	   -­‐5.983	   1.87E-­‐03	   2.227	  
GPR114	   1.072	   0.020	   -­‐5.778	   2.98E-­‐02	   1.052	  
ITK	   1.021	   0.053	   -­‐4.276	   9.06E-­‐03	   0.968	  
BCL11B	   0.708	   0.018	   -­‐5.268	   8.76E-­‐03	   0.690	  
	  
 
6.4.9.2 Polymorphprep™ vs magnetic bead isolation (treatment specific 
comparison) 
The following analyses were performed to determine if the method of 
isolation had any impact on the patterns of gene expression. Samples of 
neutrophils treated under similar incubation conditions (N=2), but prepared 
by the two different methods were compared (for example, untreated 
Polymorphprep™ vs untreated bead-isolated). This analysis identified a 
total of 25 genes in all 3 treatment groups whose expression was 
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significantly different between the two preparation methods. Of these, 23 
genes were significantly differentially expressed in the untreated samples, 
and 9 genes were significantly altered in all 3 treatment pairings (Fig 6.11).  
As with the genes listed in Table 6.3, all expression levels for genes in Fig 
6.11 were higher in neutrophil samples prepared by Polymorphprep™ 
compared to samples prepared by magnetic beads. 
 
 
Fig	   6.11	   Venn	   diagram	   showing	   differentially	   expressed	   genes	   between	   neutrophil	  
samples	   prepared	   by	   either	   Polymorphprep™	   (poly)	   or	   magnetic	   beads	   (bead).	  
Comparisons	   performed	   by	   Cufflinks	   using	   treatment	   specific	   paired-­‐samples	   from	  
two	   biological	   replicates.	   All	   genes	   displayed	   were	   significantly	   differentially	  
expressed	  due	  to	  a	  higher	  RPKM	  in	  Polymorphprep™	  prepared	  samples.	  Significance	  
(q	   <	   0.05)	   as	   calculated	   by	   Cuffdiff	   and	   adjusted	   for	   5%	   false	   discovery	   rate	   by	  
Benjamini-­‐Hochberg	  correction	  for	  multiple-­‐testing.	  See	  glossary	  for	  full	  gene	  names.	  
 
 
This independent analytical approach has confirmed the data in sections 
6.4.7-6.4.8 that neutrophil suspensions isolated by Polymorphprep™ 
TNF$poly)vs)TNF$bead)
))UT$poly)vs)UT$Bead) ))))))))GM$poly)vs)GM$bead)
ITGB7)
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express only low levels of transcripts that are attributable to contaminating 
cells. However, neutrophil suspensions isolated by magnetic beads do not 
express these transcripts. Furthermore, cytokine treatment had very little 
effect on the number of genes DE between isolation methods. This 
indicates that the contaminating cells did not respond to these cytokines 
by alterations in gene expression to these cytokines. Thus, in subsequent 
experiments, cytokine-regulated changes in gene expression can be 
attributed to altered activity of neutrophils. 
   
6.4.10 Comparison of gene expression profi les of two different 
donors fol lowing neutrophil isolation using two separate 
methods 
The previous section identified genes which showed significantly higher 
expression in samples prepared by Polymorphprep™. This section set out 
to answer a number of different questions: 
1) Does the isolation method affect gene expression in neutrophils? For 
example, can spending different lengths of time at 37°C and/or being 
subject to different centrifugal forces cause a significant change in gene 
expression? 
2) Are identical sub-populations of neutrophils isolated by different 
techniques? For example, LDGs (see section 1.4.3) which are present at 
variable levels in healthy controls or patients with inflammatory disorders, 
have different density properties and hence sediment at different rates in 
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density-gradient such as Polymorphprep™. It has been reported that LDGs 
express different genes compared to normal density granulocytes 52,81. 
Additionally, the bead isolation method only yielded 40% of the total 
number of neutrophils recovered by Polymorphprep™ (Fig.6.8), but the 
reason for this loss of cells are unknown. It is therefore possible that 
different sub-populations are isolated by the 2 techniques, and that these 
different sub-populations may have different gene expression profiles 
and/or respond differently to cytokines.  
Therefore, the analysis of the data in this section was designed to address 
these questions. This was achieved by comparing changes in gene 
expression in suspensions purified by either Polymorphprep™ (pooling 
data from each of the incubation conditions) or purified by magnetic 
beads. Data for each donor were analysed separately in order to detect 
changes in expression levels that may be donor-dependent (see appendix 
A.8 for datasets used in each comparison). Any gene whose expression is 
lower in the bead-isolated sample is likely to be due to contamination in 
Polymorphprep™ samples.  However, a gene whose expression is higher in 
the bead-isolated  samples could likely be due to either:  
 
a) The physical conditions employed of the isolation method; or 
b) A different sub-population of neutrophils. 
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6.4.11 Donor specif ic analysis of neutrophil samples prepared 
by either Polymorphprep™ or magnetic bead isolation 
For Donor 1 (low contamination donor), Cuffdiff identified 63 genes DE 
between isolation methods, whereas a higher number, 282 genes, were 
detected for Donor 2 (high contamination donor).  
Unlike previous analyses using pooled data-sets from both donors, where 
all significant genes were expressed at higher levels in Polymorphprep™ 
isolated samples, when analysing each donor independently, a proportion 
of differentially regulated genes had higher values in the bead-isolated 
samples. For example, for Donor 1, 10/63 genes showed higher expression 
in bead-isolated samples than in Polymorphprep™ samples, and in Donor 
2 92/282 showed higher expression in bead-isolated samples than in 
Polymorphprep™ samples. Interestingly, the percentage of significant 
genes expressed at higher levels in beads compared to Polymorphprep™ 
in Donor 2 is twice that seen in Donor 1 (32.7% and 15.9% respectively) 
(see Appendix Table A.9). 
6.4.11.1 Donor 1 
The 25 genes with the greatest change in RPKM between isolation 
methods for Donor 1 are listed in Table 6.4. The greatest change in RPKM 
seen in Donor 1 is for the gene FBJ Murine Osteosarcoma Viral Oncogene 
Homology (FOS) which has an RPKM of 169 in Polymorphprep™ samples 
and a significantly higher value of 1148 in magnetic bead isolated samples 
(q-value = 0.019). The next 3 genes with the greatest change in RPKM 
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between isolation methods are HBA1, HBA2 and HBB, which encode the 
alpha and beta subunits of the haemoglobin, an important protein in 
oxygen transportation in erythrocytes. Despite lacking a nucleus, 
erythrocytes and reticulocytes (immature erythrocytes) are capable of gene 
transcription and translation 255. The presence of these transcripts in 
Polymorphprep™ samples most likely represents contaminating 
erythrocytes which were not eliminated by the hypertonic lysis step. Since 
the bead isolation kit contains an antibody recognising an erythrocyte-
specific antigen (glycophorin A), this contamination is predictably absent 
from all bead-prepared samples. Although the expression values of the 
remaining genes are judged to be significant by Cuffdiff, the differences in 
RPKM values between samples are very low, with only 15/63 genes having 
a change in RPKM of >2 between isolation conditions Table 6.4. 
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Table.6.4	   List	   of	   genes	   significantly	   regulated	   between	   isolation	   methods	   in	  
neutrophils	  from	  Donor	  1	  (low	  contamination).	  Table	  shows	  the	  top	  25	  genes	  with	  the	  
greatest	   change	   in	  RPKM	  values	   (ΔRPKM)	  between	  neutrophils	   isolated	  using	  either	  
Polymorphprep™	  (Poly)	  or	  magnetic	  beads.	  Genes	  expressed	  at	  higher	  levels	  in	  bead-­‐
isolated	   samples	   are	   shaded	   grey.	   Significance	   (q-­‐value)	   as	   calculated	   by	   Cuffdiff,	  
adjusted	  for	  5%	  FDR	  by	  Benjamini-­‐Hochberg	  correction	  for	  multiple-­‐testing.	  Data	  from	  
3	  paired	  samples	  from	  Donor	  1.	  
 
Gene	  
Name	  
Poly	  
(RPKM)	  
Beads	  
(RPKM)	  
Fold	  
change	  
(log2)	  
q-­‐value	   ΔRPKM	  FOS	   169.379	   1148.700	   2.762	   1.90E-­‐02	   -­‐979.321	  HBA1	   26.138	   0.016	   -­‐10.642	   2.29E-­‐02	   26.122	  HBA2	   24.521	   0.015	   -­‐10.656	   2.29E-­‐02	   24.506	  HBB	   16.238	   0.040	   -­‐8.683	   2.95E-­‐05	   16.198	  CKS2	   1.285	   10.227	   2.993	   1.45E-­‐05	   -­‐8.943	  KLF4	   2.642	   10.591	   2.003	   3.51E-­‐02	   -­‐7.948	  LCN2	   1.292	   7.993	   2.629	   2.77E-­‐05	   -­‐6.701	  LTF	   0.799	   6.060	   2.923	   2.10E-­‐06	   -­‐5.261	  EREG	   5.489	   0.394	   -­‐3.799	   1.15E-­‐03	   5.094	  RPL10A	   6.760	   1.817	   -­‐1.896	   3.49E-­‐02	   4.943	  IL7R	   3.758	   0.328	   -­‐3.517	   1.78E-­‐07	   3.430	  CD3E	   2.761	   0.029	   -­‐6.564	   8.10E-­‐07	   2.732	  THBS1	   2.735	   0.051	   -­‐5.749	   0.00E+00	   2.684	  KIAA0090	   0.361	   2.880	   2.996	   8.10E-­‐07	   -­‐2.519	  CCR7	   2.093	   0.066	   -­‐4.981	   4.05E-­‐10	   2.027	  SERPINB2	   1.959	   0.286	   -­‐2.775	   1.06E-­‐02	   1.673	  CCL5	   1.881	   0.338	   -­‐2.474	   9.02E-­‐04	   1.543	  GIMAP7	   1.567	   0.263	   -­‐2.576	   1.47E-­‐03	   1.305	  VCAN	   1.261	   0.021	   -­‐5.907	   9.02E-­‐04	   1.240	  TCF7	   1.421	   0.209	   -­‐2.768	   2.45E-­‐02	   1.212	  LDHB	   1.317	   0.137	   -­‐3.264	   2.14E-­‐04	   1.180	  ARL4C	   1.378	   0.227	   -­‐2.603	   2.50E-­‐04	   1.151	  S1PR1	   1.300	   0.150	   -­‐3.118	   7.56E-­‐06	   1.151	  MMP8	   0.108	   1.024	   3.245	   1.33E-­‐05	   -­‐0.916	  CD5	   1.102	   0.192	   -­‐2.525	   4.52E-­‐04	   0.911	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6.4.11.2 Donor 2 
By comparison, Table 6.5 lists the 25 genes with the greatest RPKM change 
between isolation methods in samples from Donor 2. Only 3 genes (LCN2, 
HBA1 and MMP8) feature on both lists. The number of significant genes for 
Donor 2 is much greater than for Donor 1 and the magnitude of the RPKM 
differences between isolation methods are also greater in Donor 2. 
Interestingly, despite the increased purity of neutrophils isolated by 
magnetic beads (as shown earlier by flow cytometry and cytospins), 15 of 
the top 25 significant genes exhibit higher expression in bead-isolated 
samples than in Polymorphprep™ isolated samples. These include the two 
genes with the greatest change in RPKM (neutrophil defensin – DEFA1 and 
neutrophil gelatinase-associated Lipocalin LCN2). The genes that have 
higher expression in Polymorphprep™ samples are those most-commonly 
associated with other, non-neutrophil cell types, such as CLC (eosinophils), 
CD52 (lymphocytes) and PLIN2 (epithelial cells). However, the genes with 
higher expression in bead-isolated neutrophils are known neutrophil genes,  
for example Carcinoembryonic antigen-related cell adhesion molecule 8 
(CEACAM8) and Bactericidal/Permeability-Increasing Protein (BPI): in some 
cases these are neutrophil-specific genes, for example neutrophil elastase 
(ELANE) 256 and lipocalin 2 (LCN2) 257. Consequently, these genes with 
significantly higher expression in bead isolated samples cannot be 
attributed to contaminating leukocytes. 
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Table.	   6.5	   List	   of	   genes	   significantly	   regulated	   between	   isolation	   methods	   in	  
neutrophils	  from	  Donor	  2	  (high	  contamination).	  Table	  shows	  the	  top	  25	  genes	  with	  the	  
greatest	   change	   in	  RPKM	  values	   (ΔRPKM)	  between	  neutrophils	   isolated	  using	  either	  
Polymorphprep™	  (Poly)	  or	  magnetic	  beads.	  Genes	  expressed	  at	  higher	  levels	  in	  bead-­‐
isolated	   samples	   are	   shaded	   grey.	   Significance	   (q-­‐value)	   as	   calculated	   by	   Cuffdiff	  
adjusted	   for	   5%	   false	   discovery	   rate	   by	   Benjamini-­‐Hochberg	   correction	   for	   multiple-­‐
testing.	  Data	  from	  3	  paired	  samples	  from	  Donor	  2.	  
 
Gene	  
Name	  
Poly	  
(RPKM)	  
Beads	  
(RPKM)	  
Fold	  
change	  
(log2)	  
q-­‐value	   ΔRPKM	  DEFA1	   239.933	   1082.690	   2.174	   4.75E-­‐02	   -­‐842.757	  LCN2	   89.952	   447.161	   2.314	   2.45E-­‐02	   -­‐357.209	  CLC	   264.289	   15.800	   -­‐4.064	   6.14E-­‐09	   248.489	  CAMP	   32.519	   138.676	   2.092	   2.93E-­‐02	   -­‐106.157	  BPI	   24.068	   117.488	   2.287	   2.05E-­‐02	   -­‐93.420	  OLFM4	   16.438	   87.792	   2.417	   1.36E-­‐02	   -­‐71.354	  CD52	   56.669	   2.804	   -­‐4.337	   3.79E-­‐04	   53.865	  CEACAM8	   12.433	   65.236	   2.391	   9.63E-­‐03	   -­‐52.803	  DEFA4	   9.968	   57.406	   2.526	   1.26E-­‐03	   -­‐47.438	  PLIN2	   40.458	   1.758	   -­‐4.524	   2.23E-­‐08	   38.699	  MS4A3	   8.837	   45.919	   2.377	   1.54E-­‐02	   -­‐37.081	  MMP8	   9.436	   41.732	   2.145	   3.68E-­‐02	   -­‐32.297	  AZU1	   7.485	   38.436	   2.360	   4.26E-­‐03	   -­‐30.951	  ELANE	   5.851	   34.581	   2.563	   1.00E-­‐03	   -­‐28.731	  RETN	   5.085	   28.648	   2.494	   5.32E-­‐03	   -­‐23.563	  LGALS12	   23.813	   0.657	   -­‐5.180	   7.78E-­‐06	   23.157	  RGS1	   25.601	   2.924	   -­‐3.130	   4.85E-­‐04	   22.677	  THBS1	   22.995	   0.367	   -­‐5.969	   0.00E+00	   22.628	  ALOX15	   22.411	   0.047	   -­‐8.894	   0.00E+00	   22.364	  ARL4C	   22.673	   0.775	   -­‐4.871	   0.00E+00	   21.898	  HBA1	   19.632	   0.031	   -­‐9.311	   4.39E-­‐02	   19.601	  CEACAM6	   5.968	   25.207	   2.079	   2.95E-­‐02	   -­‐19.239	  H1F0	   3.009	   21.615	   2.845	   2.19E-­‐04	   -­‐18.605	  HBA2	   18.605	   0.202	   -­‐6.529	   1.92E-­‐08	   18.403	  C13orf15	   5.171	   23.425	   2.180	   1.16E-­‐02	   -­‐18.254	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6.4.12 Filtering of gene l ists from both donors to enrich for 
genes with highest expression changes between isolation 
methods 
When a filter is applied to the full list of significant genes to remove genes 
which have <2 RPKM difference between isolation methods, the number of 
genes decreases from 63 to 15 for Donor 1 and from 282 to 116 for Donor 
2 (Fig 6.12). This filtering also decreases the proportion of genes with a 
higher value in bead samples to a greater extent in Donor 1 than in Donor 
2. This reveals that of the genes DE in either donor, a greater proportion of 
those in Donor 2 have a considerable difference in RPKM (> 2), whereas the 
majority of DE genes in Donor 1 have a very small (< 2) difference in RPKM 
between isolation methods, and although deemed to be significant by 
Cuffdiff, are unlikely to have a considerable effect on overall gene 
expression profiles. 
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Fig	  6.12	  Number	  of	  genes	  significantly-­‐regulated	  in	  neutrophils	  is	  dependent	  on	  Donor	  
and	  neutrophil	   isolation	  method.	  (A)	  The	  number	  of	  genes	  significantly	  differentially	  
expressed	   (DE)	   is	  higher	   in	  Donor	  2	   than	  Donor	   1,	  and	  a	  greater	  proportion	  of	   those	  
genes	   are	   higher	   following	   Polymorphprep™	   isolation	   (white	   bars)	   than	   magnetic	  
bead	  isolation	  (black	  bars).	  (B)	  Filtering	  significant	  DE	  genes	  for	  values	  that	  only	  show	  
>2	   RPKM	   difference	   between	   isolation	   method	   values,	   dramatically	   decreases	   the	  
number	   of	   genes	   in	   Donor	   1	   but	   only	   halves	   the	   number	   of	   genes	   in	   Donor	   2.	   The	  
proportion	  of	  genes	   that	  are	  higher	   in	  bead	   isolation	   is	  also	  much	  higher	   in	  Donor	  2	  
than	  Donor	  1,	  and	  is	  less	  affected	  by	  filtering	  gene	  list.	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6.4.13 Genes enriched in bead isolated samples 
A striking finding in the list of significant genes between Donor 1 and 2 is 
the proportion of genes that are enriched in the bead-isolated samples. It 
might be predicted that if any difference existed in gene expression values, 
this would likely result from the small percentage of contamination from 
other cell types in the Polymorphrep™ isolated cells. Consequently, these 
values would be highest in Polymorphrpep™ samples and greatly 
decreased (or absent) in the bead isolated samples. In fact, of the 
significantly differentially expressed genes in Donor 2, almost a third of 
these show higher expression in bead-isolated samples (92/282) (for full list 
of the 92 genes see Appendix, Table A.10) including 12 of the top 15 
genes with greatest changes in RPKM (Table 6.5, grey shading).  
Further analysis of these genes identified several encoding neutrophil 
granule proteins and anti-bacterial peptides. These include (but are not 
limited to) lactoferrin (LTF), defensin (DEFA1), myeloperoxidase (MPO), 
neutrophil elastase (ELANE), Bacterial Permeability-Increasing protein (BPI) 
and azurocidin (AZU1). Neutrophil granule proteins are expressed and 
compartmentalised prior to maturation and release of mature cells into the 
peripheral blood 258,259. Typically, granule protein genes are not transcribed 
in fully-mature neutrophils 18,   suggesting their presence in Donor 2 
samples is indicative of the presence of a sub-population of pre-mature 
neutrophils or progenitor cells, that is otherwise absent or below the 
threshold of detection in Donor 1 samples. 
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Recent work by Villanueva and colleagues 52 has sought to define the 
transcriptional profile of LDGs in SLE.  Micro-array studies showed that a 
total of 18 genes are significantly elevated in SLE LDGs when compared to 
levels detected in control or SLE normal density granulocytes. Among the 
18 genes include those relating to granule enzymes, and molecules 
associated with ROS production, NET formation and bactericidal activity 52 
(Table 6.6). 
Analysis of genes significantly expressed between isolation methods in 
Donor 2 revealed that several of the genes have previously been shown to 
be associated with immature neutrophils and/or LDGs. This was confirmed 
by IPA-software analysis (data not shown). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
253	  
	  
Table	  6.6	  List	  of	  functions	  of	  18	  LDG-­‐associated	  genes	  as	  defined	  by	  Villanueva	  et	  al	  52.	  
 
Gene	  
symbol	  
Gene	  Name	   Function	  MMP8	   Matrix	  metallopeptidase	  8	   Gelatinase	  and	  collagenase	  activities	  MMP9	   Matrix	  metallopeptidase	  9	  CEACAM1	   Carcinoembryonic	  Antigen-­‐Related	  Cell	  Adhesion	  Molecule	  1	  (CD66a)	   Adhesion	  molecule	  CEACAM8	   Carcinoembryonic	  Antigen-­‐Related	  Cell	  Adhesion	  Molecule	  8	  (CD66b)	  RNASE2	   Ribonuclease	  2	   Non-­‐secretory	  ribonuclease	  (pyrimidine	  specific)	  RNASE3	   Ribonuclease	  3	  CAMP	   Cathelicidin	  antimicrobial	  peptide	  (LL37)	   Antimicrobial	  peptide,	  chemotaxis,	  inflammatory	  response	  regulation	  CTSA	   Cathepsin	  A	   Lysosomal	  serine	  proteases,	  antibacterial	  activity	  	  (anti-­‐gram-­‐negative)	  CTSG	   Cathepsin	  G	  ELANE	   Elastase	   Sereine	  protease,	  elastin	  degredation,	  phagocytosis,	  migration	  MPO	   Myeloperoxidase	   Microbicidal	  activity,	  catalyses	  production	  of	  ROS.	  Granule	  protein	  AZU1	   Azurocidin	  1	   Granule	  protein,	  antibacterial,	  granule	  protein	  DEFA4	   Defensin,	  alpha	  4	   Microbicidal	  peptide,	  granule	  protein	  BPI	   Bactericidal/Permeability-­‐Increasing	  Protein	   Bactericidal	  peptide,	  LPS	  binding,	  granule	  protein	  CRISP3	   Cystein-­‐rich	  secretory	  protein	   Immuno-­‐regulation	  LCN2	   Lipocalin	  2	   Iron-­‐sequestering,	  granule	  protein	  LTF	   Lactotransferrin	   Iron-­‐binding	  granule	  protein,	  multi-­‐functional	  CLU	   Clusterin	   Extracellular	  chaperone	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Analysis of the expression levels of the 18 LDG genes (defined by 
Villanueva et al) in both the Polymorphprep™ and bead-isolated samples 
from Donor 1 and Donor 2 show that all transcripts are elevated in Donor 2 
samples compared to Donor 1.  Furthermore, when comparing differences 
in gene expression of LDG genes between isolation methods, 14 of these 
18 genes are significantly elevated in bead-isolated samples from Donor 2 
compared to paired Polymorphprep™ isolated samples.  These findings 
are summarised and presented in Fig 6.13. Hierarchical clustering of 
expression values resulted in samples from the same donor grouping 
together. Taken together, these findings suggest that Donor 2 has elevated 
levels of LDGs and that bead-isolation of neutrophils enriches for this LDG 
sub population that could otherwise not be recovered by Polymorphprep™ 
isolation. 
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Fig	   6.13	   LDG	   genes	   are	   elevated	   in	   Donor	   2	   samples	   and	   enriched	   in	   bead-­‐isolated	  
samples	   compared	   to	   Polymorphprep™	   isolated	   samples.	   Heatmap	   of	   log2	  
transformed	   expression	   values	   (RPKM)	   for	   18	   LDG	   associated	   genes	   in	   bead-­‐	   or	  
Polymoprhprep™	  (Poly)-­‐	  isolated	  samples	  from	  Donor	  1	  (low	  contamination)	  or	  Donor	  
2	  (high	  contamination).	  Lowest	  expression	  values	  are	  shown	  in	  green,	  median	  values	  
shown	   in	   black	   and	   highest	   expression	   values	   shown	   in	   red.	   Hierarchical	   clustering	  
shows	   greatest	   association	   between	   paired	   samples	   from	   the	   same	   donor	   and	  
greatest	   divergence	   between	   donor	   samples.	   Clustering	   achieved	   using	   Pearson	  
correlation	  and	  average	  linkage	  by	  Multiple	  experiment	  viewer	  (MeV).	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6.4.14 Comparison of variation between donor fol lowing 
different isolation methods 
The previous section identified that different genes are expressed in 
neutrophil samples isolated by different methods, and that the differences 
are donor-dependent. However, it is unclear whether the number of genes 
which are DE between donors is altered by different isolation methods. For 
example, whether the number of genes differentially expressed between 
donors following Polymorphprep™ isolation is similar to the number of 
genes differentially expressed between donors following bead isolation.  
To answer this question, Cuffdiff anlaysis was used to identify differentially 
expressed genes between Polymorphprep™ isolated samples from Donor 
1 with Polymorphprep™ isolated samples from Donor 2. Likewise, bead-
isolated samples from Donor 1 were compared to bead-isolated samples 
from Donor 2. This analysis would identify the number of genes that were 
differentially expressed between donors for each isolation method. Since 
the purity of neutrophil preparations from both donors was similar 
following bead isolation (Donor 1 - 97.5%, Donor 2 - 99%) it might have 
been expected that fewer genes would be significantly differentially 
expressed between donors after this purification method, than for 
Polymorphprep™ isolated samples. Likewise, as there is a much greater 
difference in neutrophil purity levels between the donors following 
Polymorphprep™ preparation (Donor 1 - 96%, Donor 2 - 83%) it might also 
be predicted that a greater number of genes were differentially expressed 
257	  
	  
after preparation by this method than would be in the bead-isolated 
samples.  
However, Cuffdiff identified almost 3 times as many differentially-expressed 
genes in the Polymorphprep™ samples as were detected in the bead-
isolated samples (Table 6.7). This suggests that there is greater 
heterogeneity in gene expression profiles between donor neutrophil 
samples if samples are prepared by magnetic bead isolation rather than by 
Polymorphprep™. Indeed, it is likely the increased number of significantly 
expressed genes between donors is a consequence of the more 
heterogeneous neutrophil population selected by magnetic bead isolation, 
and that the presence of a sub-population of LDGs can significantly 
contribute to the overall neutrophil gene expression profile. 
 
Table	   6.7	   Number	   of	   significantly	   differentially	   expressed	   (DE)	   genes	   between	  
neutrophil	   samples	  prepared	  by	   either	  Polymorphprep™	   (Poly)	  or	  by	  magnetic	  bead	  
isolation	  (Bead)	  from	  Donor	  1	  (1)	  and	  Donor	  2	  (2).	  Significance	  (q<0.05)	  as	  calculated	  by	  
Cuffdiff	   adjusted	   for	   5%	   false	   discovery	   rate	   by	   Benjamini-­‐Hochberg	   correction	   for	  
multiple-­‐testing.	  Data	  calculated	  from	  3	  sets	  of	  paired	  replicates.	  	  
 
Samples	  compared	  
Poly-­‐1	  
vs	  
Poly-­‐2	  
Bead-­‐1	  
vs	  
Bead-­‐2	  
Number	  of	  DE	  genes	   531	   1544	  
	  
	  
 
  
258	  
	  
6.5 Discussion 
Recent evidence suggests that the presence of contaminating leukocytes in 
a neutrophil preparation can alter the behaviour of neutrophils, or generate 
results that are difficult to interpret 249,254. Traditional techniques for 
isolating neutrophils from peripheral blood have relied on centrifugation of 
whole blood (or erythrocyte-depleted whole blood) over density-gradient 
media and these typically achieve neutrophil purities of >95%. In recent 
years, more sophisticated techniques have emerged which can achieve 
much higher purity levels (>99%), without the need for lengthy 
centrifugation steps and the ability to automate the whole isolation 
protocol.  The costs of these latter procedures are significantly higher than 
those based on density-gradient centrifugation, but such methods are 
reported to mitigate the potential effects of contaminating cells and 
improve consistency of data obtained from different donors.  
Despite recognition of the importance of neutrophil purity for in vitro 
studies, very few studies have focused on the impact of purity and or 
isolation method on neutrophil behaviour. Indeed, no studies yet have 
determined the molecular properties of neutrophils isolated by different 
purification protocols (neither under stimulated or untreated conditions). 
In this study, peripheral blood neutrophils from two healthy controls were 
isolated using two commonly employed methods of neutrophil isolation 
(density gradient by Polymorphprep™ and magnetic bead negative 
selection). The two donors were selected because previous work had 
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identified these as having low levels (Donor 1) or high levels (Donor 2) of 
contaminating cells, which were mainly eosinophils.   
Independent quantification of neutrophil purity by cytospin and flow 
cytometry confirmed the levels of inherent cellular contamination in 
neutrophil samples from each donor. Quantification also demonstrated that 
levels of neutrophil purity achievable by each isolation method were 
broadly in line with previously published data 227,246,251. However, and 
somewhat surprisingly, the often referenced neutrophil isolation purity 
value of >99% following bead isolation 182,227,260,261 was not achieved in any 
preparation. 
Levels of contamination in leukocyte preparation purity have previously 
been suggested to affect rates of apoptosis in both neutrophil preparations 
249, and eosinophil preparations 262. However, in both of these studies, 
contamination by CD14+ cells (monocytes) was shown to be crucial to 
delaying apoptosis following lipopolysaccharide (LPS) stimulation. Given 
that levels of PBMCs were equally low (≤3%) in both donors and isolation 
methods, it is perhaps surprising that (when compared to untreated 
samples), TNFα incubation was pro-apoptotic in bead-isolated neutrophils 
and anti-apoptotic in neutrophils isolated by Polymorphprep™. Several 
reasons could explain this, firstly, only low levels of contaminating cells may 
be required to alter the affect of TNFα. Secondly, the Polymorphprep™ 
method involves exposure of cells to greater centrifugal forces that may 
have an effect on neutrophils perhaps altering their responsiveness to 
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TNFα. Finally, the apparently pro-apoptotic effect of TNFα on bead-
isolated neutrophils could be due to the fact that there are great 
differences in rates of apoptosis in untreated neutrophils prepared by these 
two methods (Poly-Untreated 64.71% ± 7.34%, Beads-untreated 37.04% ± 
4.21%). Levels of apoptosis in TNFα-stimulated neutrophils are similar 
regardless of isolation method (Poly-TNF 47.82% ± 3.20%, Beads-TNF 
52.46% ± 2.04%). This would suggest that the neutrophils that are “lost” 
during bead isolation are those with normally high rates of constitutive 
apoptosis.  
TNFα has previously been shown to exhibit bi-modal effects on neutrophils 
183,225 and other cell types 263–265, that may be time-dependent 266,  or 
concentration-dependent 265. Given that the pro-apoptotic effect of TNFα is 
more pronounced in Donor 2 bead samples than Donor 1 bead samples 
(Donor 1: +12.68% apoptosis vs control, Donor 2; +27.03% vs control), it is 
possible that eosinophils may play a role in delaying neutrophil apoptosis. 
Indeed, eosinophils are capable of expression and release of TNFα under 
activated conditions 267 and as such may be providing a consistent source 
of anti-apoptotic paracrine signalling in the Polymorphprep™ isolated 
samples, thereby delaying apoptosis in these less pure preparations of 
neutrophils. Additionally, the higher rates of apoptosis seen in all 
Polymorphprep™ samples (compared to bead isolated samples) may be 
due to the higher centrifugation steps during the isolation protocol than 
those employed in a magnetic bead preparation. Indeed, additional 
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centrifugation of bead-isolated neutrophils on Polymorphprep™ for 30 min 
increased levels of neutrophil apoptosis to levels similar to those seen in 
Polymorphprep™ isolated samples (see Appendix Fig A.5).  
Analysis of neutrophil cell-surface expression levels revealed no significant 
changes after purification by different isolation methods (Student’s t-test 
p>0.2). Whilst CD15 and CD16 are expressed at high levels on neutrophils, 
they are also expressed on other leukocytes 268 (with the exception of 
CD16b which is neutrophil specific). This might explain why levels of 
expression of these receptors were not significantly different in neutrophils 
prepared by isolation methods.  Since CD11b is known to be upregulated 
following neutrophil activation 269, the small increase in expression seen in 
Polymorphprep™ isolated neutrophils may represent an increased level of 
activation – although levels were not significantly different (p= 0.27) – 
perhaps due to the additional centrifugation time of a Polymorphprep™ 
isolation method in comparison to a magnetic bead preparation. However, 
this does not explain the slight increased expression of CD64 in bead-
isolated neutrophils (although also not significant p= 0.33), which can also 
be upregulated in neutrophils following activation, albeit by enhanced 
gene expression in response to cytokines such as IFNγ and LPS 270. 
In contrast to the increased neutrophil purity following bead isolation, the 
absolute yield of neutrophils obtained from whole blood was much lower 
than can be achieved using Polymorphprep™. It is likely that several steps 
in the bead isolation protocol contribute to this decreased yield. Firstly, 
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erythrocyte depletion of whole blood using dextran relies on the 
aggregated erythrocytes sedimenting at a faster rate than leukocytes, such 
that an erythrocyte-free upper phase is produced which is removed and 
processed further. Although this process is effective for depletion of 
erythrocytes, leukocytes in the lower portion of the tube remain there and 
will not rise into the erythrocyte-free zone. Secondly, since the isolation 
method is by negative selection, neutrophils must avoid false-positive 
selection by each of the 7 specificities of antibodies included in the bead 
isolation kit. Finally, in the last steps of the bead isolation method, pure 
neutrophils are decanted into a fresh tube, while the contaminating cells 
are retained within a magnetic field. This must be performed in a single 
motion to avoid dislodging contaminating cells from the magnetic field.  
Consequently, a proportion of this neutrophil suspension is retained within 
the tube, further decreasing the final yield of pure neutrophils. 
Regardless of the factors contributing to a decreased neutrophil yield, this 
difference in yield between isolation methods, raises considerable concerns 
for neutrophil studies where large numbers of cells are required (for 
example RNA studies across a range of time points). Moreover, in 
situations where the available volume of whole blood is restricted, for 
example in neutropenic or paediatric  patients, this method of neutrophil 
purification may be unworkable. 
RNA-Seq analysis of neutrophil samples revealed that transcripts for 
contaminating cells (either relating to bead-kit antigens or known cell 
263	  
	  
specific transcripts) were broadly in line with expected contamination levels 
measured by flow cytometry of microscopic analysis. Eosinophil transcripts 
(CD9, IL5RA and CCL2) were at highest levels in Donor 2 Polymorphprep™ 
samples, with CD9 being the highest non-neutrophil transcript. 
Interestingly, despite its use as an eosinophil-specific cell surface antigen in 
the bead-isolation kit, neutrophils are known to express CD9 on their cell 
surface 271, albeit under disease conditions. However, this could 
compromise the efficacy of the bead isolation kit in experiments isolating 
neutrophils from patients with inflammatory diseases. 
It is clear from both the data presented here and previously published work 
that magnetic bead isolation of neutrophils is more efficient at removing 
contaminating leukocytes than Polymorphprep™. However, despite 
general acceptance that this method provides more highly-pure neutrophil 
suspensions, experiments using RNA-Seq have revealed that transcripts 
unique to contaminating cells are still detectable within the bead-isolated 
samples. Indeed, levels of the monocyte marker, CD163 are higher in 
bead-isolated samples from Donor 1 than in Polymorphprep™ isolated 
samples from Donor 2. This highlights the importance and effects of donor 
variation on the purity of the samples irrespective of the isolation method. 
When assessing the number of genes that were differentially-regulated 
between the two isolation methods using datasets for both donors, it was 
found that only a small number of genes were significantly regulated (16 
genes). Furthermore, when comparing treated samples from both isolation 
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methods (for example GM-poly vs GM-bead, N=2) there is only a single 
additional significant gene in each case (integrin beta 7 (ITGB7) and 
Indoleamine 2,3-dioxygenase 1 (IDO1) for GM-CSF and TNFα samples 
respectively), suggesting that differentially expressed genes between 
isolation methods are not influenced greatly by the presence of 
inflammatory stimuli. 
In contrast, when Polymorphprep™ and bead isolated samples were 
analysed in a donor specific manner, a greater number of genes were 
found to be significantly differentially expressed between the two isolation 
methods (in particular samples from Donor 2). Surprisingly, several genes 
are found to be elevated in the bead-isolated preparations. Detailed 
analysis revealed many of these genes are expressed in low density 
granulocytes, cells that are present in the circulation of patients with SLE 52.  
Whilst the exact properties and functions of LDGs remain largely 
undefined, they have increasingly been associated with abnormal immune 
responses and in particular, auto-immune disease 52,79–81,272. It is therefore 
somewhat surprising neutrophil samples from a healthy control (Donor 2) 
showed elevated levels of LDG-associated genes, implying high levels of 
LDGs in the blood of this healthy donor. This suggests that elevated 
transcription levels of LDG-genes alone are not sufficient to induce or 
reflect a diseased state.  Alternatively, elevated levels of LDGs in peripheral 
blood may indicate susceptibility to disease. Alternatively, heterogeneity in 
a leukocyte population may be normal but overlooked as many studies 
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would not normally use isolation methods that specifically enrich LDGs. It is 
clear from the experiments described in this thesis that LDGs are not 
normally isolated in the neutrophil band prepared by Polymorphprep. It is 
also unclear if the high levels of eosinophils present in Donor 2 blood are 
related to the increase in LDGs also seen in this donor.  
Whether LDGs represent a sub-class of mature, normal density neutrophils 
(NDGs) or a sub-population of immature neutrophils is still unclear. At 
present, the transcriptional regulation of neutrophil granule proteins during 
maturation is poorly understood, but the classical view is of 3 subsets of 
granules that develop due to temporal expression of granule genes during 
development. Proteins localised to each granule type are sequentially-
transcribed during maturation in the bone marrow, beginning with 
azurophilic granule proteins. However, more recently, other marker 
proteins have been discovered with a non-classical transcriptional pattern 
20,21,273 suggesting there is much greater granule heterogeneity than 
previously thought. This is highlighted by the LDG genes expressed in 
Donor 2 bead-isolated neutrophils, which show elevated levels of 
transcripts for several azurophilic granule proteins (MPO, DEFA4, BPI, 
ELANE, AZU1, CTSA, CTSG).  The presence of these transcripts is 
indicative of a transcriptional profile of a neutrophil progenitor cell such as 
a myelocyte or metamyelocyte 18.   
Regardless of the structure and function of LDGs, it is clear that bead-
isolation methods for purifying neutrophils provide a method of enriching 
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the LDG population that might exist. Conversely, since Polymorphprep™ 
relies on cell density for population separation, any LDGs are excluded 
from the neutrophil layer and most likely retained in the PBMC layer. 
Consequently, the level of neutrophil-heterogeneity following 
Polymorphprep™ isolation is decreased. Indeed, the number of 
significantly DE genes between datasets of two donors of 
Polymorphprep™ isolated samples is considerably less than the number of 
DE genes between 2 datasets of bead-isolated samples (Poly - 531 genes , 
beads – 1544 genes, q<0.05 - 5% FDR). This suggests that there is more 
heterogeneity between two samples of neutrophils, both with >97.5% 
purity prepared by bead-isolation than in the two Polymorphprep™ 
isolated samples, which had 96% and 83% neutrophil purity. This raises 
important questions for the use of magnetic beads to produce ultra-pure 
neutrophil samples, where levels of LDGs (or other sub-types of 
neutrophils) in the population may vary among donors. This is of particular 
relevance when analysing samples from patients with inflammatory 
diseases, such as SLE. Additionally, a comprehensive study of LDGs is 
unlikely using samples of neutrophils isolated by Polymorphprep™. 
In summary, whilst neutrophil purity is of significant importance for in vitro 
studies using high-sensitivity assays such as RNA-Seq or mass 
spectrometry, density-gradient based separation protocols such as 
Polymorphprep™ solution provide a suitable method of isolating 
unprimed, viable neutrophils, with an overall purity exceeding 96%. The 
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major contribution of contamination is from eosinophils. Magnetic bead 
isolation is effective for increasing neutrophil purity to approximately 98% 
but does so at the expense of overall yield and increased costs. 
Furthermore, despite having greater purity levels than Polymorphprep™ 
samples, bead-isolated neutrophil populations exhibited far greater 
heterogeneity due to the enrichment of an LDG-like sub-population. These 
data highlight the mechanistic differences between isolation methods and 
the inherent variation found between donors that plays an important role in 
the overall gene expression profile of neutrophils. It is therefore important 
that the success and reliability of a neutrophil assay be judged on more 
than the metric of purity, and should take into account several additional 
factors that ultimately can impact on neutrophil gene expression. 
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Chapter	   7:	   Future	   analyses	   of	  
the	  bioinformatic	  pipeline 
7.1 Introduction 
The pipeline of bioinformatic analyses described in Chapter 3 has enabled 
an accurate quantification of neutrophil gene expression following 
stimulation with several cytokines (Chapter 4 and 5), or in neutrophil 
suspensions of different levels of purity (Chapter 6). In each of these 
chapters, absolute gene expression values were calculated, and the RPKM 
metric was used to define relative values between (or within) samples. 
Subsequent bioinformatic analysis and predictions were made using the 
expression values and sets of significantly-associated gene lists (as 
calculated using the expression values). This approach has enabled 
accurate measurements of neutrophil gene expression under various 
conditions and has identified important consequences of different 
neutrophil isolation techniques. However, whilst RNA-Seq provides a 
suitable platform for measurement of absolute gene expression values, 
which is broadly comparable to similar analyses using microarrays, the 
greatest advantage of RNA-Seq over other methods of gene expression is 
the ability to quantify multiple genetic features from a single sequencing 
run. For instance, data collected during a single sequencing run can be 
post hoc analysed to quantify splice usage, SNP discovery and indels.  
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Whilst full analysis of the datasets to extract this genetic information was 
beyond the scope of this project, during the development of the 
bioinformatic pipeline, the software and methods necessary for quantifying 
these additional genetic features were incorporated into the final pipeline. 
The portions of this final bioinformatic pipeline, which were developed but 
not used in the analysis of neutrophil samples, are detailed below. In the 
time available for this project, it was not possible to fully extract all of this 
information from the datasets.  
7.2 Methods 
Neutrophil were isolated by Polymorphprep™ isolation from 3 healthy 
donors (Donors 1-3, see Appendix Table A.3 for further details). RNA 
samples were collected as previously described (see sections 2.2.2.2 and 
2.2.9) and samples were analysed by RNA-Seq using the bioinformatic 
pipeline described in Chapter 3. The following results demonstrate the 
downstream analyses available using raw data files obtained from the 
mapping stage of the bioinformatics pipeline (i.e. .Bam files from Tophat) 
or using the default output files relating to isoform expression, as provided 
by Cufflinks/Cuffdiff (isoforms.fpkm_tracking.txt). 
The software programmes and specific command options for each analysis 
are indicated in the text. 
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7.3 Results 
7.3.1 SNP discovery using RNA-Seq data 
Single nucleotide polymorphisms (SNPs) represent the most common form 
of genetic variation within a genome, occurring around once every 100-300 
bases 274. In recent years, genome-wide association studies (GWAS) have 
linked many SNPs with human diseases such as RA, diabetes and SLE 275–277. 
There are currently more than 62x106 identified SNPs in the human 
genome 278. While the vast majority of SNPs (~88%) are located in 
intergenic or intronic regions of the genome 279, RNA-Seq data provides a 
source of data for characterising SNPs located within human exomes. It was 
recently shown that RNA-Seq data with as little as x10 coverage was 
sufficient to identify 92% of expected SNPs within expressed exons 280. For 
comparison datasets analysed here have approximately x40 coverage. 
Analyses characterising SNPS in the neutrophil transcriptome before and 
after stimulation is of little value since the genetic sequence will be 
unchanged during the time course of an in vitro experiment.  However, it 
can be informative when comparing differences between donors or more 
importantly, patients with inflammatory disease where neutrophil 
dysregulation is implicated in disease progression, such as RA 3. For 
example, a SNP located in a functionally-important region, such as a 
receptor-binding pocket may represent a locus that confers an increased or 
decreased response to drug therapy. For instance, responses to the B-cell 
depleting anti-inflammatory drug Rituximab have been associated with 
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SNPs in the FcGR genes, the IL-6 gene and the B-Lymphocyte stimulator 
(BLyS) gene 281. Furthermore, SNPs in the tumour necrosis factor alpha 
induced protein 3 (TNFAIP3) gene,  which is expressed in neutrophils 181, 
have been associated with a number of inflammatory conditions, such as 
SLE 282, psoriasis 283, diabetes 276 and RA 277.  
7.3.1.1 SNP quantification in neutrophils using Samtools mpileup 
The software package Samtools 284 provides a means of quantifying all 
SNPs within a dataset by comparison of each nucleotide location with a 
reference sequence (either transcriptome or genome). The proportion of 
reads expressing the polymorphism at each location is used to determine if 
the SNP is significant, a product of sequencing error, or if coverage is too 
low to conclude either. 
RNA-Seq data (.Bam file) was used to quantify the total number of SNP 
identifiable in neutrophils from a single donor. The software Samtools was 
used to merge 3 .Bam files produced by Tophat during mapping into a 
single file using the command: 
 
samtools	  merge	  ./output/location	  path/to/file1	  path/to/file2	  path/to/file3	  
 
The Samtools commands “mpileup” and “bcftools” were applied to the 
merged .Bam file using the following command: 
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samtools	  mpileup	  –uf	  path/to/genome.fa	  path/to/merged.bam	  |	  bcftools	  view	  
–bvcg	   -­‐	   >	   var.raw.merged.bcf	   bcftools	   view	   var.raw.marged.bcf	   |	   perl	  
vcfutils.pl	  varFilter	  –D100000	  >	  var.flt.merged.vcf	  
 
 
This command compares the mapping file (.Bam) with the reference 
genome (genome.fa) to identify SNPs. This command also uses a bespoke 
Perl script (vcfutils.pl) to filter SNP with extremely high coverage, which are 
less reliable since they may represent areas of high repetition. The data is 
then outputted as a .vcf (variant calling file). 
The .vcf file details all variants identified within the merged .Bam file, in 
addition to several other informative values on each SNP, such as quality 
(Phred score, see section 3.4.4.3 ), read depth, allele frequency and 
significance (p-value). Samtools identified 98,212 SNPs with an average 
read depth of 42.4 reads and Phred-score quality value of 44.5 (Table 7.1). 
This shows that that RNA-Seq can effectively identify a large number of 
polymorphisms that exists between healthy donors, with high fidelity. 
 
Table	   7.1	   Summary	   of	   SNP	   analysis	   of	   neutrophil	   RNA-­‐Seq	   data	   from	   a	   single	   donor	  
using	  Samtools	  “mpileup”	  command	  and	  bcftools	  software	  284.	  
 
SNP	  attribute	   Value	  
No.	  of	  SNPs	   98,212	  
Average	  read	  depth	  per	  SNP	   42.4	  
Average	  quality	  value	  (Phred)	  per	  SNP	   44.5	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7.3.1.2 Identification and visualisation of specific SNPs 
In addition to the location of each SNP within a dataset, the deep read- 
coverage potential of RNA-Seq data provides a means of estimating the 
allele frequency usage of any heterozygous SNPs. The .vcf output file 
produced by the Samtools pipeline (detailed above) includes details of 
allele frequency for each SNP, but the large volume of data within the .vcf 
file is not suitable for manual curation of small, specific regions of interest. 
An alternative approach for SNP discovery and characterisation of allele 
frequency, is using the integrative genomics viewer (IGV) 285,286. This 
software package provides a graphical user interface (GUI) for browsing the 
read mapping data produced by a software mapper (for example, the .Bam 
file produced by Tophat or Bowtie). In addition to graphically representing 
the reads mapped to each location, single polymorphisms in the data 
sequence are highlighted. Given sufficient coverage of reads at the SNP 
location, the number of reads that correspond to each allele type will 
indicate the overall usage of each allele.  
As one example of this, analysis of neutrophil RNA-Seq data (from the 
Illumina platform) from two separate donors was analysed using IGV. 
Manual assessment identified a SNP located in the 3’-untranslated region 
of the β-actin gene (ACTB) that was present in both samples. The 
coordinates of the SNP corresponded to a known SNP with accession 
number rs7612 (dbSNP Build 141). This SNP is known to be quad-allelic, 
that is, example alleles with each of the four possible nucleotides at this 
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particular location have been identified in the human population. The RNA-
Seq data allows us to identify that the donor exhibits a heterozygous SNP 
at this location whereby 54% of reads are represented by cytosine (C) and 
the remaining 46% by thymine (T). In contrast, a second donor exhibits a 
homozygous SNP at this location as 100% of the 12,410 reads which map 
to that location are represented by thymine (T) (Fig 7.1). 
 The depth of coverage and sensitivity afforded by RNA-Seq allows 
accurate measurements of SNP discovery and allele usage that would 
otherwise be difficult to achieve in conjunction with transcriptome-wide 
characterisation of genes via other methodologies. 
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Fig	   7.1	   Visualisation	   of	   RNA-­‐Seq	   50bp	   read	   fragments	   in	   the	   Integrative	   Genomics	  
Viewer	   (IGV)	   aligned	   to	  human	   reference	  genome	   (hg19).	   Two	   samples	  of	  untreated	  
neutrophil	   RNA	   from	   two	   healthy	   donors	   show	   the	   presence	   of	   a	   single	   nucleotide	  
polymorphism	   (SNP)	   at	   the	   same	   location	  within	   the	  β-­‐actin	   beta	   gene.	   The	   human	  
reference	  genome	  sequence	  used	  as	  reference	  (hg19-­‐RefSeq)	  contains	  a	  cytosine	  (C)	  at	  
this	  location	  (which	  can	  be	  seen	  in	  the	  lower	  frame	  of	  the	  screen	  shot).	  The	  first	  donor	  
has	  a	  heterozygous	  SNP,	  with	  54:46	  of	  reads	  containing	  either	  cytosine	  (C),	  or	  thymine	  
(T)	  respectively,	  at	  the	  SNP	  location.	  In	  contrast,	  the	  second	  donor	  has	  a	  homozygous	  
nucleotide	  whereby	  all	  reads	  contain	  thymine	  (T)	  at	  this	  location.	  	  
	  
 
7.3.2 Splice variant discovery  
An estimated 92-94% of multi-exonic genes within the human 
transcriptome are subject to alternate splicing, with ~86% having a minor 
isoform frequency of >15% 102. Alternate isoforms of genes not only 
influence the structure of the translated protein, but also have significant 
effect on function. For example, the gene myeloid cell leukaemia-1 (MCL-1) 
plays an important role in neutrophil survival through its actions as an anti-
apoptotic member of the B-cell like-2 (BCL-2) family of proteins 232,287. 
However, MCL-1 has been shown to undergo alternative splicing to yield 2 
possible minor isoforms, MCL-1S (short) and MCL-1ES (extra-short), both of 
which are translated into shorter proteins with pro-apoptotic function 288,289.   
7.3.2.1 Splice variant discovery in neutrophils using Cufflinks (Cuffdiff) 
Since annotation software, such as Cufflinks or DESeq, provide a 
normalised score for each exon within a gene, it is possible to estimate the 
relative isoform usage for any particular gene between two or more RNA-
Seq samples, provided a suitable reference sequence defining each 
isoform is inputted into the annotation software. Indeed, as part of its 
default output, Cuffdiff can quantify all splice variants within a sample 
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which can be used to estimate the splice variant usage between two or 
more samples 168.  
Following annotation and DE analysis of neutrophil samples (untreated, 
GM-CSF and TNFα) using Cuffdiff (as previously described), isoform usage 
was calculated for the gene MCL-1 which has 3 known alternatively spliced 
isoforms: long form (MCL-1L, NM0211960); short form (MCL-1S, 
NM182763); or extra short form (MCL-1ES, NM001197320). RPKM values for 
each isoform were extracted from the Cuffdiff output file 
“isoforms.fpkm_tracking.txt” and percentage usage calculated for each 
isoform in each treatment (Fig 7.2) 
Values for MCL-1L decreased in both GM-CSF and TNFα treated samples 
compared to control. Consequently, the relative levels of MCL-1S and MCL-
1ES were increased, with the greatest increase seen in MCL-1ES isoform in 
GM-CSF-treated neutrophils (untreated 4%, GM-CSF 8.3%). 
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Fig	  7.2	  MCL-­‐1	   isoform	  usage	  in	  neutrophils	  following	  cytokine	  treatment.	  Neutrophils	  
were	  treated	  with	  (or	  without)	  GM-­‐CSF	  (5	  ng/mL)	  or	  TNFα	  (10	  ng/mL)	  for	  1	  h.	  RNA	  was	  
sequenced	  on	  the	  Illumina	  platform	  and	  quantified	  by	  Tophat/Cufflinks.	  RPKM	  values	  
calculated	  by	  Cuffdiff	  for	  the	  3	  isoforms	  of	  MCL-­‐1	  (long	  form,	  short	  form	  or	  extra	  short	  
form).	  Values	  represent	  mean	  of	  3	  biological	  replicates.	  
	  
 
7.3.2.2 Visualisation of isoform usage 
As described above,  RNA-Seq mapping data can be analysed by GUI 
based analysis programs, such as IGV 285,286, to provide a visual 
representation of the mapping results. In addition to SNPs, this method of 
analysis can also be employed to visualise the isoform usage or splice 
junction sites at a particular area of interest. Fig 7.3 demonstrates how the 
reads mapping to the MCL-1 gene can be visualised. Reads that originate 
from all three MCL-1 isoforms are evident and the depth of coverage at 
splice junctions can be assessed (Fig 7.3). This method of visualising 
mapped reads can also be used to identify other transcriptional features, 
GM
70.50%  Long
21.20%  Short
8.30%  Extra short
TNF
72.40%  Long
22.50%  Short
5.10%  Extra short
UT
75.00%  Long
21.00%  Short
4.00%  Extra short
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such as transcriptional start sites (TSS), by assessing the location of reads in 
relation to the predicted TSS as seen in the reference sequence. 
 
	  	  
	  
Fig	   7.3	   Alternative	   splicing	   of	   the	  MCL-­‐1	   gene	   visualised	   in	   the	   Integrative	  Genomics	  
Viewer	   (IGV)	   and	   by	   standard	   gel	   PCR.	   (A)	  Mapped	   reads	   from	   neutrophil	   RNA-­‐Seq	  
data	  (Illumina	  platform)	  are	  displayed	  using	  IGV.	  Reads	  are	  represented	  as	  grey	  blocks	  
whilst	  a	  blue	  line	  connects	  reads	  that	  span	  exon	  boundaries.	  Histogram	  at	  top	  of	  panel	  
represents	   the	   depth	  of	   coverage	   at	   each	  base	   location.	  Human	   reference	   sequence	  
(hg19-­‐RefSeq)	   isoform	   structure	   represented	   by	   blue	   bars	   at	   base	   of	   panel.	   (B)	   PCR	  
analysis	  of	  neutrophil	  RNA	  using	  primers	  designed	  to	  detect	  all	  three	  isoforms	  of	  MCL-­‐
1.	   PCR	   bands	   correspond	   to	   MCL-­‐1L	   (1053bp)	   and	   MCL-­‐1S	   (805bp).	   No	   product	  
corresponding	  to	  MCL-­‐1ES	  (594bp)	  was	  detected.	  Gel	  data	  is	  representative	  of	  at	  least	  
4	  biological	  donors	  (collected	  and	  reproduced	  with	  permission	  by	  D.	  Chiewchengchol	  
2013).	  
	  
 
For comparison, gel PCR was used to determine levels of MCL-1L, MCL-1S 
and MCL-1ES in untreated neutrophils. Primers were designed to amplify full 
length transcripts of all three MCL-1 isoforms. Following cDNA 
amplification, samples were run on an agarose gel. Levels of MCL-1ES were 
undetectable in samples from at least 4 biological donors (Fig 7.3B) (data 
collected and reproduced with permission by D. Chiewchengchol) 
Reference Sequence (RefSeq)
NM_021960 MCL1 (long)
NM_001197320 MCL1 (extra short)
NM_1827630 MCL1 (short)
MCL1 
(long)
MCL1 
(short)
MCL1 
(extra-short)
1000bp
800bp
600bp
Hyper
Ladder I
MCL1 (long)
MCL1 (short)
A B
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The changes seen in isoform abundance in MCL-1 following neutrophil 
stimulation are small, but highlight the accuracy and sensitivity available by 
using a bioinformatics approach to detect isoform levels. 
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7.4 Discussion 
The above analyses demonstrate the capacity of raw RNA-Seq data to be 
re-analysed by different software packages to extract novel results 
regarding alternative genetic features that complement gene expression 
values.  
SNP discovery can inform on important structural changes in crucial 
protein-coding areas or even in non-coding areas which are increasingly 
recognised as important determinants of gene expression profiles, whilst 
also being implicated in several diseases 290–294. Indeed, a recent study 
identified several SNPs located within (or adjacent to) functional elements 
in human neutrophils from patients with juvenile idiopathic arthritis (JIA) 295.  
Whilst a fully comprehensive study of SNP and other polymorphisms in 
neutrophils would require a different methodology, specifically a genome-
wide sequencing approach, the ability to use RNA-Seq data to analyse SNP 
located in mRNA transcripts provides an additional benefit over array-
based analyses.  
Similarly, the accuracy of RNA-Seq to quantify absolute values of transcript 
levels allows gene expression values to be quantified in terms of all 
associated splice variants. When applied to neutrophil expression of MCL-
1, each of the 3 known splice variants were identified and changes to the 
ratios of expression were found following stimulation of neutrophils. 
Differential usage of splice variants in neutrophils has previously been 
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shown for several genes, including 5-lipoxygenase 296, glucocorticoid 
receptor297 and the pantetheinase family of genes 298 
However, whilst this approach using Cufflinks is informative and of great 
use for discovering changes in isoform abundance, it is important to 
appreciate that this form of analysis is semi-quantitative. Since most 
isoform sequences differ only in a small portion of their sequence, reads 
that map to common areas of the reference sequence cannot be 
definitively assigned to any one isoform, thus only reads that map to an 
isoform-unique portion of their sequence can be accurately quantified. 
Paired-end sequencing can decrease the number of reads un-assignable to 
a particular transcript by providing a pair of read fragments known to 
originate from the same transcript and lying a known distance from each 
other. However, ultimately, mapping software must apply some degree of 
estimation when assigning a level of significance to splicing events 145. 
In summary, the software-based analyses described in this Chapter 
demonstrate an extension to the bioinformatics pipeline presented in 
Chapter 3. They provide informative data that could complement a 
concurrent global gene expression analysis. In combination, these methods 
represent a set of robust analyses for a comprehensive study of the 
neutrophil transcriptome. 
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Chapter	  8:	  Conclusions	  
8.1 Overall conclusions and outcomes 
Neutrophils constitute the largest cellular component of the immune 
system. It is now widely appreciated that neutrophils are central to the 
immune response and are capable of regulating both the innate and 
adaptive immune systems through the expression and release of several 
immune regulators 4,5. Whilst the functional mechanisms of neutrophils in 
both health and disease are well characterised, the molecular changes that 
underlie neutrophil regulation were poorly defined. Transcriptomics 
represents an attractive, analytical approach to neutrophil gene expression 
by providing a mechanism of quantifying the entire population of 
transcripts at a particular time point or following stimulation. A limited 
number of studies have analysed the global transcriptional profile of 
neutrophils, with the majority looking at gene expression changes during 
neutrophil maturation, or over several time points following stimulation by 
a single cytokine 181,245,258,299. Moreover, at the outset of this research, the 
neutrophil transcriptome had yet to be characterised using modern RNA-
Seq technology. The benefits of RNA-Seq over established microarray 
technology are numerous, not least the ability to garner information on 
various genetic features from a single experimental run. Despite the 
improvements of RNA-Seq technology, the corresponding bioinformatic 
software remains eclectic in their functionality and ease of use. Such that, 
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published bioinformatic methods are often disparate and difficult to 
compare or judge equally. Indeed, the bioinformatic community has yet to 
decide on a set of software tools or quantification techniques that 
represent the best practices for analysis of NGS data.  
The aims of this research were to develop a robust, pipeline of methods 
and bioinformatic analyses using open-source or commercially available 
software that could accurately measure the gene expression profiles of 
neutrophils under different inflammatory conditions. This pipeline would 
then be used to fully quantify neutrophil gene expression following 
stimulation with a variety of inflammatory mediators, or following two 
commonly used neutrophil-isolation methods.  
Development of the bioinformatic pipeline in Chapter 3 explored the 
relative merits of both the SOLiD and Illumina sequencing platforms, in 
addition to paired-end and single-end sequencing techniques. Despite 
both platforms and sequencing techniques correlating well to qPCR data 
during validation experiments, the higher mapping rate and read quality 
achieved by Illumina sequencing platform determined it as the platform of 
choice for future experiments. Whether the lower quality values achieved 
with the SOLiD platform were due to: the added complexity associated 
with paired-end sequencing; technical or human error; or were attributable 
to the technology platform as a whole, is unclear. However, it is unlikely 
that a single-end sequencing experiment using SOLiD technology could 
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improve upon the read quality values and mapping rates achieved by the 
Illumina platform.  
Quantification of mapped reads is predominantly achieved in one of two 
ways, either using the raw number of reads assigned to each gene in a 
count-based approach, or by further transforming the raw counts into a 
value normalised to both the size of the read library, and the length of the 
gene being quantified (i.e. an RPKM value). The choice of quantification 
methods for neutrophil gene expression values had a significant effect on 
the number of DE genes between samples; this effect was even seen 
between two count-based approaches (DESeq and edgeR). The greater 
number of DE genes identified following count-based methods was likely 
due to the techniques used by the software to model the variation within 
the read population. Although this approach is known to estimate 
biological variance poorly, and suffer from over-sensitivity 163,300,301, it has 
been employed for several RNA-Seq studies and remains a popular choice 
for differential expression studies 302–305. However, the ability to directly 
compare two separate genes within the same dataset (or between 
datasets), and the compatibility with downstream software offered by the 
Cufflinks quantification route, led to the count-based quantification method 
being discounted from the final bioinformatic pipeline in favour of 
Cufflinks/Cuffdiff.  
Downstream analysis of gene expression data is an increasingly popular 
area of bioinformatic analysis 199, since many sequencing service providers 
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also offer basic gene expression quantification, non-bioinformatically 
trained research labs are increasingly reliant on downstream analytics to 
extract meaningful data from large amounts of raw gene-expression data. 
Many of the most popular software packages utilise large databases of 
canonical biological data to model the raw data against. Software of this 
kind are often designed for ease of use by non-bioinformaticians, but are 
only available via a commercial licence. Whilst this excludes some 
researchers from the best available software purely on financial grounds, 
the benefit of commercial analysis-software is two-fold. Firstly, the technical 
support and usability of software is often far superior to open-source 
equivalents. Secondly, the professional curation of the information 
databases is consistently maintained, meaning that the data resources are 
constantly up-to-date and comprehensive, whilst also providing validation 
of all canonical interactions with supporting publications. For these 
reasons, the commercially available pathway analysis software IPA 220 was 
employed as part of the bioinformatic pipeline. This provided invaluable 
capacity in downstream analysis that was not feasible using open-source or 
freely available software. However, other downstream analyses such as 
hierarchical clustering and heat-map generation were achieved using open-
source software. The pipeline described in Chapter 3 therefore represents 
a robust set of tools for analysing the gene expression profiles of 
neutrophils that is both comprehensive in capacity and modest in technical-
ability requirements. 
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In Chapters 4 and 5, the bioinformatic pipeline was employed to 
investigate the effect of inflammatory cytokine stimulation on neutrophil 
gene expression. The similar priming effects of GM-CSF and TNFα on 
neutrophils are well characterised, but a global comparison of the 
molecular changes following priming has not previously been studied. 
Analysis revealed that despite similar expression in common genes, each 
cytokine induced expression of discrete gene sets that were as a 
consequence of differential transcription factor activation. This led to the 
discovery that the delay in neutrophil apoptosis – seen following 
stimulation with either cytokine – was regulated by STAT activation in the 
case of GM-CSF and NFκB activation in TNFα stimulation. The discovery 
that cytokines regulate neutrophil function via differential expression of 
genes and activation of signalling pathways has important implications for 
the study of neutrophil-dysfunction in inflammatory disease. Not least for 
providing a novel set of biomarkers that can identify the predominant 
cytokines that may be driving inflammation in different patients.  
Analysis of cytokine-induced changes in neutrophils was expanded in 
Chapter 5 to cover other cytokines associated with inflammation. In 
addition, the effect of multiple cytokine stimulation was investigated. IL-1β, 
IL-6 and IL-8 are known inflammatory mediators; but their effect on 
neutrophils is less defined. IL-6 and IL-1β are crucial activator of many 
immune cell-types, while IL-8 is a strong chemo-attractant of neutrophils. 
However, all these cytokines were found to have very little effect on 
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neutrophil gene expression. Whilst it comes as no surprise that the chemo-
attractive capacity of IL-8 is independent of de novo gene expression – 
since localising to the site of inflammation requires rapid execution – the 
inability of IL-6 and IL-1β to induce gene expression by 1 h was less 
predicted. In contrast, IFNγ, G-CSF and dual treatment with GM-CSF and 
TNFα induced significant changes in gene expression, and differential 
activation of signalling pathways. These results highlight the specific 
functional and molecular changes induced in neutrophils by similar 
inflammatory mediators and reveals how stimulation by different cytokines 
can alter the neutrophil phenotype thus potentially altering how they 
respond to later stimulation and/or regulate other cells of the immune 
response.  
Fig 8.1 summarises the multiple genetic characteristics that have be 
quantified using the bioinformatics pipeline developed herein (Fig 8.1A) 
and the differences in neutrophil phenotypes resulting from different 
cytokine stimulation (Fig 8.1B). 
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Fig	   8.1	   Summary	   of	   neutrophil	   bioinformatics	   pipeline	   capacity	   and	   findings.	   (A)	  
Analysis	   of	   neutrophil	   RNA	   by	   RNA-­‐Seq	   and	   neutrophil	   bioinformatics	   pipeline	   has	  
provided	   a	   mechanism	   to	   quantify	   several	   genetic	   characteristics	   such	   as	   raw	   gene	  
expression	   or	   transcription	   factor	   activation	   from	   a	   single	   RNA-­‐Seq	   experiment.	  
Characteristics	  studied	  in	  greatest	  detail	  are	  shown	  in	  bold.	  (B)	  Schematic	  summary	  of	  
the	  phenotypic	   changes	   induced	   in	  neutrophils	   by	  different	   inflammatory	   cytokines,	  
including:	   specific	   signalling	   pathway	   activation;	   change	   in	   levels	   of	   overnight	  
apoptosis	  (%	  change	  compared	  to	  untreated);	  and	  number	  of	  genes	  with	  a	  significant	  
increase	   (red	   arrow)	   or	   decrease	   (green	   arrow)	   in	   gene	   expression	   compared	   to	  
control	  (q<0.05,	  FDR	  5%).	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With the advent of more sensitive techniques to isolate neutrophils from 
whole blood, greater emphasis has been placed on the appropriateness of 
established isolation methods for highly sensitive assays such as 
proteomics or transcriptomics. In Chapter 6, the impact of neutrophil 
isolation methods, and levels of non-neutrophil contamination on 
neutrophil gene expression were investigated. As predicted, magnetic 
bead isolation resulted in a greater purity of neutrophils, the lack of 
contaminating cells was confirmed by gene expression analysis for non-
neutrophil transcripts which were lower in bead isolations than in samples 
isolated by Polymorphprep™. The use of two healthy donors with disparate 
levels of non-neutrophil contamination provided a mechanism for 
highlighting the impact low and high contamination has on the overall 
gene expression profile of neutrophils (either untreated or following 
cytokine stimulation). However, despite a purer population of neutrophils 
following bead isolation, RNA-Seq analysis revealed that there was greater 
genetic heterogeneity between donors than when neutrophils were 
isolated by Polymorphprep™. This difference was largely due to a 
subpopulation of neutrophils which were enriched in Donor 2 but not 
Donor 1. These cells were likely the source of LDG-associated transcripts 
which were also elevated in Donor 2. These results were surprising since 
LDG associated genes have only previously been identified in the context 
of inflammatory disease 52,77,81,272. What is still unclear is if there is any 
association between the high levels of eosinophils and the high levels of 
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LDGs both seen in Donor 2. Importantly, this research has identified that 
bead isolation of neutrophils can exhibit greater heterogeneity between 
donors due to an enrichment of neutrophil sub-populations. Furthermore, a 
lower overall yield and greater cost per isolation for magnetic bead 
isolations suggests that the increased level of purity achievable must be 
weighed up against these factors when determining a suitable method of 
isolation. 
8.2 Future directions 
8.2.1 Future research 
Both the methods described here, and the results identified during the 
research would benefit from further development and analysis. Aspects of 
the bioinformatic pipeline that were developed but not applied to all 
datasets were summarised in Chapter 7, these include methods for 
determining differential splice usage and SNPs discover. Full 
characterisation of SNPs is likely only useful for situations where healthy 
neutrophils are being compared to those from inflammatory disease. But 
an analysis of differential splice usage in neutrophil genes following 
cytokine stimulation could be very informative. 
The benefit of developing a robust bioinformatic pipeline of analysis is that 
it can readily be applied to several different situations to efficiently analyse 
the neutrophil transcriptome under these different conditions.  
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Given the interesting results identified following dual stimulation of 
neutrophils it would also be of interest to extend this research to 
investigate the effect of multiple other cytokines on neutrophil gene 
expression. For example several cytokines have been shown to have 
synergistic effects when regulating the immune system in combination 306, 
including TNFα with IFNγ 307,308 or IL-12 309 but their effect on neutrophils is 
less known. 
Equally, whilst a 1 h time point was entirely adequate for studying initial 
gene expression in neutrophils following stimulation, results indicate that 
neutrophil phenotype may be differentially altered dependent on the initial 
stimulus. Hence, neutrophils ability to respond to a later, secondary signal 
may be significantly different and would represent an interesting area of 
research. Indeed a more comprehensive study investigating gene 
expression over several hours (looking at several time points) would also be 
of interest and would inform on the speed and magnitude of differential 
gene expression by different cytokine stimulation. 
However, perhaps the most informative of future research would be to 
investigate the gene expression changes in neutrophils following non-
sterile stimulation. Whilst directly incubating neutrophils with 
microorganisms would be unfeasible for RNA-Seq studies – due to the 
contamination of neutrophil RNA with microorganism RNA – non-sterile 
inflammatory conditions could be simulated by direct receptor agonists.  
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Activation of neutrophils by exogenous molecules is mediated by receptors 
such as TLRs, NLRs and C-lectin like receptors 5. Whilst many of the 
phenotypic changes in neutrophils following activation by bacterial 
products and inflammatory cytokines are similar, it would be of interest to 
investigate if the molecular changes induced by bacterial products are 
distinct from those seen following cytokine stimulation. Indeed, the 
discovery of specific signalling pathways or target molecules that could 
regulate neutrophil activation following endogenous stimulation without 
compromising neutrophils ability to respond to exogenous signals would 
be of great interest for studies into autoimmune disease where reducing 
the activation levels of the immune system yet maintaining host defence is 
of upmost importance. 
8.2.2 Future of RNA-Seq 
The future direction of RNA-Seq analysis in general is set to increase in 
magnitude and ubiquity. With the development of 4th generation 
sequencers reducing cost and increasing the speed at which samples can 
be sequenced, RNA-Seq analysis will undoubtedly become a standard 
practice in many research laboratories and clinical environments. Whilst this 
can only be of benefit to scientific research and modern day healthcare, 
storage of the vast amounts of data will undoubtedly move towards cloud 
based solutions. But this raises its own issues such as long term storage 
costs. All but the largest cloud-based companies are susceptible to 
commercial failure; whilst the financial ebb and flow nature of scientific 
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funding may mean that the indefinite, secure, storage of valuable biological 
data may be a luxury of the past. 
In summary this research has gone some way to reveal the molecular 
changes in neutrophils under different conditions by the development and 
employment of a robust set of bioinformatic tools. These tools have 
uncovered a greater regulation in gene expression by neutrophils than was 
perhaps appreciated. Whilst several avenues of further research have been 
directly highlighted by this research the methods described here can 
ultimately be employed for a variety of other studies involving RNA-Seq 
and continue to uncover important scientific discoveries. 	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Appendix	  
 
Table	  A.1	  List	  of	  bioinformatic	  software	  and	  versions.	  
Bioinformatic	  software	  versions	  
Bioinformatic	  
software	   Version	  Bowtie	   2.0.07	  Tophat	   1.2.1-­‐1.4.1	  Cufflinks	   2.02	  Samtools	   0.1.18	  IPA	   n/a	  IGV	   2.2.7	  Microsoft	  Office	   2011	  edition	  R	   2.15.2	  EdgeR	   3.0.8	  DESeq	   1.10.1	  cummeRbund	   2.6.2	  
 
	  
Table	  A.2	  Details	  of	  computer	  hardware	  used	  for	  analysis.	  
 
Computer	  system	  (analysis	  
Mac)	  
Mac	  Pro	   iMac	  
Operating	  system	   Mac	  OSX	  10.7-­‐10.8	   Mac	  OSX	  10.85	  
Computer	   processing	   unit	  
(CPU)	  
8	  x	  2.4GHz	  Intel	  
Core	  i5	  
4	  x	  3.4GHz	  Inter	  
Core	  i7	  
Random	   access	   memory	  
(RAM)	  
16GB	  DDR	  RAM	   32GB	  DDR3	  RAM	  
(1600	  MHz)	  
Hard	  drive	  memory	  (HDD)	   4	  x	  1TB	  –	  7200	  
Serial	  ATA	  HDD	  
3TB-­‐7200rpm	  Serial	  
ATA	  HDD	  
Graphical	  processing	  unit	   ATI	  Radeon	  HD	  
5770	  1GB	  
NVIDIA	  GeForce	  GTX	  
680MX	  2048	  MB	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#!/bin/sh	   
#$	  -­‐cwd	  -­‐V	  -­‐pe	  smp	  4	  -­‐l	  h_rt=4:0:00 
cufflinks	  	  
-­‐b\	  
/home/hbt/volatile/iGenomes_bowtie2_indexes/Homo_sapiens/UCSC/hg19/Sequ
ence/Bowtie2Index/genome.fa	  \ 
-­‐p	  4	  -­‐-­‐max-­‐bundle-­‐frags	  100000000	  -­‐q	  -­‐o	  ./path/to/folder	  -­‐-­‐no-­‐update-­‐check	  \ 
-­‐G	  
/home/hlwright/volatile/Homo_sapiens/UCSC/hg19/Annotation/Genes/genes.gtf	  
\ 
$1	  \ 
	  
Fig	  A.1	  Example	  of	  command	  script	  for	  use	  on	  HPC.	  Script	  shows	  commands	  for	  
running	  cufflinks	  to	  annotate	  a	  .bam	  file	  using	  a	  reference	  genome	  (.fa)	  and	  
transcriptome	  (.gtf).	   	  
	  
	  
	  
	  
	  
	  
	  
	  
Fig	  A.2	  Example	  of	  Agilent	  Bioanalyser	  output	  data.	  Figure	  shows	  two	  examples	  of	  RIN	  
results.	  (Left)	  Example	  of	  RNA	  with	  poor	  integrity	  (RIN	  =	  2.9).	  (Right)	  example	  of	  RNA	  
with	  high	  integrity	  (RIN	  =	  8.3).	  Major	  peaks	  in	  high-­‐integrity	  sample	  relate	  to	  16S	  and	  
28S	   ribosomal	   RNA	   population.	   Integrity	   is	   calculated	   based	   on	   the	   ration	   between	  
both	  peaks.	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Table	  A.3	  Table	  listing	  the	  details	  of	  blood	  donors	  and	  method	  of	  neutrophil	  isolation	  
Polymorphprep™	  (P),	  	  magnetic	  bead	  isolation	  (B).	  
 
Donor	  
No.	  
Age	  
(approx.)	  
Sex	   Date	  of	  
donation/sample	  
preparation	  
Neutrophil	  
isolation	  method	  
	  
1	   25-­‐35	   M	   31-­‐1-­‐11	  10-­‐12-­‐12	  28-­‐8-­‐13	   P	  P	  P/B	  
2	   55-­‐65	   M	   30-­‐4-­‐12	   P	  
3	   25-­‐35	   F	   22-­‐1-­‐13	   P/B	  
4	   25-­‐35	   F	   28-­‐1-­‐13	   P	  
5	   45-­‐55	   M	   21-­‐8-­‐13	   P	  
6	   25-­‐35	   F	   17-­‐9-­‐13	   P	  
	  
	  
 
 
 
Table	  A.4	  Table	  details	   the	  RNA	   integrity	  and	  concentration	   for	   samples	  analysed	  by	  
RNA-­‐Seq.	   Table	   also	   lists	   the	   number	   of	   raw	   reads	   produced	   per	   sample	   during	  
sequencing.	  All	  samples	  sequenced	  by	  SOLiD	  platform	  (50	  +	  35	  bp	  paired-­‐end	  reads). 
	  
Donor	   Sample	  name	  
No.	  of	  raw	  
reads	  
No.	  of	  raw	  
reads	  
(reverse)	  
RIN	   RNA	  (ng/mL)	  
TBH	  
Untreated	   127885988	   127885989	   8.2	   95	  
TNFα	   69005645	   69005646	   7.0	   134	  
GM-­‐CSF	   75544747	   75544748	   7.5	   164	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Table	   A.5	   Table	   details	   the	   RNA	   integrity	   and	   concentration	   for	   each	   RNA	   sample	  
analysed	  by	  RNA-­‐Seq.	  Table	  also	  lists	  the	  number	  of	  reads	  produced	  per	  sample	  during	  
sequencing.	  All	  samples	  sequenced	  by	  Illumina	  platform	  (50	  bp	  single-­‐end	  reads).	  
 
Donor	   Sample	  name	   No.	  of	  raw	  reads	   RNA	  Integrity	  number	  (RIN)	  
RNA	  	  
(ng/mL)	  
TBH	  
UT	   66,552,453	   7.3	   218	  
GM-­‐CSF	   64,445,900	   8.4	   188	  
TNFα	   65,625,666	   8.8	   196	  
EWS	  
UT	   50,794,935	   7.6	   64	  
GM	   48,015,235	   6.9	   82	  
TNFα	   47,326,637	   4.1	   37	  
IFNγ	   48,514,806	   6.6	   84	  
IL-­‐1B	   50,565,105	   6.0	   86	  
0h	   48,110,305	   6.4	   76	  
G-­‐CSF	   47,994,097	   7.3	   60	  
MB	  
GM-­‐CSF+TNFα	   54,548,520	   7.5	   144	  
IL-­‐8	   58,462,542	   8.0	   126	  
UT-­‐Poly	   46,444,696	   8.1	   124	  
GM-­‐Poly	   49,516,666	   8.0	   137	  
TNF-­‐Poly	   56,689,600	   7.8	   140	  
UT-­‐Bead	   59,067,617	   7.2	   84	  
GM-­‐Bead	   61,595,651	   7.0	   117	  
TNF-­‐Bead	   49,785,361	   6.4	   88	  
TBH	  
UT-­‐Poly	   43,862,843	   7.7	   44	  
GM-­‐Poly	   44,465,453	   8.6	   46	  
TNF-­‐Poly	   44,391,372	   7.4	   36	  
UT-­‐Bead	   42,044,643	   8.2	   40	  
GM-­‐Bead	   43,095,188	   8.6	   27	  
TNF-­‐Bead	   42,044,643	   8.2	   42	  
WN	   IFNα	   63,186,628	   8.1	   90	  
CA	  
UT	   69,311,246	   5.7	   59	  
IFNγ	   75,916,629	   6.6	   66	  
IL-­‐1B	   79,791,533	   7.3	   74	  
G-­‐CSF	   74,729,800	   6.9	   75	  
IL-­‐8	   69,593,692	   6.9	   38	  
GM-­‐CSF+TNFα	   72,530,839	   7.0	   58	  
TS	  
UT	   72,168,424	   7.5	   131	  
IFNγ	   65,554,973	   7.7	   121	  
IL-­‐1B	   121,354,425	   7.4	   142	  
G-­‐CSF	   72,434,747	   6.9	   98	  
IL-­‐8	   98,504,872	   7.1	   135	  
GM-­‐CSF+TNFα	   72,530,839	   7.1	   102	  
299	  
	  
	  
	  
Fig	  A.3	  PCR	  gel	  of	  neutrophil	  cDNA	  products	   following	  amplification	  with	  Mcl-­‐1	  
primers,	   samples	   isolated	   using	   either	   TRIzol®	  method	   or	   RNeasy	   kit	   with	   or	  
without	   additional	   DNA	   digestion	   step.	   Mcl-­‐1	   band	   highlighted	   by	   red	   arrows,	  
lane	  numbers	  highlighted	  in	  red.	  
	  
Loading	  legend:	  
1. 0h	  Trizol	  
2. 0h	  RNeasy	  
3. 2h	  UT	   	   	   RNeasy	  
4. 2h	  TNF	  
5. 2h	  GM-­‐CSF	  
6. 0h	  Trizol	  -­‐	  Undigested	  
7. 0h	  RNeasy	  
8. 2h	  UT	   	   	   RNeasy	  (undigested)	  
9. 2h	  TNF	  
10. 2h	  GM-­‐CSF	  
11. Negative	  control	  (H2O)	  
12. Positive	  control	  (K562	  -­‐	  CML	  cell	  line)	  
13. Genomic	  DNA	  control	  (HeLa	  cell	  line) 
	  
	  
Table	  A.6	  List	  of	  44	  GO-­‐terms	  significantly	  enriched	  by	  genes	  which	  are	  DE	  between	  
GM-­‐CSF	   and	   TNFα	   treated	   neutrophils.	   GO-­‐terms	   relating	   to	   cell	   death	   and/or	  
apoptosis	   are	   shown	   in	   bold.	   Significance	   (q-­‐value)	   calculated	   using	   a	   5%	   false	  
discovery	  rate	  (FDR)	  
	  
GO	  Term	   GO	  Category	   No	  of	  
Genes	   FDR	  (q-­‐value)	  
GO:0042981	   regulation	  of	  apoptosis	   58	   3.17E-­‐06	  
GO:0043067	   regulation	  of	  programmed	  cell	  death	   58	   4.61E-­‐06	  
GO:0010941	   regulation	  of	  cell	  death	   58	   5.21E-­‐06	  
GO:0006952	   defense	  response	   52	   2.81E-­‐07	  
GO:0006955	   immune	  response	   52	   1.51E-­‐05	  
GO:0016265	   death	   51	   1.84E-­‐04	  
GO:0010604	   positive	   regulation	   of	   macromolecule	  metabolic	  process	   51	   2.49E-­‐02	  
GO:0009611	   response	  to	  wounding	   50	   1.43E-­‐08	  
GO:0008219	   cell	  death	   50	   3.72E-­‐04	  
1   2   3   4  5   6   7  8   9  10 11 12 13 
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GO:0031328	   positive	   regulation	   of	   cellular	   biosynthetic	  process	   49	   2.23E-­‐04	  
GO:0009891	   positive	  regulation	  of	  biosynthetic	  process	   49	   3.48E-­‐04	  
GO:0012501	   programmed	  cell	  death	   48	   1.78E-­‐05	  
GO:0006915	   apoptosis	   47	   3.16E-­‐05	  
GO:0051173	   positive	   regulation	   of	   nitrogen	   compound	  metabolic	  process	   46	   6.20E-­‐04	  
GO:0010557	   positive	   regulation	   of	   macromolecule	  biosynthetic	  process	   46	   9.51E-­‐04	  
GO:0006357	   regulation	   of	   transcription	   from	   RNA	  polymerase	  II	  promoter	   46	   1.58E-­‐02	  
GO:0045935	   positive	   regulation	   of	   nucleobase,	  nucleoside,	   nucleotide	   and	   nucleic	   acid	  metabolic	  process	   42	   9.88E-­‐03	  
GO:0010628	   positive	  regulation	  of	  gene	  expression	   41	   4.15E-­‐03	  
GO:0045941	   positive	  regulation	  of	  transcription	   40	   5.06E-­‐03	  
GO:0006954	   inflammatory	  response	   39	   3.60E-­‐09	  
GO:0019220	   regulation	  of	  phosphate	  metabolic	  process	   36	   6.54E-­‐03	  
GO:0051174	   regulation	  of	  phosphorus	  metabolic	  process	   36	   6.54E-­‐03	  
GO:0007243	   protein	  kinase	  cascade	   35	   3.18E-­‐05	  
GO:0042325	   regulation	  of	  phosphorylation	   35	   7.09E-­‐03	  
GO:0045893	   positive	   regulation	   of	   transcription,	   DNA-­‐dependent	   34	   2.99E-­‐02	  
GO:0051254	   positive	   regulation	   of	   RNA	   metabolic	  process	   34	   3.63E-­‐02	  
GO:0043066	   negative	  regulation	  of	  apoptosis	   32	   4.10E-­‐04	  
GO:0043069	   negative	   regulation	   of	   programmed	   cell	  
death	  
32	   5.58E-­‐04	  
GO:0060548	   negative	  regulation	  of	  cell	  death	   32	   5.94E-­‐04	  
GO:0001775	   cell	  activation	   30	   4.67E-­‐05	  
GO:0045321	   leukocyte	  activation	   29	   4.09E-­‐06	  
GO:0001817	   regulation	  of	  cytokine	  production	   24	   1.92E-­‐05	  
GO:0046649	   lymphocyte	  activation	   23	   4.93E-­‐04	  
GO:0006916	   anti-­‐apoptosis	   22	   3.49E-­‐03	  
GO:0001819	   positive	  regulation	  of	  cytokine	  production	   15	   1.26E-­‐03	  
GO:0050867	   positive	  regulation	  of	  cell	  activation	   15	   1.62E-­‐02	  
GO:0032496	   response	  to	  lipopolysaccharide	   14	   1.20E-­‐03	  
GO:0002237	   response	  to	  molecule	  of	  bacterial	  origin	   14	   4.41E-­‐03	  
GO:0002696	   positive	  regulation	  of	  leukocyte	  activation	   14	   4.57E-­‐02	  
GO:0031349	   positive	  regulation	  of	  defence	  response	   12	   2.70E-­‐02	  
GO:0051100	   negative	  regulation	  of	  binding	   11	   2.27E-­‐02	  
GO:0043433	   negative	   regulation	   of	   transcription	   factor	  activity	   10	   1.52E-­‐02	  
GO:0043392	   negative	  regulation	  of	  DNA	  binding	   10	   4.41E-­‐02	  
GO:0032675	   regulation	  of	  interleukin-­‐6	  production	   9	   2.13E-­‐02	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Table	   A.7	   Gene	   expression	   values	   (RPKM)	   for	   25	   cytokines/chemokines	   genes	  
differentially	   expressed	   by	   neutrophils	   following	   treatment	   with	   a	   range	   of	  
cytokines/chemokines,	  for	  heatmap	  of	  values	  see	  Fig	  5.8.	  
	  
Gene	  
name	  
UT	   GM-­‐CSF	   TNFα	   GM+TNF	   IFNg	   G-­‐CSF	   IL-­‐1B	   IL-­‐8	   IL-­‐6	  
Bmp6	   2.76	   3.70	   3.08	   2.57	   2.07	   2.03	   1.99	   3.21	   2.55	  
Ccl20	   0.17	   0.27	   12.85	   28.68	   0.11	   0.33	   1.14	   0.32	   0.42	  
CcL3	   4.53	   13.98	   206.16	   113.53	   2.88	   4.04	   41.54	   2.25	   7.73	  
Ccl4	   33.23	   38.86	   1858.67	   980.83	   21.61	   22.41	   281.55	   17.10	   30.56	  
Ccl5	   14.30	   8.58	   8.50	   10.50	   19.06	   16.98	   18.56	   9.98	   17.11	  
Cxcl1	   243.48	   1869.48	   639.56	   2804.08	   130.20	   273.83	   660.67	   288.21	   289.16	  
Cxcl14	   1.86	   2.80	   1.92	   2.74	   1.85	   2.18	   2.15	   1.85	   3.26	  
Cxcl2	   9.92	   69.82	   52.27	   155.76	   6.19	   12.83	   40.53	   13.36	   13.88	  
Cxcl3	   0.73	   2.77	   4.71	   10.73	   0.31	   1.05	   2.30	   1.16	   0.51	  
Cxcl6	   3.97	   2.53	   2.86	   1.55	   2.07	   4.37	   4.74	   2.58	   4.96	  
Cxcl9	   0.00	   0.00	   0.00	   0.00	   2.84	   0.02	   0.00	   0.01	   0.00	  
Il1a	   0.83	   50.49	   56.14	   652.64	   1.57	   3.16	   4.18	   3.18	   0.30	  
Il1b	   369.34	   6410.42	   3614.27	   17674.90	   864.85	   1071.83	   890.18	   1103.73	   302.74	  
IL1RN	   81.50	   1106.43	   2599.95	   7499.70	   191.37	   716.42	   153.22	   82.04	   109.22	  
Il8	   2362.95	   12539.90	   6327.35	   17734.70	   840.31	   961.66	   4031.00	   3964.57	   1905.32	  
Lif	   0.98	   0.23	   1.02	   1.69	   0.41	   0.59	   1.27	   3.25	   1.76	  
Ltb	   108.54	   99.99	   136.69	   79.53	   118.20	   106.45	   141.29	   83.71	   155.54	  
Osm	   104.43	   1120.90	   135.06	   1612.75	   94.93	   163.21	   157.90	   238.22	   167.48	  
Pf4	   1.04	   2.24	   0.86	   0.80	   0.81	   0.91	   1.41	   0.68	   0.98	  
Prmt2	   14.85	   13.26	   13.20	   9.54	   16.11	   17.17	   15.41	   13.09	   14.34	  
Tnfsf10	   51.59	   73.52	   37.17	   34.56	   126.96	   80.16	   47.41	   47.40	   51.52	  
Tnfsf12	   12.76	   9.87	   9.91	   7.42	   16.60	   15.02	   16.13	   11.00	   17.30	  
Tnfsf14	   76.46	   33.72	   62.24	   14.49	   20.78	   22.77	   61.56	   81.74	   65.29	  
Tnfsf15	   0.96	   4.18	   0.74	   3.31	   0.38	   4.37	   1.54	   1.36	   0.55	  
Tnfsf8	   9.08	   20.46	   7.17	   10.85	   6.03	   7.01	   8.71	   12.48	   5.73	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Fig	  A.4	  Example	  of	  flow	  cytometry	  gating	  on	  forward-­‐scatter	  (x-­‐axis)	  	  and	  side-­‐scatter	  
(y-­‐axis)	   ,	   used	   to	   filter	   out	   non-­‐granulocyte	   cells	   and	   cellular	   debris	   from	   further	  
analysis.	  
 
 
 
Fig	   A.5	   Neutrophils	   apoptosis	   following	   overnight	   	   (18	   h)	   incubations	   with	   either	   5	  
ng/mL	  GM-­‐CSF	   (GM)	   (grey	  bars),	   10	  ng/mL	  TNFα	   (TNF)	   (checkered	  bars)	  or	   remained	  
untreated	   (UT)	   (white	   bars).	   Neutrophils	   were	   isolated	   by	   either	   Polymorphprep™	  
(Poly),	  magnetic	  bead	  preparation	  (Beads)	  or	  magnetic	  bead	  preparation	  followed	  by	  
a	  30	  min	  centrifuge	  on	  Polymorphprep™	  (Bead	  +	  Poly).	  Levels	  of	  neutrophil	  apoptosis	  
were	  measured	  by	  annexin	  V,	  propridium	  iodide	  staining.	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Table	  A.8	  List	  of	  data	  sets	  used	  in	  Cuffdiff	  comparisons	  in	  Chapter	  6.	  
Figure/table	  of	  
reference	  
Sample	  list	  1	   Sample	  list	  2	  
Table	  6.3	  
UT-­‐poly-­‐donor-­‐1	  GM-­‐poly-­‐donor-­‐1	  TNF-­‐poly-­‐donor-­‐1	  UT-­‐poly-­‐donor-­‐2	  GM-­‐poly-­‐donor-­‐2	  TNF-­‐poly-­‐donor-­‐2	  
UT-­‐beads-­‐donor-­‐1	  GM-­‐beads-­‐donor-­‐1	  TNF-­‐beads-­‐donor-­‐1	  UT-­‐beads-­‐donor-­‐2	  GM-­‐beads-­‐donor-­‐2	  TNF-­‐beads-­‐donor-­‐2	  
Fig	  6.11	  
UT-­‐poly-­‐donor-­‐1	  UT-­‐poly-­‐donor-­‐2	  	  GM-­‐poly-­‐donor-­‐1	  GM-­‐poly-­‐donor-­‐2	  	  TNF-­‐poly-­‐donor-­‐1	  TNF-­‐poly-­‐donor-­‐2	  
UT-­‐beads-­‐donor-­‐1	  UT-­‐beads-­‐donor-­‐2	  	  GM-­‐beads-­‐donor-­‐1	  GM-­‐beads-­‐donor-­‐2	  	  TNF-­‐beads-­‐donor-­‐1	  TNF-­‐beads-­‐donor-­‐2	  
Table	  6.4	  
UT-­‐poly-­‐donor-­‐1	  GM-­‐poly-­‐donor-­‐1	  TNF-­‐poly-­‐donor-­‐1	   UT-­‐beads-­‐donor-­‐1	  GM-­‐beads-­‐donor-­‐1	  TNF-­‐beads-­‐donor-­‐1	  
Table	  6.5	  
UT-­‐poly-­‐donor-­‐2	  GM-­‐poly-­‐donor-­‐2	  TNF-­‐poly-­‐donor-­‐2	   UT-­‐beads-­‐donor-­‐2	  GM-­‐beads-­‐donor-­‐2	  TNF-­‐beads-­‐donor-­‐2	  
Table	  6.6	  
UT-­‐poly-­‐donor-­‐1	  GM-­‐poly-­‐donor-­‐1	  TNF-­‐poly-­‐donor-­‐1	   UT-­‐poly-­‐donor-­‐2	  GM-­‐poly-­‐donor-­‐2	  TNF-­‐poly-­‐donor-­‐2	  UT-­‐beads-­‐donor-­‐1	  GM-­‐beads-­‐donor-­‐1	  TNF-­‐beads-­‐donor-­‐1	   UT-­‐beads-­‐donor-­‐2	  GM-­‐beads-­‐donor-­‐2	  TNF-­‐beads-­‐donor-­‐2	  
	  
	  
Table	  A.9	  Poly	  vs	  beads	  in	  both	  donors.	  Number	  of	  significant	  genes	  in	  samples	  from	  
each	  isolation	  method.	  
 	   Donor	  1	   Donor	  2	  
Number	  of	  gene	  significantly	  
differentially	  expressed	  
63	   282	  
Number	  of	  significant	  genes	  with	  
higher	  RPKM	  	  in	  Polymorphprep™	  
samples	  
53	  	  (84.1%)	   190	  (67.3%)	  
Number	  of	  significant	  genes	  with	  
higher	  RPKM	  	  in	  Bead	  	  samples	  
10	  (15.9%)	   92	  (32.7%)	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Table	   A.10	   List	   of	   genes	   significantly	   regulated	   between	   isolation	   methods	   in	  
neutrophils	   from	   Donor	   2	   (high	   contamination).	   Table	   shows	   all	   92	   genes	   with	   a	  
significantly	  higher	  RPKM	  values	  in	  neutrophils	  isolated	  using	  magnetic	  bead	  (Beads)	  
than	   neutrophils	   isolated	   by	   Polymorphprep™	   (Poly)	   using	   sample	   from	   Donor	   2.	  
Significance	   (q-­‐value)	   as	   calculated	   by	   Cuffdiff	   adjusted	   for	   5%	   false	   discovery	   rate	  
(FDR)	   by	   Benjamini-­‐Hochberg	   correction	   for	   multiple-­‐testing.	   N=3	   paired	   technical	  
replicates.	  
	  
Gene	  
Name	  
Poly	  
(RPKM)	  
Beads	  
(RPKM)	  
Fold	  
change	  
(log2)	   q-­‐value	   ΔRPKM	  
DEFA1	   239.933	   1082.69	   2.174	   4.75E-­‐02	   -­‐842.757	  
LCN2	   89.952	   447.161	   2.314	   2.45E-­‐02	   -­‐357.209	  
CAMP	   32.519	   138.676	   2.092	   2.93E-­‐02	   -­‐106.157	  
BPI	   24.068	   117.488	   2.287	   2.05E-­‐02	   -­‐93.42	  
OLFM4	   16.438	   87.792	   2.417	   1.36E-­‐02	   -­‐71.354	  
CEACAM8	   12.433	   65.236	   2.391	   9.63E-­‐03	   -­‐52.803	  
DEFA4	   9.968	   57.406	   2.526	   1.26E-­‐03	   -­‐47.438	  
MS4A3	   8.837	   45.919	   2.377	   1.54E-­‐02	   -­‐37.081	  
MMP8	   9.436	   41.732	   2.145	   3.68E-­‐02	   -­‐32.297	  
AZU1	   7.485	   38.436	   2.36	   4.26E-­‐03	   -­‐30.951	  
ELANE	   5.851	   34.581	   2.563	   1.00E-­‐03	   -­‐28.731	  
RETN	   5.085	   28.648	   2.494	   5.32E-­‐03	   -­‐23.563	  
CEACAM6	   5.968	   25.207	   2.079	   2.95E-­‐02	   -­‐19.239	  
H1F0	   3.009	   21.615	   2.845	   2.19E-­‐04	   -­‐18.605	  
C13orf15	   5.171	   23.425	   2.18	   1.16E-­‐02	   -­‐18.254	  
CTSG	   2.296	   20.538	   3.161	   7.90E-­‐06	   -­‐18.242	  
PRTN3	   2.929	   19.16	   2.71	   2.88E-­‐04	   -­‐16.231	  
PNP	   2.584	   16.629	   2.686	   3.74E-­‐02	   -­‐14.045	  
GJB6	   1.717	   14.542	   3.082	   1.06E-­‐03	   -­‐12.825	  
MPO	   1.643	   12.589	   2.938	   7.69E-­‐05	   -­‐10.946	  
EHD4	   2.231	   11.691	   2.39	   5.17E-­‐03	   -­‐9.46	  
DEFA5	   1.824	   9.096	   2.318	   1.45E-­‐02	   -­‐7.271	  
HS3ST3B1	   0.901	   7.983	   3.148	   1.56E-­‐03	   -­‐7.082	  
SNAPC1	   2.382	   9.253	   1.958	   4.28E-­‐02	   -­‐6.871	  
RAB13	   2.113	   8.268	   1.968	   3.50E-­‐02	   -­‐6.155	  
PTGES	   0.828	   5.651	   2.772	   1.81E-­‐02	   -­‐4.824	  
C20orf27	   1.399	   6.109	   2.127	   1.45E-­‐02	   -­‐4.711	  
ZNF277	   1.57	   6.216	   1.985	   4.10E-­‐02	   -­‐4.646	  
BEX1	   0.947	   5.21	   2.459	   3.06E-­‐03	   -­‐4.262	  
RRM2	   1.113	   4.687	   2.074	   3.27E-­‐02	   -­‐3.573	  
CD177	   1.113	   4.621	   2.053	   3.12E-­‐02	   -­‐3.508	  
SEMA6B	   0.971	   4.275	   2.138	   3.33E-­‐02	   -­‐3.304	  
SERPINB10	   0.784	   4.077	   2.379	   4.53E-­‐03	   -­‐3.293	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CHIT1	   0.868	   4.034	   2.217	   2.93E-­‐02	   -­‐3.166	  
ABCA13	   0.776	   3.866	   2.317	   8.56E-­‐03	   -­‐3.09	  
PAPSS2	   0.647	   3.297	   2.349	   4.50E-­‐03	   -­‐2.65	  
SCD	   0.74	   3.174	   2.1	   1.63E-­‐02	   -­‐2.434	  
ETHE1	   0.563	   2.742	   2.284	   1.97E-­‐02	   -­‐2.179	  
PRRT4	   0.394	   2.567	   2.703	   1.60E-­‐03	   -­‐2.173	  
COL17A1	   0.485	   2.296	   2.242	   7.05E-­‐03	   -­‐1.81	  
MCM4	   0.351	   1.897	   2.434	   1.56E-­‐03	   -­‐1.546	  
CLEC11A	   0.299	   1.829	   2.613	   6.45E-­‐03	   -­‐1.53	  
LOC285758	   0.287	   1.738	   2.601	   4.85E-­‐02	   -­‐1.452	  
HS3ST3A1	   0.217	   1.639	   2.916	   1.21E-­‐03	   -­‐1.422	  
MKI67	   0.307	   1.661	   2.435	   3.81E-­‐02	   -­‐1.354	  
FSTL3	   0.301	   1.565	   2.376	   9.63E-­‐03	   -­‐1.264	  
C19orf77	   0.224	   1.356	   2.596	   1.71E-­‐02	   -­‐1.132	  
CDT1	   0.265	   1.394	   2.394	   5.20E-­‐03	   -­‐1.129	  
MTSS1	   0.24	   1.233	   2.363	   3.66E-­‐03	   -­‐0.993	  
MYBL2	   0.296	   1.288	   2.12	   1.68E-­‐02	   -­‐0.992	  
FAM108C1	   0.277	   1.202	   2.12	   2.93E-­‐02	   -­‐0.926	  
ZNF367	   0.257	   1.164	   2.178	   1.16E-­‐02	   -­‐0.907	  
ITGA9	   0.148	   1.052	   2.826	   5.75E-­‐04	   -­‐0.904	  
TPX2	   0.162	   0.992	   2.616	   1.28E-­‐03	   -­‐0.83	  
ANLN	   0.166	   0.992	   2.579	   1.90E-­‐02	   -­‐0.826	  
PCOLCE2	   0.16	   0.983	   2.622	   6.76E-­‐03	   -­‐0.823	  
TPSB2	   0.055	   0.878	   3.987	   1.43E-­‐02	   -­‐0.823	  
LOC200772	   0.023	   0.775	   5.055	   9.28E-­‐04	   -­‐0.752	  
STX1A	   0.07	   0.82	   3.548	   9.96E-­‐04	   -­‐0.75	  
KIF2C	   0.135	   0.846	   2.653	   2.84E-­‐03	   -­‐0.712	  
KIF11	   0.196	   0.872	   2.151	   1.26E-­‐02	   -­‐0.676	  
GJB2	   0.055	   0.713	   3.701	   5.65E-­‐04	   -­‐0.658	  
CDK1	   0.09	   0.749	   3.049	   1.45E-­‐02	   -­‐0.658	  
TCTEX1D1	   0.131	   0.776	   2.569	   1.09E-­‐02	   -­‐0.645	  
E2F8	   0.055	   0.672	   3.617	   8.91E-­‐05	   -­‐0.617	  
GLB1L	   0.15	   0.711	   2.246	   2.64E-­‐02	   -­‐0.561	  
SHB	   0.123	   0.678	   2.469	   4.17E-­‐03	   -­‐0.556	  
NEIL3	   0.085	   0.616	   2.85	   4.71E-­‐03	   -­‐0.53	  
CDC45	   0.093	   0.597	   2.677	   3.19E-­‐02	   -­‐0.503	  
LAPTM4B	   0.106	   0.608	   2.524	   2.33E-­‐02	   -­‐0.502	  
KCNH4	   0.021	   0.465	   4.489	   2.88E-­‐03	   -­‐0.445	  
BUB1B	   0.12	   0.54	   2.167	   4.50E-­‐02	   -­‐0.419	  
TRIM16	   0.063	   0.45	   2.831	   1.14E-­‐02	   -­‐0.387	  
NPR3	   0.022	   0.395	   4.189	   6.54E-­‐05	   -­‐0.373	  
CPXM1	   0.024	   0.372	   3.953	   2.86E-­‐02	   -­‐0.348	  
EXO1	   0.081	   0.426	   2.389	   3.50E-­‐02	   -­‐0.345	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C1orf106	   0.053	   0.373	   2.806	   3.29E-­‐02	   -­‐0.32	  
PROM1	   0.027	   0.318	   3.55	   1.97E-­‐02	   -­‐0.291	  
IQGAP3	   0.037	   0.319	   3.116	   7.68E-­‐04	   -­‐0.282	  
DEPTOR	   0.017	   0.275	   4.043	   2.48E-­‐02	   -­‐0.258	  
ASPM	   0.084	   0.332	   1.983	   2.93E-­‐02	   -­‐0.248	  
ZNF711	   0.024	   0.271	   3.496	   4.59E-­‐03	   -­‐0.247	  
CIT	   0.063	   0.282	   2.158	   2.37E-­‐02	   -­‐0.219	  
ZNF521	   0.015	   0.219	   3.902	   1.49E-­‐03	   -­‐0.204	  
MYOF	   0.047	   0.249	   2.413	   1.40E-­‐02	   -­‐0.202	  
DNAH10	   0.048	   0.248	   2.36	   5.32E-­‐03	   -­‐0.2	  
DIAPH3	   0.018	   0.217	   3.571	   2.60E-­‐02	   -­‐0.199	  
B4GALT6	   0.026	   0.212	   3.017	   1.53E-­‐02	   -­‐0.185	  
PRKG2	   0.011	   0.171	   3.967	   3.86E-­‐02	   -­‐0.16	  
KCNQ5	   0.03	   0.172	   2.505	   3.46E-­‐02	   -­‐0.142	  
KIAA1211	   0.011	   0.144	   3.689	   9.38E-­‐03	   -­‐0.133	  
HSPG2	   0.009	   0.12	   3.76	   8.21E-­‐04	   -­‐0.111	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